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Abstract 
Therapeutic drug monitoring is primarily undertaken for narrow therapeutic inde:\ 
drugs, such as immunosuppressants. These drugs have reduced the incidence of acute 
rejection and improved allograft survival. However, due to their narrow therapeutic 
index, small variations in blood levels may result in inadequate levels of 
immunosuppression or toxic drug concentrations. To overcome these problems 
individual dose regimen based-on phannacokinetic monitoring has been proposed in the 
past years. Indeed, several studies have previously documented a significant association 
between cyclosporine whole blood levels and patient's clinical outcome, expressed as 
rejection episodes as well as drug-related adverse events. 
Novel immunosuppressive agents have been recently introduced on the market (such as 
rapamycins and mycophenolic acid-releasing formulations). However, data on their 
phannacokinetics, which in tum could be useful for the definition of therapeutic ranges, 
are scanty. To address this issue we have used a chromatographic method for the 
measurement of mycophenolic acid levels in kidney transplant recipients. Although this 
immunosuppressant is usually given in a fixed daily dose regimen, we found a positive 
correlation between drug levels, but not dose, and renal function. As additional analysis, 
significant phannacokinetic interactions between mycophenolic acid and concomitant 
immunosuppressive regimens have been identified. Similarly, novel chromatographic 
methods for the analysis of rapamycins in the whole blood have been developed in our 
laboratory, and applied to identify phannacokinetic interactions between these anJ other 
inununosuppressive agents. In the last part of my research project. I have also presented 
preliminary data on the application of pharmacogenetics analysis in patients given 
cyclosporine as part of their immunosuppressive regimen. 
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In conclusion, it can be reasonably speculated that TDM based on pharmacokinetic. as 
well as novel pharmacogenetic approaches, can be considered as reliable tools to guide 
drug dosing in organ transplantation setting, ultimately resulting in a significant 
improvement of long term graft and patient survival. 
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Chapter 1 
INTRODUCTION 
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Organ transplantation as a treatment modality for patients with end-stage organ diseas~s 
of the kidney, heart, liver, pancreas and small bowel has achieved impressi\-e results in 
the past two decades, thanks to a better understanding of basic immunobiology. more 
advanced measures for medical and surgical management, and n~w pharmacological 
treatments [1]. Indeed, although immunosuppressive therapies to overcome host 
reaction to allografts have been employed since the early days of clinical 
transplantation, immunosuppressive agents and treatment protocols are constantly 
evolving [2]. 
Historical perspective 
The pharmacological era of immunosuppression began In 1916, when Hektoen [3] 
showed that benzene treatment reduced antibody production in experimental animals. 
Later, Schwartz et al observed that treatment with 6-mercaptopurine, a competitive 
inhibitor of many purine synthetic pathways, reduced antibody production and 
prolonged skin allograft survival in rabbits [4]. Subsequently, azathioprine (AZA) - an 
imidazole derivative developed to prevent the susceptibility of the unshielded mercapto-
group of 6-mercaptopurine to hydrolysis in the gut - was shown by CaIne and 
colleagues [5] to prolong the survival of human renal transplants. In the same period, 
steroids, the second stage in the development of therapeutic immunosuppression, 
showed various effects to reduce inflammatory processes mediated by mononuclear 
cells [6]. From 1964 to 1978, renal transplants were carried out using combinations of 
azathioprine and the steroid prednisone, showing about a one-year graft survi val rate in 
50% of recipients. However, even in successful cases, this approach was complicated by 
bone-marrow suppression, gastrointestinal disorders or opportunistic infections [7 J. 
Thus, new, potent, selective and less toxic drugs were urgently needed. Since the 
introduction of cydosporine (CsA) in 1978 [8]. there has been linle douht about it:-; 
..., 
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value as the single most important agent in the armamentarium of maintenance 
immunosuppression for organ transplantation. In the middle nineties triple-drug therapy 
with cyclosporine, corticosteroids and azathioprine became the most frequently used 
regimen for kidney recipients [9]. 
More recently, better understanding of the basic immune mechanisms and more insights 
in the pharmacokinetic properties of different molecules have led to the development of 
several new xenobiotic immunosuppressants (tacrolimus, mycophenolate mofetiI. 
sirolimus, everolimus, FTY720), novel formulations of traditional drugs (cyclosporine 
Neoral, mycophenolate sodium), as well as polyclonal antilymphocyte agents 
(antilymphocyte or antithymocyte globulins [ALG, ATG]) or monoclonal antibodies 
specifically directed against immunological targets (anti-CD3 [OKT3]. anti-CD52 
[alemtuzumab or campath-IH], anti-CD20 [rituximab]), which have entered clinical 
trials in the past few years [2]. Altogether, these new drugs contributed to great 
evolvement of immunosuppressive drug regimens for maintenance of solid organ 
allografts observed over the past few decades, increasing I-year graft survival from less 
than 40% in the early '60 to an actual survival of over 900/0 [10]. 
Despite the great results obtained in the short-terms, it should be pointed out that current 
anti-rejection drugs, however, invariably reduce systemic immunity non-selectiyely 
which translates in more risk of infections and cancer. Moreover, these agents present 
several side effects and, in some instance, can be extremely toxic for the graft, 
especially for the kidney [11]. all factors that can contribute to chronic rejection. 
ultimately resulting in poor long term graft survi val and graft loss [12]. 
It was soon realized that adverse events associated \\ith phannacologic 
imnlUllosuppression were mainly related to daily drug exposure and could be minimizcLi 
to some extent by carefully titration of the optimal individualized dosage. Sevcral 
appn)aches havc been used to assess the appropriateness of the dosing regimen for an 
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immunosuppressive drug. The first involved the assessment of clinical response. This 
approach, however, has serious limitations, because signs of rejection or toxicity may be 
difficult to recognize, or the clinical manifestations can appear late, so that patients do 
not recover also after drug withdrawal [13]. Therefore, it was clear that alternative 
approaches had to be developed, giving birth to a new important and exciting tield of 
study: Therapeutic Drug Monitoring (TDM). 
A TDM program [14] for immunosuppressive drugs must include consideration 
concerning the use of specific and sensitive analytical methods, identification of the 
optimal biological matrix, and choice of the best parameter to be assessed as surrogate 
marker of drug activity. Traditional TDM has been performed using pharmacokinetic 
approaches [14], but also complementary strategies have been developed in the last few 
years [15,16]. The ultimate goal of traditional as well as innovative TDNI studies is to 
tailor the best immunosuppressive regimen for each patient. 
The pharmacokinetic approach 
Pharmacokinetics involves the measurement of drug concentrations in biological fluids 
and the subsequent relationship of these levels to drug dosing and ultimately to clinical 
events. The assumption is that the plasmalblood concentration mirrors the concentration 
at the site of action. Drug levels could be greatly influenced by environmental factors, 
such as hepatic or renal dysfunction, as well as hormonal levels and/or pharmacokinetic 
interactions \\ith other co-administered drugs. all combinations that can VaI)' 
significantly during the course of treatment [17]. These observations provide support for 
phanl1acokinetics, because periodical evaluations of drug exposure are able to identit\ 
external intluences, and can predict daily drug exposure and clinical outcome. This 
approach, also termed as clinical phannacokinetic monitoring, has been applied to th~ 
field of organ transplantation starting from the end of 1960s [17J. Sinc~ th~n. s~v~ral 
- 9 -
studies have shown the predictive impact of pharmacokinetics on decreased mortality. 
morbidity and efficacy/adverse events from immunosuppressive drug therapy [18.19]. 
Although pharmacokinetics represents a step forward, as compared to the simply 
observation of clinical response, it presents some limitations. Pharmacokinetic studieS 
can start only when a given drug is administered to the patients. requiring the 
assumption of steady state conditions and patient's compliance. ~oreover. there is still 
controversy about which are the best phannacokinetic parameters that should b~ 
considered to monitor drug effect. The area under the time-concentration curve (AVC) 
represents the golden standard to assess daily drug exposure. Unfortunately. measuring 
Aue requires the collection and analysis of multiple samples, which is costly and time-
consuming for patients and clinical staff. To overcome these problems, alternative 
approaches have been developed by limited Sampling Strategy (LSS), a technique 
aimed to estimate a phannacokinetic parameter, as AVC, using a small number of 
samples [20]. Several equations have been developed so far, but there is still lack of 
agreement on the choice of the optimal LSS for each immunosuppressive ag~nt. 
All these limitations provide the rationale for searching complementary/additional 
strategies to manage narrow therapeutic index drugs beyond pharmacokinetics. 
Pharmacodynamic monitoring of immunosuppressive drugs 
Phannacokinetics has been used for many years to relate immunosuppressants dose to 
drug exposure in vivo. Although this is the primary method to measure drug absorption. 
distribution, metabolism, excretion and interactions with other drugs. it does not directly 
assess the phannacological effects on immune cells . . 10 \'1\'0. As r~sults 
pharmacokinetics cannot account for the inter-subject variability in the s~nsitivities to 
immune suppression bv similar blood concentrations of immunosuppressants. 
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Therefore, the current practice of relying solely on pharmacokinetics for clinical 
decisions on the dosage and the choice of immunosuppressants is far from ideal. 
In contrast to pharmacokinetics, pharmacodynamics of immunosuppressants quantitates 
drug effects at its target site, after drug exposure to immune cells in vivo. If 
measurement at the target is not possible, the enzyme activity should be measured in a 
matrix that provides good surrogate marker for enzyme activity at the target site [15] . 
. Pharmacodynamic assays of orally active immunosuppressants either measure the drug 
effect on a discrete molecule that is important for lymphocyte activation or measure 
more complex biological events required for normal immune functions [21]. Indeed, 
pharmacodynamic assays have been reported for the monitoring of esA, azathioprine, 
mycophenolate mofetil, and rapamycin [15,21]. 
Pharmacodynamic monitoring might provide better understanding of mechanisms of 
actions of different immunosuppressants, as well as direct assessment of 
pharmacologic-induced immunosuppression. These approaches have, therefore, the 
potential to augment pharmacokinetic monitoring to optimise the dosing regime of anti-
rejection drugs. However, because many of pharmacodynamic assays are time-
consuming and not amenable for use in routine clinical laboratories [15], the future 
challenge is to develop robust methods to facilitate the further evaluation and 
application of these approaches. 
Pharmacogenetics as a new tool to tailor immunosuppressive therapy 
The advent of the genomic era has brought several new fields of study, including 
pharmacogenomics, which seeks to link drug treatment with the individual's genetic 
make-up. This new science holds many promises for improved treatment of a large 
variety of medical conditions, including immunosuppression for organ transplantation 
[22], providing a promising and complementary tool to traditional TDM. The key-point 
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is to understand whether clinical pharmacogenomics is already applicable today to 
organ transplantation. Early observations focused simply on drug metabolism [23]. 
However, today there is great interest in the full spectrum of drug disposition, including 
absorption, distribution, and pharmacological targets. One of the potential advantages of 
this type of approach lies on the common metabolic pathways for several 
immunosuppressive agents. CsA, tacrolimus, sirolimus and the novel rapamycin-
analogue everolimus are all transported by P-glycoprotein - a protein encoded by the 
multidrug resistant gene t (MORt) - and metabolised by the cytochrome 3A4 
(CYP3A4) and to a less extent by CYP3A5 [24]. Thus, the study of patient's genotype 
can provide predictive value for regimens which include the concomitant administration 
of several drugs, a common condition for organ transplant recipients. 
The presence of variants in genes encoding for the drug targets or other genetic 
polymorphisms with indirect effects on drug response are less known. Thus, they 
represent an exciting challenge for the future. However, one should consider that also 
many non-genomic factors, including concomitant drug administration, 
pharmacological enzyme-induction, and illness may have a significant impact on the 
above mentioned proteins, and must be taken into account also when a 
pharmacogenomic approach is planned. 
Therapeutic drug monitoring of novel immunosuppressants: preliminary experience 
withMPA 
MMF is widely used in kidney or heart transplantation using a fixed-daily dose 
regimen. However, data are recently emerging that provide the scientific basis for 
therapeutic drug monitoring of MP A in transplant patients receiving MMF, the parent 
drug, in combination with other immunosuppressive agents. There is a significant 
relationship between the dose-interval MPA AVC and risk for acute rejection based on 
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retrospective investigations in renal and heart transplant patients and on prospective 
investigations in renal transplant patients [17,19]. The MPA dose-interval AUe varies 
naturally by more than 10-fold in renal and heart transplant patients. Other significant 
sources of pharmacokinetic variability for MP A include the effects of concomitant 
medications - especially when new drugs (i.e sirolimus) are concomitantly used - and 
the effects of disease states such as renal dysfunction and liver disease on the steady 
state MP A exposure. MP A is extensively bound to albumin, with a range of protein 
binding of 97-99% in patients with normal renal and liver function. Factors that alter the 
protein binding can affect the relationship between total concentration and free 
concentration which, in turn, is pharmacologically active [114]. For this reason, under 
circumstances of perturbed binding, the interpretation of total MP A plasma 
concentration must take into account the altered MP A binding. Further research is, 
however, needed to draw defInite conclusion on this topic. 
Individualized MMF dose evaluation, guided by MP A plasma concentrations, is 
becoming the standard of practice at a growing number of transplant centers worldwide 
because of these factors and because of the need to closely evaluate the 
immunosuppressionafforded by MP A when a change in the immunosuppression 
regimen in stable transplant patients is planned. Investigations of therapeutic drug 
monitoring strategies with the goal to optimize the use of MMF, focusing in particular 
on drug-to-drug interactions, are ongoing. Based on statistics from the Analytical 
Services International Ltd, there are nearly 80 centres participating in the MP A 
program. Most of them are European, whereas only a few centers in America are 
currently monitoring MP A. However, given the emerging strong support for the clinical 
outcome benefit of MP A monitoring, it can be expected that greater demand for MP A 
monitoring will occur, focusing also on the pharmacokinetics of MP A released from the 
recently developed enteric-coated formulation [107]. 
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Therapeutic drug monitoring of novel immunosuppressants: preliminary experience 
withSRL 
SRL was recently approved in Europe, where the licence specifies its use for 
prophylaxis of graft rejection in adult kidney transplant recipients, and with the use of 
blood concentration monitoring. TDM of SRL is still in its infancy but data have 
accumulated from several clinical trials, some of which were concentration-controlled, 
showing that there is a good correlation between SRL trough concentration (as 
surrogate marker of SRL AVC) and clinical outcome, expressed as rejection episodes 
and drug-related toxicity [17,18]. Therefore, to date, all the monitoring 
recommendations refer to this sampling. Preliminary evidence is also available that SLR 
exposure could be significantly influenced by concomitant CsA administration. 
However, the potential drug-to-drug interactions between SRL and other agents usually 
administered to organ transplant recipients are unknown. When SRL is used in 
combination with a calcineurin inhibitors predose concentrations are generally targeted 
in the range 5-15 ng/mL [17,18], whereas specific SRL ranges in CsA- or TRL-sparing 
regimen are lacking. 
Therapeutic drug monitoring of immunosuppressive agents in the Centre of Bergamo: 
single-centre experience with CsA 
CsA is the principal immunosuppressant currently used to prevent graft rejection after 
organ transplantation. Given the appreciable interindividual variation both in clinical 
response and in drug exposure despite the same dosage regimen, it was early realized 
that close monitoring of CsA blood levels was a useful adjunct to its optimal 
administration. In particular, the AVC, either calculated from the individual complete 
phannacokinetic profile or predicted using LSS, was identified as the best predictor of 
CsA daily exposure and clinical outcome [25]. These approaches are, however. time 
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consuming and seldom feasible in routine out-patient clinical monitoring. Thus, m~1 
of trough (Co) blood CsA concentration has been widely adopted to adjust CsA dose in 
individual subjects since twenty years ago. In the last few years, however, e\'idence has 
accumulated that blood sampling at 2 h post-dosing (C2), might provide a better 
estimate of CsA exposure than the traditional Co-based monitoring [25]. It should be 
pointed that the defInition of the best single-point sampling (Co or C2) to monitor patient 
exposure to CsA is still a matter of debate. This concern is mainly related to the limited 
data available showing the clinical usefulness of using single point strategy to monitor 
daily CsA exposure. The utility of CsA Co was initially proposed based upon reports of 
a correlation between low trough values and increased incidence of acute rejection 
episodes, as well as high concentrations and nephro- or hepatotoxicity [26]. 
Nevertheless, this approach was proven as not always reliable in routine clinical 
practice due to the fact that some patients experienced a worst outcome despite CsA Co 
levels within the therapeutic range. In search of more accurate single point sampling 
markers of CsA drug monitoring, in the last few years C2 has been proposed as a useful 
surrogate of the maximum drug concentration (Cmu), which in turn is effective in 
predicting acute rejection [27]. It should be pointed, however, that no studies have 
formally compared the predictive value of these two samplings in term of clinical 
outcome. Therefore, we have strictly measured serial Co and C2 levels in over 330 
kidney transplant recipients during the first 6 months post-surgery and found that CsA 
trough levels early post-transplant (day 2, 9 and 14) were the strongest predictor of 
acute rejection over 6 month follow-up [28]. In particular, Co levels within 300 to 440 
ng/mL were associated with the lowest risk of rejection, while C2 levels considered 
alone had no predictive value at all. The large number of phannacokinetic 
measurements (Co; N=2236 and C2; N=2128) together with the stringent follow-up 
protocol, suggests that the predictive value of C2 is overrated, at least in the early phase 
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post-surgery. To extend our findings, we have retrospectively analyzed full 
pharmacokinetic profiles of 58 patients at more than one year post surgery [29]. A 
logistic regression analysis of the interaction between pharmacokinetic parameters and 
graft function showed that Co but not C2 significantly predicted long-term clinical 
outcome, expressed as renal function deterioration. Altogether, these findings suggest 
that C2 is not a superior surrogate marker of the daily CsA exposure than Co, either in 
the short and long-term. period post-surgery. Additionally, by analyzing full CsA 
pharmacokinetic profiles, we have shown that not all kidney transplant recipients 
behave in the same manner as for absorption, distribution, metabolism and elimination 
of CsA. In particular, interindividual variation in the absorption process may segregate 
distinct population of patients [29]. Of note, patients with an "atypical" absorption 
profile are those which benefit less from single point-based limited sampling strategy to 
monitor daily CsA exposure [29], a condition that may expose these patients to chronic 
over- or under- cyclosporine exposure with dramatically clinical consequences. This 
concept was exemplified by our fmdings that in some patients the use single point-based 
monitoring may result in inadequate immunosuppression, leading to a significant 
increased risk to develop long-term complications of chronic CsA overexposure, such 
as Kaposi's Sarcoma (KS), a skin cancer. Indeed, we have compared the incidence of 
KS in transplant patients receiving Neoral or Sandimmune as a part of their 
immunosuppressive therapy [30]. 668 kidney transplant recipient followed at our 
Nephrology Unit from 1970 to 2003 entered this retrospective analysis. 300 were on 
CsA Sandimmune-based and 308 on CsA Neoral-based therapy. The primary endpoint 
was the occurrence of KS. The disease was diagnosed in 20 out of 608 patients given 
CsA with an incidence rate of 4.7 per 1000 patients per year. No episodes of KS were 
found in the pre-CsA era. Among patients on CsA, those treated with Neoral had 4 fold 
higher incidence rates of KS than in the Sandimmune group (10.7 vs 2.3 per 1000 
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patients per year). Kaplan-Meier analysis shows that patients on Neoral had lower 
cumulative KS-free probability than those on Sandimmune. Cox's analysis documented 
that Neoral was a positive predictor of KS development as compared to Sandimmune 
(hazard ratio: 2.237). Among patients on Neoral those who developed KS had higher 
daily exposure to the drug assessed by pharmacokinetic studies. Therefore, we 
concluded that in recipients of kidney transplant CsA Neoral increases the risk of KS as 
compared to the Sandimmune formulation, possibly due to enhanced drug 
bioavailability and ultimately patient's daily CsA exposure. To avoid or limit these 
dramatic consequences, we would suggest that all transplant recipients, beside Co or C2 
routine monitoring, should undergo at least one pharmacokinetic profile in order to be 
classified according to CsA absorption pattern. 
It should be pointed, however, that drug concentration measurements are only a part of 
the decision tree for dose adjustment. They must be viewed in the context of other 
complementary fields that include biochemical and clinical analysis, as well as novel 
therapeutic monitoring approaches. As an example of this concept, we have conducted a 
randomized trial aimed at investigating whether per-protocol biopsies, in combination 
with routine pharmacokinetic studies, could be useful tools to implement steroid or CsA 
sparing regimens in kidney transplant recipients [187]. As main result, we have found 
that per-protocol biopsy more than one year after transplantation is a safe procedure to 
guide change of immunosuppressive regimen and to lower the risk of major drug-
related side effects. Alternative approaches, beside pharmacokinetics, have been 
recently proposed to tailor the best immunosuppressive regimen for each patient. For 
instance, pharmacodynamic monitoring involves measurement of the biological effect 
of the drug at its target site [15]. Indeed, we have previously developed a method for the 
assessment of calcineurin, the pharmacological target of CsA, in whole blood. When we 
applied this assay to monitor kidney transplant recipients we found that CsA levels did 
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not predict daily calcineurin activity, whereas a single determination of the eIlZ)me at 
baseline was a useful surrogate for the daily inhibition of the enzyme by CsA [188]. It 
should be pointed out, however, that phannacodynamic tests are actually too complex 
for clinical use and often require radioactive materials. As additional drawbacks, studies 
aimed at investigating the potential predictivity of pharmacodynamic approaches in 
terms of rejection and/or drug toxicity are still lacking. 
Those involved in TDM are now realizing that individual patient's exposure to 
immunosuppressive agents can be influenced by the genetic background. Indeed, it has 
been proposed that interinvidual differences in CsA response may be due, at least in 
part, to sequence variants in genes encoding drug-metabolizing enzymes, drug 
transporters, or drug targets. Recently, genetic variants in the CYP3A4 and CYP3A5 
genes, responsible for the metabolism of CsA, have been described, and shown to be 
associated with an impaired enzyme activity [41]. Another factor that might influence 
drug disposition is the P glycoprotein (p-gp), the product of the MDRI gene. This 
protein is an efflux pump, which removes lipophilic drug, like CsA, tacrolimus and 
sirolimus, from the intracellular space. Several polymorphisms have been found for the 
MD R 1 gene [41]. Of these, three mutant alleles on exons 12, 21 and 26 correlate with 
expression of MDRI gene, and function of P-gp. Actually, only few studies have 
investigated the impact of these polymorphisms on the bioavailability of CsA or 
tacrolimus. Most of them showed contradictory results [41]. Many factors can explain 
the great heterogeneity in the preliminary pharmacogenetic analyses, including limited 
number of subject considered, and weakness of pharmacokinetic parameters studied, 
which often do not include full AVCs. The major limitation of these approaches. 
however, is the study of single polymorphism rather then the potential influence of 
additive factors such as the haplotypes, that generally contain more infonnation than did 
individual SNP. Therefore, further investigations in this field are needed. 
- 1 g -
Aims of the present study 
According to the actual knowledge in the field of therapeutic drug monitoring of 
immunosuppressive agents, my research activity will be devoted to: 
develop an analytical method useful for the assessment of ~1PA plasma len~ls in 
kidney transplant recipients, with the goal to optimizing ~1~IF dosing in th~se 
patients; 
study potential drug-to-drug interactions between ~lP A and other agents 
commonly administered to kidney transplant recipients; 
compare the pharmacokinetics of MPA from patients given l\1~IF with that 
derived from the novel enteric-coated mycophenolate sodium formulation; 
develop an UPLC-UV method applicable for TDM of sirolimus in the routine 
clinical practice, with the goal to study the effect of concomitant 
immunosuppressive therapy and to optimize drug dosing; 
to assess the role of SNPs in the MDRI gene in predicting CsA exposure in a 
large population of kidney transplant recipients. 
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Chapter 2 
SCOPE OF THE THESIS 
-~o -
The aim of this thesis is to apply TDM studies to kidney transplant recipients to 
optimise the management of new immunosuppressive agents, with the ultimate goal to 
improve patient clinical outcome. In particular, I have focused my research on the 
pharmacokinetics of mycophenolic acid (MP A)-releasing formulations - namely 
mycophenolate mofetil (MMF) as well as mycophenolate sodium (EC-MPS) - and 
sirolimus (SRL), with particular emphasis on the potential drug-to-drug interactions 
between these novel immunosuppressants and other agents commonly administered to 
kidney transplant recipients. Additionally, in the last part of the thesis, I have also 
presented preliminary data on pharmacogenetics, a new science which could represent a 
complementary approach to pharmacokinetics for the individualisation of 
immunosuppressive therapy for each patient. 
Mycophenolic acid 
MP A is a potent immunosuppressive agent commonly used following organ 
transplantation [31]. At clinically relevant concentrations, MP A is approximately 97% 
bound to plasma albumin. It has been shown that the unbound, rather than the total 
concentration of MP A is a predictor of MP A inhibitory effect on inosine 
monophosphate dehydrogenase (lMPDH). Therefore, the measurement of the free 
concentration of MP A, in addition to the total drug concentration, is advisable for 
pharmacokinetic investigations. 
MPA is metabolized to an inactive glucuronide conjugate MP AG, a pharmacologically 
active acyl glucuronide metabolite and a 7 -O-glucoside metabolite. MP A is primarily 
excreted renally as MP AG and to some extent in the bile. MP AG is excreted in the gut 
and reabsorbed as MP A, a mechanism commonly known as enterohepatic recirculation 
(EHC) resulting in the occurrence of a secondary plasma peak 6-12 h after oral M~fF 
administration [31]. 
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As a guide to dosage adjustment, it is advisable to measure the concentration of ~IPA 
(total and free) and MPAG in transplant recipients. An eIlZ)me multiplied immunoassay 
technique is available on the market, however this method overestimates the MP A 
concentrations due to cross-reactivity with the MPA metabolites [32]. Therefore, high-
performance liquid chromatography (HPLC) methods remain the standard for 
detennination of MP A and its major metabolite MP AG. Thus, simple and rapid 
methods for the quantification of total, free MP A and MP AG, which could be reliably 
applied for TDM studies, are welcome. 
Sirolimus 
Sirolimus (SRL), a 31-membered triene macrolide lactone with a hemiketal-masked a-
P-dioxocarboxamide and a molecular weight of 913.6 Da, is a novel antirejection drug 
with potent immunosuppressive activity both in vitro and in vivo [33,34]. Studies in 
humans have shown a relationship between trough blood SRL concentrations and 
immunosuppressive efficacy and toxicity of the drug [18]. This suggests that monitoring 
of the SRL concentrations is advisable to optimize drug dosing regimen. 
Since the drug has a narrow therapeutic index (NTI), it is important to develop an 
adequate method to quantify SRL in biological matrices. Several HPLC methods have 
been developed so far for quantifying SRL in whole blood with extraction steps using a 
variety of solvents and mixtures, or with liquidlliquid and subsequent solid phase 
extraction [35]. These HPLC methods used both ultraviolet (UV) and mass 
spectrometry (MS) detection (HPLC-MS or HPLClMSIMS). Although these methods 
meet many or all generally accepted criteria for validated analysis of 
immunosuppressive drugs, they are often cumbersome, have a very long sample 
preparation and/or chromatographic time, require glassware preparation (silanized or 
light protected tubes), use toxic solvents (i.e. l-chlorobutane) or involve equipments 
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(HPLC-MS) not commonly available in the clinical laboratory that need great 
investment. Therefore, given the increasing use of SRL in clinical transplantation. there 
is now need for more feasible methods to be applied in the routine clinical practice 
which also would allow simultaneous measurement of large number of samples. 
Development and validation of analytical methods for the measurement of 
immunosuppressants in plasma or whole blood 
The application of TOM to routine clinical practice requires the measurement of drugs 
concentrations in biological fluids. On this regard, selective and sensitive methods for 
the quantitative evaluation of drugs are critical for the successful conduct of 
pharmacokinetic studies. It is, therefore, mandatory to demonstrate that a particular 
method used for quantitative measurement of analytes in a given biological matrix is 
reliable and reproducible for the intended use. Thus, before to apply TOM to MPA and 
SRL monitoring, I have worked for the development of HPLC methods useful for the 
quantification of these immunosuppressants and, most important, I have assessed 
whether the performance of the assays was in agreement with the FDA Guidance for 
Bioanalytical Method Validation [36]. As described in Chapters 3-5, I have determined 
selectivity, accuracy, precision recovery, linearity and stability for each of the analytes 
assessed in the present thesis (namely, MP A, MP AG, SRL and CsA), using HPLC 
methods with UV detection developed in our Laboratory. Once proven acceptable 
performance, these methods have been subsequently applied to TDM ofMPA and SRL. 
Therapeutic drug monitoring of MP A 
In the second part of the thesis I have faced with TOM of MP A, the active metabolite of 
MMF and EC-MPS. MP A is now routinely used in solid organ transplantation in a fixed 
daily dose regimen. However, no correlation has been shown between drug dose and 
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clinical outcome [37]. Therefore, alternative approaches to guide MP A dosing have 
been advocated. 
To address this issue, we have taken advantage from the MYcophenolate Steroid 
Sparing (MY.S.S.) Study [38]. This multicenter, prospective randomised parallel group 
trial compared clinical outcome in recipients of cadaver-kidney transplant over 6-
month treatment with MMF or azathioprine (AZA) along with CsA and steroids (phase 
A), and over 15 more months without steroids (phase B). Ninety out of the 356 patients 
in the MY.S.S. study were enrolled from the Centre of Bergamo, and half of these were 
given MMF. Therefore, we decided to measure MP A plasma levels (trough levels and 
MPA AUCO-12 predicted using a LSS with sampling at: 0, 20, 40, 75 and 120 after MMF 
administration) in the 46 patients from the centre of Bergamo, and try to correlate MP A 
pharmacokinetic parameters with clinical outcome during the fJISt 6-9 months (Chapter 
6). Graft function was expressed as creatinine clearance, and MMF tolerability was 
evaluated by periodical assessment of blood cell count. At the completion of phase A, 
patients entered phase B if they had no more than two acute rejection episodes, no 
episodes of steroid-resistant rejection during phase A and had stable renal function with 
no proteinuria. Nearly 50% of the patients enrolled in phase A entered phase B [38]. To 
investigate the impact of steroids withdrawal on MP A pharmacokinetics, we measured 
MP A plasma trough levels, predicted MP A AUCO-12 and MP A free fraction in 26 
patients out of 46 who completed phase B and in an additional control group of patients 
who did not discontinue steroids. This additional analysis, presented in Chapter 7, 
introduced a "hot topic" in the field of organ transplantation, the problem of drug-to-
drug interactions. Kidney transplant recipients are chronically given with 3 or more 
immunosuppressive agents which, sometimes, are substrates or act as inducers or 
inhibitors for the same transport-metabolic system. This might be dangerous for the 
patients, especially when they are treated with fixed drug regimens, as usually done 
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with MMF. Indeed, evidence is available that CsA and tacrolimus exerted a different 
effect on the entero-hepatic recirculation ofMPA from glucuronidated metabolites [39]. 
However, no data were available on the pharmacokinetics of MP A in patients given 
MMF in combination with SRL, when compared with that drawn from patients treated 
with MMF and CsA. Therefore, as a part of a protocol aimed at investigating the 
efficacy of Campath-IH induction therapy in a steroid-free regimen, we measured MP A 
plasma levels in patients treated with low-dose SRL or low-dose CsA both in addition 
to low-dose MMF. To better compare the effects of both drugs on MPA enterohepatic 
recirculation, full pharmacokinetic profiles (at 0, 20, 40, 75, 120 min and at 3, 4, 5, 6, 7, 
8, 10 and 12 h), instead of limited samplings (at 0, 20, 40, 75 and 120 min), were 
collected. Results of this study are given in Chapter 8. Patients given Campath-l H in 
combination with CsA and MMF were also used as reference group in a subsequent 
study aimed at assessing the pharmacokinetics of MP A from a cohort of patients given 
CsA and the new enteric-coated formulation of MP A (EC-MPS) as part of an 
intensified, multi-factorial therapy open trial. As described in Chapter 9, MPA exposure 
after EC-MPS administration was determined using a full sampling (at 0, 20, 40, 75, 
120 min and at 3, 4, 5, 6, 7, 8, 10 and 12 h) both at month 6 and 12 post-surgery, and 
compared with that observed in the control group of patients given MMF and CsA. 
Therapeutic drug monitoring of SRL 
Rapamycins, namely SRL and everolimus, are a new class of immunosuppressive 
agents characterized by peculiar mechanisms of action, narrow therapeutic index, and 
strong relation between drug exposure and patients' outcome (40), all conditions that 
require strict therapeutic drug monitoring. In 2001, after the development of the HPLC 
method with ultraviolet detection for the assessment of SRL whole blood levels 
(described in Chapter 4), our Laboratory has become a centralized institution in Italy to 
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measure drug concentrations in blood samples from 40 Italian Transplant Centres. Over 
2,600 SRL trough levels were assessed from nearly 500 kidney transplant recipients. All 
Centres referring to our Laboratory for the assessment of SRL concentrations were 
asked to provide information on SRL daily dose and concomitant immunosuppressive 
regimen. Given the large number of SRL measurements available, we sought to 
investigate the possible effect of concomitant immunosuppressive regimens (such as 
CsA, tacrolimus, MP A and steroids) on SRL exposure, expressed as dose-adjusted 
whole trough levels (Chapter 10). As additional aim, we analysed patients with serial 
SRL measurements with the goal to assess intra-and interpatient variability, and to 
develop an algorithm useful to guide changes of SRL dosing. 
Preliminary applications with pharmacogenetics 
The advent of the genomic era gives birth to pharmacogenetics, a science that studies 
how the genome may affect the action of a drug. This science is of particular importance 
for drugs characterized by a narrow therapeutic index, such as the immunosuppressants 
[41]. Preliminary studies focused on polymorphisms of genes encoding for enzymes 
actively involved in drug metabolism, drug transport, and pharmacological target. 
Pharmacogenomics holds promise for improvement in the ability to individualize 
immunosuppressive therapy based on the patient's genetic profile, and can be viewed as 
a support to the traditional pharmacokinetic-based therapeutic drug monitoring. Our 
preliminary experience of pharmacogenetic approaches applied to CsA monitoring was 
presented in Chapter 11. These data referred to 120 out of 356 kidney transplant 
recipients from the MY.S.S. trial who gave written infonned consent for genetic testing. 
Presence of single nucleotide polymorphisms (SNPs) in the gene encoding for the P-
glycoprotein was assessed. 
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Finally, the findings of all the studies presented above were discussed and put in the 
perspective of a better improvement of long term patient's outcome after organ 
transplantation (Chapter 12). 
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Part I 
DEVELOPMENT OF ANALYTICAL METHODS 
FOR THE MEASUREMENT OF MYCOPHENOLIC 
ACID, SIROLIMUS AND CYCLOSPORINE 
-:8 -
Bioanalytical method validation 
The assessment ofMPA (total and free), MPAG, SRL and CsA was done using HPLC 
methods. Prior to the application of HPLC methods to TOM of novel 
immunosuppressants, the performance of these assays was tested in accordance with the 
FDA Guidance for Bioanalytical Methods Validation for Human Studies [36]. 
Measurement of each analyte in the biological matrix should be validated. Typical 
method development and establishment for a bioanalytical method include 
detennination of selectivity, accuracy, precision, recovery, and calibration curve, 
stability of analytes in spiked samples and application of the method to routine drug 
analysis. Acceptance criteria for each on the above mentioned parameters are described 
below. 
Reference standards 
Analysis of MP A, SRL and CsA in the biological matrix (plasma or whole blood) was 
carried out using samples spiked with reference standards and using quality control 
samples (QCs). To avoid bias in the preparation of the spiking solutions only 
authenticated analytical reference standards of known identity and purity were used 
(either certified reference standards or commercially supplied reference standards 
obtained from a reputable commercial source). 
Selectivity 
The selectivity of each method was evaluated as lack of matrix interference by analysis 
of human drug-free blood samples from different volunteers (n=15). To investigate 
potential endogenous interference, blank samples were spiked with high concentrations 
of the most common immunosuppressive agents and analyzed. In additio~ to test 
potential concomitant medication or xenobiotic interference, blood from different 
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transplant patients on immunosuppressive therapy and most common antifun;al. 
antihypertensive and hypolipidemic agents were analyzed. 
Linearity 
The linearity of each method was tested by constructing standard curves from the lower 
limit of quantification (LLOQ) to the upper limit of quantification, plotting the peak 
height ratios of the drug to internal standard (IS) versus the nominal drug concentration. 
and applying a linear least squares regression analysis without weighing Each method 
was considered linear if the coefficients of regression (~), calculated as mean of 10 
curves was equal or better than 0.99. 
Imprecision and inaccuracy 
The within- and between-day coefficient of variation (CV%) and the inaccuracy of each 
method were assessed by calculating daily and overall CV s and bias values for QC 
(usually five replicates at each concentration per analytical run) that were assayed in 
five separate analytical runs. The methods were considered acceptable if imprecision at 
each concentration was less than 15% for both within and between day variability. The 
inaccuracy should be between ± 150/0. 
Lower limit of quantification 
The lowest standard on the calibration curve was accepted as LLOQ if the analyte 
response at the LLOQ was at least 5 times the response compared to blank response. In 
addition the analyte peak should be identifiabk. discrete. and reproducible with an 
impreclslon -::::20% and inaccuracy between::: 200/0. 
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Recovery 
To determine the extraction efficiency, the peak-height ratios of spiked blood samples 
(plasma for MP ~ MP AG) were compared to those obtained from direct injections of 
the same amount of the analyte. The assay was accepted if recovery exceeded 60%. 
Dilution integrity 
. The ability to dilute samples originally above the upper limit of the standard curve 
should be demonstrated by inaccuracy and imprecision parameters in the validation. To 
establish dilution stability, samples at high concentrations were diluted two folds and 
five folds using the adequate drug-free biological matrix. Deviation from the nominal 
value was determined on three replicates. 
Stability studies 
Stability procedures evaluate the stability of the analyte during sample collection and 
handling, after long-term (frozen at the intended storage temperature) and short-term 
(bench top, room temperature), storage, and after going through freeze and thaw cycles 
and the analytical process. Conditions used in stability experiments reflect situations 
likely to be encountered during actual sampling handling and analysis. The procedure 
should also include an evaluation of analyte stability in stock solutions. 
Each analyte stability (MP A, SRL and CsA) was determined after three freeze-thaw 
cycles using the appropriate biological matrix. Six aliquots, each at two concentrations 
(one in the low and one in the high range) were prepared. Three aliquots were analyzed 
o promptly prepared, the other three were stored at -20 C thawed at room temperature 
and refrozen under the same conditions. The cycle was repeated for two more times and 
analyzed on the third cycle. Comparison between mean results was performed 
calculating the percentage difference. 
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Short term stability of the analytes, simulating work bench conditions, was e\aluateJ on 
six aliquots, each at two concentrations stored at -200 C. Three aliquots were thaweJ at 
room temperature over a time period of 15 hours. After 15 hours the other three aliquots 
were thawed and both sets were extracted and processed. Means of the response were 
compared and percentage difference calculated. 
Long term stability has been established storing eighteen aliquots of two concentrations 
at -20°C and measuring the concentration over a period of 28 days. ~1em 
concentrations obtained have been compared to the mean of back-calculated valu~s for 
the standards at the same concentrations from the fITst day of long term stability. 
Stability of MPA, SRL and CsA in the autosampler was evaluated for 24 hours. Ten sets 
of quality control were extract and placed in the autosampler at room temperature (at 
+4°C for SRL). Five sets of samples were analyzed immediately, the other five sets ~4 
hours later. Long term stability of standard working solutions was evaluated at two 
temperatures (+4 and -20°C) and over 28 days. 
Application of validated method to routine drug analysis 
Each calibration curve, generated in each analytical run, covered the expected unknOVtl1 
sample concentration. Samples below LLOQ or above the highest standard were not 
considered (samples with higher concentrations were diluted and reassayed). During 
each analytical run a number of QC samples prepared separately were analyzed (usually 
one at the start and one at the end of the analytical run). If QC (matrix spiked with the 
analyte) fallout the 15% of their respective nominal \·alues. the run \vas rejected. \\ ben 
available, samples from the \lPA. SRL and CsA International Proficiency Testing 
Scheme (IPTS). were also processed [4~.43]. 
, ... 
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Chapter 3 
DETERMINATION OF TOTAL, FREE MYCOPHENOLIC ACID 
AND ITS GLUCURONIDE METABOLITE USING HPLC WITH UV 
DETECTION 
, , 
--'.' -
Total and free MPA plasma concentrations were measured by HPLC. introducing S\.I;T:e 
modifications to already published methods [44,45,46]. ~fPAG was estimated as \IP.-\ 
after hydrolysis mediated by p-glucuronidase (see below). 
TotalMPA 
Human plasma, chemicals and materials 
Calibration standards and QCs were prepared using pools of plasma samples from 15 
healthy volunteers and from 20 kidney and liver transplant recipients not gi ven ~ I~IF or 
EC-MPS (used to test potential concomitant medications). 
Standards of MPA and MPAG were initially donated by Roche Phannaceuticals (Palo 
Alto, CA). After 2002, MPA was bought from Sigma (St Louis, MO)~ together with p-
toluic acid (PTA, used as internal standard). All the batches of MP A have a purity > 
98% and were provided with the certificate of analysis. Acetonitrile, methanol were 
HPLC grade and were purchased by BDH (UK), all other chemicals were from Sigma. 
HPLC quality deionized water was prepared using Milli Q50 (\1illipore, Bedford, t\IA). 
Bond-Elut CI8, 200 mg, 3 ml cartridges were obtained from Varian (Leini, Italy). 
Stock solutions, calibrators, and quality control standards 
Stock solutions, containing 10, 100 mgIL of MPA and 50 mgIL PI A were prepared in 
methanol and stored at 4°C until use. Aliquots of the stock MPA solutions were diluted 
with drug free plasma to give 6 calibrators (0.1, 1,5, 10,20 and 40 ~IPA mg,'L). Two 
in-house QCs were prepared in drug-free plasma with a final concentration of 2 and 20 
mg/L \1PA. Calibrators and QCs were stored at -20°C until use. 
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Sample preparation 
Over 95% of ~PA is bound to albumi~ whereas only a limited amount of the drug is 
distributed within blood cells [39]. Therefore, plasma is the matrix of choice for the 
assessment of MP A levels in the blood. 
Five hundred microliters of plasma was mixed with 1.5 mL of water. 50 IlL of internal 
standard and 750 ~L of 0.1 N HC!. The mixture was applied to a C 18 solid phase 
extraction column pre-conditioned with 2 mL of methanol followed by 2 mL of water. 
The column was dried and then eluted with 1 mL of methanoVO.1 ~ acetate buffer 
(80:20 v/v) pH 4. Samples were collected in HPLC vials. 
HP Le apparatus and conditions 
A System Gold HPLC equipped with a model 166 UV detector set at 254 nm and a 
model 507 autosampler (Beckman, Fullerton, CA) were used. The autosampler was kept 
at room temperature, and a 50 JlL aliquot sample was injected. The separation was 
carried out at room temperature using a C18 column, 250 x 4.6 mrn, 5 /lm (Hypersil 
BDS, Hewelett Packard, Ge). A guard column (LiChrosper 100 RP-18, 5 /lm) was 
placed just before the column. The mobile phase for elution of the column was 45%) 
acetonitrile and 55% aqueous phosphoric acid (0.05%), at flow rate of 0.8 mL/min. Data 
were collected and processed using a 32 Karact software for HPLC system (Beckman. 
Fullerton, CA). 
Assay validation 
\lethod performance was determined in accordance with the FDA Guidance for 
Bioanalytical Methods Validation for Hwnan Studies [36]. 
MPAG 
MPAG was enzymatically hydrolyzed to MPA using ~-glucuronidase (100,000 U.'rnL. 
Sigma, St Louis, MO). This enzyme must be stored at 4°C under darkling conditions. to 
avoid degradation. ~-glucuronidase solution was diluted \\ith phosphate bufTer (0.1 ~L 
pH 6) to reach a concentration of 100 VlmL, and 950 ~L of the final solution was added 
to 50 ~L of plasma for each sample. The mixture was incubated for 1 h at 37°C and 
then processed as for total MP A determination. Final MP A concentration was the sum 
of the contribution of MPA present in each sample, and MPA derived from \IPAG. 
Therefore, MPAG concentration was estimated by subtracting the \IPA concentration 
(previously analyzed without ~-glucuronidase) from total drug concentration\. measured 
after addition of ~-glucuronidase, and normalizing for the molecular weight of both 
compounds. 
FreeMPA 
Materials 
The Centifree Micropartition System (Amicon, Beverly, MA) with a molecular weight 
cut-off of 30 KD was used to obtain an ultrafiltrate for free MP A determination, and the 
devices were centrifuged in a Beckman centrifuge with fixed angle rotor (JA21). 
Because some batches of filters were found to contain impurities that interfered with the 
chromatograms, all filters were routinely sonicated and washed with methanoVwater 
(1: 1) before use. 
Stock solutions, calibrators, and quality control standards 
\Vorking solutions of ~lPA (1 mgIL) and PTA (2.5 mg.,1.J) wen~ prepared in methanol. 
The \ IPA working solution was used to prepare 6 calibrators in ultraliltrate of drug free 
plasma (0.005, 0.02, 0.04, 0.1, 0.5 and 1 mgIL). Two set of QCs were prepared in 
methanol (at concentration of 0.01 and 0.7 mgIL) and stored at -20°C until use. 
Sample preparation 
For ultrafiltration procedure, 800 f.1L of plasma was added to the sample reservoir and 
the tube centrifuged at 5500 rpm (at 20°C) for 40 minutes, yielding approximately 400 
. f.1L of ultrafiltrate. Three hundred-fifty f.1L of ultrafiltrate was mixed with IS (50 J.1L) 
and with a phosphate buffer (l0 f.1L, pH 2), and transferred in a polypropylene vial. 
HP Le apparatus and conditions 
HPLC system and column were the same used for the assessment of total MPA. 
Injection volume was 100 f.1L. The mobile phase consisted of solution A (250 ml 
acetonitrile and 300 mL of 20 mM phosphate buffer pH 3.0) and solution B (700 ml of 
acetonitrile and 300 mL of 20 mM phosphate buffer pH 6.5), eluted at flow rate of 1.2 
mL/min with a gradient from 3% B to 100% B as follows: 
Time (min) %B Duration (min) 
4.5 25 0.5 
12.0 100 0.5 
14.5 3 0.5 
30.0 inject 0.1 
Compounds were quantified by absorbance at 215 nm. Data were collected using a 
recorder Shimadzu and processed with Microsoft Excel. 
Assay validation 
Method performance was detennined in accordance with the FDA Guidance for 
Bioanalytical Methods Validation for Human Studies [36], as previously described. 
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TotalMPA 
Chromatographic separation 
Results 
As shown in Figure 1, MP A (retention time 6.3 min) and IS (retention time 4.6 min) 
were well resolved and no interference was observed from plasma peaks at the elution 
. times of these analytes. In addition, analysis of plasma samples from transplant 
recipients receiving immunosuppressants other that MMF revealed no interfering peaks 
from endogenous and exogenous compounds. The chromatographic run required 8 min 
per sample. 
Linearity 
The assay was linear in the concentration range from 0.1 to 100 mgIL with a mean 
regression coefficient value of 0.999 of 10 replicated curves (0.1, 0.5, 1, 5, 10, 20, 40, 
60, 80, and 100 mg/L). For routine assessment ofMPA plasma levels we used a 6-point 
equation (0.1,0.5, 1,5, 10,20 and 40 MPA mg/L). 
Imprecision, inaccuracy and LLOQ 
Imprecision and inaccuracy were tested, both as intra-and inter-day evaluations, at 5 
concentrations (0.1, 1, 10, 20 and 40 mg/L). As shown in Table 1, the method was 
accurate and precise, with inaccuracy and imprecision less than 10%. LLOQ was set at 
0.1 mgIL. 
Recovery 
The solid-phase extraction procedure had an average recovery of 770/0 for MP A and 
72% for PTA, verified at 2 concentrations (2 and 20 mgIL). 
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Stability studies 
Stability studies were performed using plasma samples spiked with MPA at 2 and 20 
mgIL. MP A concentration values were not affected by freeze-thaw cycles as well as by 
short-term (at room temperature for 10h h) and long-term stability tests (stored at -20°C 
for 1 month). Moreover, both drug concentrations were stable also in the autosampler, 
at room temperature, for at least 24 h. Working solutions (MPA 10 and 100 mgIL) were 
stable at 4°C for at least 1 month (see Table 2). 
Application of the validated method to routine MP A analysis 
The present method has been used to routinely measure MP A plasma trough levels as 
well as complete (from 0 to 12 h) and predicted (from 0 to 2 h) MP A AUCo-12 in kidney 
transplant recipients given MMF or EC-MPS as part of their immunosuppressive 
regimen. Two in-house QCs were used during each analytical run (MP A at 2 and 20 
mg/L). The temporal distribution of the inaccuracy of our HPLC method is presented in 
Figure 2. From June 2005, the method is enrolled in the MP A International Proficiency 
Testing Scheme, with a mean inaccuracy of 6%. 
MPAG 
To test the feasibility of the proposed procedure, we added fresh ~ glucuronidase to 9 
samples spiked with know amount of MPAG (namely,S, 10, 20, 40, 60, 80, 160, 320 
and 500 mg/L) and the mixture was incubated for 1 h at 37°C. Subsequently, the 
samples were processed as previously described for MP A. In these experimental 
conditions, more than 99% of the glucuronide was converted to MP A. 
Beta glucuronidase, stored at °4C and protected from the light, was stable for at least 6 
months. When exposed to the light, these enzymes gradually lose its activity (tested 
periodically using known amount of MP AG). 
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FreeMPA 
Chromatographic separation 
Figure 3 shows the first part of the chromatograms from ultrafiltrate drug-free samples 
spiked with different MP A solutions (we did not collect data during the equilibrating 
period). The retention time of IS and MPA were 7.9 and 12.4 min. The total 
chromatographic run required 30 min per sample. 
Linearity and LLOQ 
The method was linear in the concentration range from 0.005 to 1 mg,!L of \lPA 
---
(~=0.992), and the LLOQ was 0.005 mg/L. 
Imprecision and inaccuracy 
The performance of the HPLC method for the assessment of free \lPA was worSL than 
that used for the measurement of total MP A. However, inaccuracy and imprecision WLre 
still in agreement with the FDA Guidelines (see Table 3). 
Stability 
The concentrations of MPA (0.01 and 0.5 mg/L) prepared in drug free ultratiltrJte 
remained unchanged after three cycles of freeze and thaw, and were not atTected by 
storage of the samples at room temperature for 12 h or by storage of ultrafillrate 
samples in the autosampler for at least 24 h. In every instance th~ percentage diffLr~nce 
from the nominal "alues was below 150/0. 
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Legend to Figures 
Figure 1. Typical chromatograms of mycophenolic acid (YIP A) and para-toluic aciJ 
(PTA, internal standard) from human plasma spiked with r..1PA (0.5 mg. 'L) and frvm a 
patient given mycophenolate mofetil (MMF) as part of the immunosuppressive regimen 
(11.3 mg/L). For comparison drug-free plasma taken from healthy volunteer is also 
given (Bk). 
Figure 2. Temporal distribution of the inaccuracy of the HPLC method used for the 
assessment of MPA plasma concentrations, calculated from two in-house quality 
controls (at 2 and 20 mgIL). 
Figure 3. HPLC chromatograms of free MPA and PTA of ultrafiltrate from healthy 
volunteer (Bk) and from a patient under treatment with MMF (free \lPA 0.07 mg/L). 
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Table 1. Perfonnance of the HPLC method for the detennination of plasma MP A concentration 
Spiked MP A concentration (mglL) 
0.1 1 10 20 40 
Within-day assay 
Mean ± SO (ng/mL) 0.11 ± 0.01 1.1 ± 0.05 10.0±0.1 19.9 ± 0.4 40.1 ± 0.3 
Imprecision (CVV/o) 9.1 4.5 1.0 2.1 0.7 
Inaccuracy ru/o) 7.9 6.5 0 -4.5 -0.5 
Bdwl'cn-day assay 
f\1ean ± Sf) (llglmL) 0.0<) :i 0.01 1.1 -1: 0.1 10.I±O.3 19.9 lO.5 40.4 J 0.7 
Imprecision (C J rr;,~) 11. I 9.1 3.0 2.5 1.7 
Inaccuracy (%) -8.9 7.7 1.0 -1.0 1.0 
Table 2. Results of the stability studies using plasma samples spiked with MPA 
Parameters Results (%) * 
2 mg/L 20 mg/L 
Freeze-thaw (3 cycles) -2.4 + 1.7 
Short term plasma samples (10 h at room temperature) + 3.2 t 2.1 
Long-term plasma sample (28 days at _20DC) 
- 2.0 +3.3 
Autosampler (24 h at room temperature) t 2.0 - 1.1 
Long-tenn stock solution (28 days at -20°C) + 3.0 +4.4 
Long-term stock solution (28 days at +4°C) +4.0 12.X 
·l"of1lparis(}11 bdween meu" results was perji)rmeJ calculating the percenluge difference 
Table 3. Performance of the HPLC method for the determination of free MPA 
Spiked free MP A concentration ("'gIL) 
0.005 0.02 1.0 
Within-day assay 
Mean ± SD (ng/mL) 0.006 ± 0.0011 0.022 ± 0.003 1.12 :1: 0.08 
Imprecision (CVO/u) 18.3 13.6 7.1 
Inaccuracy ~/o) 20.0 10.0 12.0 
Between-day assay 
Mean:1 SD (llg/mL) 0.006 ± 0.0011 0.0191-0.002 1.15 ± 0.05 
Imprecision (C J '%) 18.3 10.5 4.3 
Inaccuracy (%) 20.0 -5.0 14. <) 
Chapter 4 
ASSESSMENT OF SIROLIMUS CONCENTRA TIO~S IN WHOLE 
BLOOD BY HPLC WITH UV DETECTIO~ 
- .t8 -
Human whole blood samples, chemicals and materials 
For the preparation of in-house QCs and calibration standards, different pools of whole 
blood samples from 15 healthy volunteers was used. In addition, subsequent to signing 
of an informed consent form, EDT A anticoagulated whole blood samples were obtained 
from 30 kidney, heart and liver transplant recipients not given SRL. 
Standard samples of SRL (purity ranging from 97 to 98%, according to different 
. batches) and 32-0-desmethoxyrapamycin (internal standard, IS) were generous gifts 
from Wyeth-Ayerst Research Laboratories (princeton, NJ) and furnished with adequate 
information on drug source, lot number, expiration date and certificate of analysis. 
Acetonitrile and methanol (BDH, Milan, Italy) were HPLC grade; acetone and hexane 
HPLC grade were supplied by Fluka (Milan, Italy). Zinc sulphate heptahydrate, 
analytical grade, was purchased from Fluka and a 5% solution was prepared in distilled 
water. All other chemicals were analytical grade. Bond-Elut C 18, 200 mg, 3 ml 
cartridges were obtained from Varian (Leini, Italy). 
Stock solutions, calibrators and quality control standards 
Stock solutions containing 50 and 100 lJg/mL were appropriately prepared in methanol 
for SRL and IS, respectively. SRL working solutions of 100,500, and 2000 ng/mL were 
prepared in 50/50 methanol/water, and for IS a working solution of 1000 ng/mL was 
prepared in methanol. All the solutions were stored at -20°C. 
Taking into account the therapeutic range of SRL trough levels, calibrator samples were 
prepared mixing appropriate volumes of SRL from stock working solutions to EDT A 
anticoagulated human whole blood from healthy volunteers to achieve different 
concentrations from 2.5 to 60 ng/mL (2.5, 5, 10, 15, 20, 40, and 60 ng/mL). Calibrators 
were prepared by diluting each spiking solution to 10 ml with K3 EDTA control human 
whole blood in 10 ml volumetric flasks. The flasks were stopper and shaken to mix. 
- 49-
Pools are measured into 1 mL aliquots in polypropylene tubes and frozen at -20°C until 
use. Three in-house QCs, representing the low, medium and high concentrations. were 
prepared in drug-free whole blood with a final concentration of 3, 10 and 30 nglmL 
SRL. Calibratio~ QCs and reference standards were aliquoted and stored at -20°C until 
use . 
. Sample preparation 
SRL is extensively distributed in red blood cells, independently of concentration and 
temperature [47], so we decided to use whole blood as the preferred matrix for method 
validation. 
One millilitre volume of whole blood sample was pipetted into disposable 
polypropylene tubes and supplemented with 50 flL of IS solution (1000 nglmL). The 
tubes were vortex-mixed for 40 seconds; 1.5 mL of zinc sulphate solution was first 
added followed by a 1.5 mL acetone. The tubes were vortex-mixed for a further 50-60 
seconds and centrifuged at 3000 g for 5 minutes at room temperature. The clear 
supernatant was poured into another polypropylene tube, diluted with 2 mL distilled 
water, mixed and loaded onto a Bond-Elut cartridge (preconditioned with 1 mL 
acetonitrile followed by 1 mL methanol and finally by 1 mL distilled water) placed on a 
Vac Elut 20 Manifold (Varian). The Bond-Elut cartridges were washed with 1.5 mL of 
70% methanoU30% water. In each step the solvent was allowed to drop out from the 
cartridge. Then 500 flL hexane was added and the column was allowed to go dry under 
vacuum. SRL and IS were eluted in polypropylene tubes with 1 mL acetonitrile. In all 
steps the flow rate did not exceed 1 mUmin. The eluate was taken to dryness either 
under a gentle nitrogen stream in a water bath at 37°C or in a model RC 10.09 
centrifugal evaporator (Jouan, Saint-Herblain, France) and the residue was dissolved in 
0.15 mL of water-methanol-acetonitrile (40/30/30) and transferred in a polypropylene 
-so-
vial. Internal calibration curves for SRL were prepared for each set of samples. At least 
60 samples (including controls and calibration curve) can be extracted in 4 h and 
processed by HPLC in less than 20 h. 
HP Le apparatus and conditions 
A System Gold HPLC equipped with a model 166 UV detector set at 278 run and a 
model 508 auto sampler (Beckman, Fullerton, CA) with the sample tray kept at 4°C, 
were used. A 90 JlL aliquot of sample was injected onto reversed-phase C 18, 5 J.1M, 
guard column (Alltima, 7.5 x 4.6 mm, Alltech, Sedriano, Milan, Italy) connected to a 75 
x 4.6 mm column packed with Ultrasphere C8, 3 J..lm (Beckman) heated at 50°C by a 
Model 880 oven (Spark-Holland, Emmen, The Netherlands) and was eluted by a 
mixture of distilled water/methanollacetonitrile (34/30/36) pwnped at a rate of 1 
mllmin. Due to the high percentage of the organic phase that may dry off, resulting in 
increased retention time, the mobile phase was prepared every one or two days before 
analysis, filtered and degassed under vacuum using a polycarbonate O.4-J..lm membrane. 
An in-line filter (0.5 Jlm) was placed between the autosampler and the column. Data 
were collected and processed using a 32 Karat software (Beckman, Fullerton, CA). 
Method Validation 
Method performance was determined in accordance with the FDA Guidance for 
Bioanalytical Methods Validation for Human Studies [36], as described above. 
In addition, the present method has been enrolled in the Sirolimus international 
Proficiency Testing Scheme [42]. For the Proficiency Test initially 78 blinded samples, 
packaged as 5 batches of samples each, were analyzed. In addition. ongoing proficiency 
was tested by analyzing 3 blinded samples from the Reference Laboratory every month. 
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Results 
Chromatographic separation 
Figure 4 displays the chromatograms of extracts prepared from a blank blood spiked 
with known amounts of SRL and from blood of a transplant patient given SRL. The 
retention time of SRL and IS were 13.1 and 14.5 min, respectively, and the 
chromatographic step required 18 min per sample. Both SRL and IS eluted as 
symmetrical and relatively sharp peaks. Blank blood samples from healthy volunteers 
did not show peaks corresponding to SRL and IS retention times. This was confinned in 
30 kidney, heart and liver transplant recipients in a SRL-free regimen. Representative 
chromatogram of a blank sample is shown in Figure 4. On the other han<L a 
concentration-dependent increase in the SRL peak height was documented when known 
amounts of the drug were added to blood samples to achieve a final concentration of 2.5 
and 40 ng/mL, respectively. Moreover, a distinct peak of SRL was found in the blood 
sample collected from a kidney transplant patient given SRL as a part of the 
immunosuppressive therapy. Furthermore, no chromatographic interference was found 
between SRL or IS and other immunosuppressants such as esA, MP A, azathioprine and 
steroids as shown when blood samples from transplanted patients were added in vitro 
with SRL, or when blood from healthy subjects was spiked in vitro with SRL and 
immunosuppressants. Even high concentration of the above mentioned drugs did not 
affect the SRL chromatographic profiles. 
Occasionally a sharp peak occurred in some chromatograms at about 10.5-11 min -
which did not affect the assay's performance - probably dependent on the different lot of 
Bond-Elut cartridges used. 
The minimal overlapping between SRL and IS peaks observed when concentrations 
higher than 40 ng/mL were analyzed did not influence the accuracy of the analysis. This 
was confinned by injecting a lower volume (40 J.1L) of the same sample at t\\~o 
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concentration levels. The complete separation between the analytes was restored and 
results were similar (40 J.1L injection: 39.4±1.1 nglmL; 90 J.1L injection: 39.8±1.0 
ng/mL. 40 J.1L injection: 80.7±5.5 nglmL; 90 J.1L injection: 82.5±4.7 nglmL). 
Linearity 
Linearity was determined by least-squares linear regression analysis of the peak height 
of SRLIIS versus SRL concentration. The method demonstrated excellent linearity over 
the range of2.5-100 nglmL (~, calculated as mean of 10 curves, was 0.998). 
Since SRL trough levels from organ transplant recipients were greatly below the upper 
limit of quantification, we decided to use 7 points ranging from 2.5 to 60 ng/mL for the 
calibration curves used in the routine clinical practice. Linear regression of the peak 
height ratio of the drug/lS versus the concentration for calibration curves produced a 
coefficient of regression greater than 0.998. A typical equation describing the 
calibration curve was y=0.02358 (SE:0.00015)x + 0.02075 (SE:0.00313). 
Imprecision and inaccuracy 
The within-day and between-day coefficients of variation for SRL in whole blood are 
reported in Table 4. The within-day imprecision of the assay, as estimated by the 
coefficient of variation of the measurement from spiked samples, was below 6.6%. The 
between-day coefficient of variation was still low (8.0%). The precision of our method 
was good also when replicates from a patient sample were considered (mean 7.7+0.4 
nUml; CV 5.7%, n=5). The inaccuracy of the method was low and, as expected, data 
were better for the highest SRL concentration tested (40 ng/mL). The result of 
inaccuracy obtained with the lowest concentration of the drug (2.5 ng/mL) was still 
acceptable (8.8%). 
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The extraction procedure of the samples was tested with different blood yolurnes 
(ranging from 300 to 600 JlL) at 7.5 nglmL (mean 7.9+0.4 nglmL; n=5) and 22.5 nglmL 
(mean 22.0+0.7; n 5). In each instances we obtained an acceptable precision (CV less 
than 6.0%). These results suggest that there is no need of additional changes in the 
method protocol when small volume of samples is available. 
LLOQ 
The LLOQ was established at 2.5 nglmL, in agreement with the FDA Guidelines 
(signal/noise ration> 5, imprecision below 20%, inaccuracy between +20%). This is a 
suitable value to detect accurately the expected low SRL trough concentration in 
transplant patients. 
Recovery 
The overall recovery, calculated by comparing the peak-height ratios of spiked samples 
with those obtained by direct injections of the same amount of SRL and IS, was 
checked at 5 and 20 ngimL. The overall recovery was 64.4 + 3.0% for SRL and 63.3 + 
1.9% for IS. 
Dilution integrity 
To establish dilution stability, blood samples at concentration of 100 and 200 ng/mL 
were diluted with SRL-free whole blood, and SRL concentration was determined on 
three replicates. A two-fold dilution of samples with concentration of 100 ng/mL and 
200 ng/mL was associated with an inaccuracy of -2.1 + 3.60/0 and 1.4 + 3.9010, 
respectively, while a S-fold dilution of 200 ng/mL revealed an inaccuracy of -S.4 + 
4.3%. 
• S4· 
Stability studies 
Stability studies were performed using whole blood samples spiked with SRL at 5 and 
50 nglmL. As shown in Table 5, SRL concentration values were not significantly 
affected by freeze-thaw cycles as well as by short-term (at room temperature for 15 h) 
and long-term stability tests (at least 28 days stored at -20°C). Both concentrations of 
SRL were stable, also when leaved in the auto sampler for at least 24 h. 
Working solutions of SRL (methanol/water 50/50) were stable for at least 28 days if 
kept at -20°C, but not at 4°C. 
Application of validated method to routine drug analysis 
We have applied the validated method for the assessment of SRL daily blood 
concentration profile after the morning oral drug administration in several kidney 
transplanted patients. In addition, the present method has been used to routinely monitor 
SRL trough levels from heart and kidney transplant recipients given the drug as part of 
their immunosuppressive regimen. An analytical run was usually performed every 7-10 
days. Two or three in-house QC (prepared separately from the calibration curves) were 
used during each analytical run. In addition monthly samples from the SRL IPTS were 
processed. Temporal distribution of the inaccuracy of our HPLC method (from results 
of the SRL IPTS) from November 2001 to September 2005 is presented in Figure 5. 
The median inaccuracy of the present method was -6.0% (95% confidence intervals: -
8.9 to -3.1 %). 
-ss -
Legend to Figures 
Figure 4. Typical chromatograms of sirolimus (SRL) and internal standard (I.S.) from 
drug-free blood taken from healthy volunteer (Bk), blood spiked with 2.5, 40 ng1mL 
SRL, and a trough blood sample (7.1 ng/mL) taken from a kidney transplant recipient 
immediately before the next oral dose of SRL. 
Figure 5. Temporal distribution of the inaccuracy of the HPLC method used for the 
assessment of SRL whole blood concentrations, derived from the results of the 
Sirolimus International Proficiency Testing Scheme. 
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Table 4. Performance of the HPLC method for the determination ofSRL concentration in whole blood 
Spiked SRL concentration (ng/mL) 
2.5 5 10 20 40 
Within-day assay 
Mean ± SO (ng/mL) 2.7± 0.2 5.0 ± 0.4 10.3 ± 0.2 19.1±0.7 39.3 ± 0.6 
Imprecision (CVO/o) 7.4 8.0 1.9 3.7 1.5 
Inaccuracy CU/o) 8.0 0.0 3.0 -4.5 -l.X 
Between-day assay 
ivkan 1: SD (nglmL) 2.7 ± 0.2 5.0 ± 0.2 10.3 ± 0.3 1 R.X ! 0.5 42.3 ! o.x 
Illlpn:cision (('1"%) 6.6 3.1 2.7 2.7 I.X 
I nacc urac y (%) x.x -0.8 3.0 -5.X 5.7 
Table 5. Results of the stability studies using whole blood samples spiked with SRL 
Parameters Results (%) * 
5ng/mL 50 ng/mL 
Freeze-thaw (3 cycles) 
- 4.1 +2.5 
Short tenn blood samples (15 h at room temperature) + 7.7 - 1.9 
Long-tenn blood sample (28 days at -20°C) +2.4 + 3.7 
Autosampier (24 h at 4°C) 14.4 -I 3.1 
Long-tenn stock solution (28 days at -200 e) 
-+- 4.0 1 6.1 
Long-term stock solution (28 days at 14°C) 1- 32 125 
·(·Uf1IIJtJri.WII Dt'lH't't'II 1Tlt'(Jf/ resul/s was perfurmed ("£l/eu/£l/inK the percen/age dijference 
Chapter 5 
MONITORING OF CYCLOSPORINE IN WHOLE BLOOD 
USING A HPLC-UV METHOD 
- nl -
CsA was measured by UPLC with uv detectio~ using the method from Kahn et al 
[48], with some modifications, as described below. 
Human whole blood, chemicals and materials 
Calibration standards, QCs and blanks were prepared using pools of whole blood 
samples from healthy volunteers (n 15) and from kidney (n=10) and liver (n-l0) 
transplant recipients not given CsA. 
CsA and cyclosporine D (IS) were kindly supplied by Novartis Pharma (Basel, CH), 
with a declared purity of 100%. Methanol and acetonitrile (BDH, UK) were of HPLC 
grade. All other solvents were of analytical grade (Sigma, St Louis, MO). Deionized 
water was prepared using a Milli Q50 system (Millipore, Bedford, MA). 
Stock solutions, calibrators and QCs 
Stock solutions containing 100 mg/L of CsA and IS, as well as working solutions (10 
mg/L for CsA and 20 mgIL for IS) were prepared in methanol. For calibration of the 
analytical system appropriate volumes of CsA from stocked working solutions were 
added to 1 mL EDT A anticoagulated human whole blood to achieve 7 different CsA 
concentrations (20, 50, 100, 200, 500, 1000 and 2000 ng/mL). QCs were prepared 
spiking known volumes of CsA from working solutions to drug free whole blood in 
order to obtain three concentrations (30, 300, 900 ng/mL CsA). CsA solutions, 
calibrators and QCs were stored at -20°C. 
Sample preparation 
To one mL of peripheral vein blood samples we added IS (50 ~L), hydrochloric acid 
O.2N (1 mL), and heptane (1 mL). The mixture was vortexed for 10 sec to lyse the 
blood cells. Subsequently we added diethyl ether (8 mL) and each tube was tightly 
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capped. Extraction of CsA was effected on a reciprocal shaker. The organic phase was 
clarified by centrifugation for 15 min at 3000 RPM. The ether layer was decanted into a 
clear glass tube and washed with sodium hydroxide 0.1 N (lmL). Following a second 
centrifugation for 10 min, the ether layer was transferred into a clean glass tube and 
evaporated to dryness under a gentle nitrogen stream in a water bath at 37°C. The 
residue was redissolved in 200 J.1L of the mobile phase and washed by vortexing for 30 
sec with heptane (1 mL). The sample was finally centrifuged (10 min at 3000 RPM) and 
the lower ,aqueous layer transferred in a polypropylene vial. 
HP Le apparatus and conditions 
A system Gold HPLC with a IN detector set at 214 run and a model 580 auto sampler 
(Beckman, Fullerton, CA) was used. A 50 J.1L of aqueous layer was injected into a C-8 
HPLC column (150 x 4.6 mm, 5 ~, Beckman) heated at 72°C by a LC oven 101 
(perkin Helmer, Milan). Isocratic liquid chromatography separation was carried out 
using a mobile phase of water/methanol/acetonitrile (27/32/41) at a flow rate of 1 
mL/min. Data were collected and processed using a 32 Karact software (Beckman). 
Method Validation 
Method performance was determined in accordance with the FDA Guidance for 
Bioanalytical Methods Validation for Human Studies [36], as described above. 
Since July 2003, this method is enrolled in the Cyclosporine international Proficiency 
Testing Scheme [43]. Ongoing proficiency is tested by analyzing 3 blinded samples 
from the Reference Laboratory every month. 
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Results 
Chromatographic separation 
Figure 6 displays the chromatograms of extracts prepared from a CsA-free sample. a 
blank blood spiked with known amounts of CsA and from blood of a transplant patient 
given CsA. The retention time of CsA and IS were 12 and 16.5 min, respectively, and 
the chromatographic step required 20 min per sample. 
Linearity and LLOQ 
Linearity was determined by least-squares linear regression analysis of the peak height 
of CsAlIS versus CsA concentration. The method demonstrated excellent linearity from 
20 to 5000 ng/mL (~, calculated as mean of 10 curves, was 0.996). The LLOQ was 
established at 15 ng/mL (inaccuracy: 12.3 + 3.3%, imprecision: 15.8 + 4.9%). 
Imprecision and inaccuracy 
The within- and between-day performance of this method was assessed by calculating 
CV% and bias values for the three QCs (30, 300 and 900 nglmL in five replicates at 
each concentration per analytical run) that were assayed in 5 separate analytical runs. As 
shown in Table 6, the performance was satisfactory. 
Recovery 
The overall recovery, checked at 50 and 1000 nglmL ofCsA, was 70.4 + 3.8% for CsA 
and 68.3 + 4.5% for IS, respectively. 
Dilution integrity 
To establish dilution stability, blood samples at concentration of 1000 and 4000 nglmL 
were diluted with CsA-free whole blood, and CsA concentration was detennined on 
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three replicates. A two-fold dilution of samples with concentration of 1000 nglmL and 
4000 nglmL was associated with an inaccuracy of 4.5 + 2.1% and 2.2 = 3.9%, 
respectively, while a 5-fold dilution of 4000 ng/mL revealed an inaccuracy of -3.8 + 
2.8%. 
Stability studies 
Stability studies were performed using whole blood samples spiked with CsA at 50 and 
1000 ng/mL. CsA concentration values were not significantly affected by freeze-thaw 
cycles as well as by short-term (at room temperature for 15 h) and long-term stability 
tests (at least 28 days stored at -20°C). Both concentrations of CsA were stable, also 
when leaved in the autosampler for at least 24 h at room temperature. Working solutions 
ofCsA were stable for at least 2 months, kept at 4°C (Table 7). 
Application o/validated method to routine drug analysis 
The present method has been used to routinely monitor CsA trough levels and full 
pharmacokinetic profiles from kidney transplant recipients given the drug as part of 
their immunosuppressive regimen. An analytical run was usually performed every 2-4 
days. Three in-house QC were used during each analytical run in addition to samples 
from the CsA IPTS (when available). Temporal distribution of the inaccuracy of our 
HPLC method compared with results from the IPTS is presented in Figure 7. The 
median inaccuracy of the present method was -7.9% (95% confidence intervals: -9.8 to 
2.8%). 
- 65· 
Legend to Figures 
Figure 6. Chromatograms of cyclosporine (CsA) and LS. (cyclosporine 0 or CsO) from 
whole blood sample spiked with 25 nglmL CsA and from kidney transplant recipients 
given CsA as part of their immunosuppressive regimen (CsA Co: 243 nglmL, CsA C2: 
581 nglmL). 
Figure 7. Temporal distribution of the inaccuracy of the HPLC method used for the 
assessment of CsA whole blood concentrations, derived from the results of the 
Cyclosporin International Proficiency Testing Scheme. 
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Table 6. Performance of the HPLC method for the determination of CsA levels 
Spiked CsA concentration (ng/mL) 
30 300 900 
Within-day assay 
Mean ± SD (n};lmL) 32±2 297 ± 15 888 ± 23 
Imprecision (CVO/o) 6.3 5.1 2.6 
Inaccuracy (1/0) 6.7 -1.0 -1.3 
Between-day assay 
~ kan ± SD (1l};lmL) 28 ± 3 299 ± 12 X90 ± 21 
Imprecision (( 'J F%) 10.7 4.0 2.4 
Inaccuracy (%) -6.7 -0.3 -1.1 
j 
Table 7. Results of the stability studies using whole blood samples spiked with esA 
Parameters Results (%) * 
50 nglmL 1000 nglmL 
Freeze-thaw (3 cycles) 3.4 -2.3 
Short tenn blood samples (15 h at room temperature) -I- 6.7 - 1.7 
l,ong-tenn blood sample (28 days at -20°C) + 3.1 -/ 1.3 
Autosampler (24 h at room temperature) + 5.0 - 2.2 
Long-tenn stock solution (28 days at -20°C) + 2.0 -I 2.1 
I ,ong-term stock solution (28 days at 14°C) I 3.2 - 1.5 
·coml,oriso" ht'fll't't'fI mea" results W(H perfurmed calc-lIlatinK the pt'rcentaKe dt/F'rt'IIl'C 
Part II 
THERAPEUTIC DRUG MONITORING OF 
MYCOPHENOLIC ACID-RELEAS/l\rG 
FORMULATIONS 
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Chapter 6 
PHARMACOKINETICS HELP OPTIMIZI:\,G ;\lYCOPHE~Ol'-\ TE 
MOFETIL DOSING IN KIDNEY TRANSPLANT RECIPIE:\TS 
-, 
- --
Introduction 
Three large double-blind randomized trials in kidney transplant recipients [49,50,51] 
have shown that addition of MMF, a novel immunosuppressive drug [52], to CsA and 
prednisone allowed reduction in the rate of acute rejection during the first 6 or 12 
months after transplantation as compared to azathioprine- or placebo-treated patients. 
Since then, MMF has been widely used in a fixed daily dose of 2 g, in two divided 
administrations, as a part of a combination regimen with CsA and steroids. A fixed 
dosage of MMF has been proposed also for patients undergoing heart or liver 
transplantation, based on results of clinical trials [53,54], as well as for the limited 
nwnber of patients with chronic nephropathies unresponsive to conventional treatment 
[55]. 
MMF is the morpholinoethyl ester prodrug form of the active immunosuppressive 
molecule MP A, toward which is rapidly converted following oral ingestion [56]. MP A 
is, itself, metabolized to the phenolic glucuronide (MP AG), which is mostly eliminated 
in the urine [56]. By selectively and reversibly inhibiting IMPDH, a key enzyme in the 
de novo pathway of purine synthesis, MP A prevents the proliferation of both T and B 
lymphocytes [52,56]. 
Thus, as in the case of CsA and tacrolimus [57,58,59], individualizing MMF dose 
instead of using a fixed dose, might help to optimize immunosuppression and minimize 
potential toxic effect. This would require routine therapeutic drug monitoring by 
measuring plasma MP A concentration. Previous studies have shown a correlation 
between the MPA AVC and the risk of graft rejection [37]. However, contrary to C~ 
data showing the usefulness of monitoring MP A concentration or defining a therapeutic 
window in tenns of plasma MPA concentrations are scanty [60]. 
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In the current study we examined 1) the need of optimizing MMF dosing by ~lPA 
pharmaCOkinetic monitoring in stable kidney transplant patients: 2) the possible 
association between MPA pharmacokinetic parameters and kidney graft functio~ and 
3) whether measurement of free MP A compared to total plasma MP A concentration 
provides additional information as for MMF -induced change in blood cell count 
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Methods 
Patients 
Forty-six consecutive adult renal transplant patients (17 female, 29 male) who had 
received kidney graft from 6 to 9 months before, were studied (Table 8). All were 
recipients of first kidney transplant from cadaver donors, aged 15 to 58 years. They 
were on triple immunosuppressive therapy with CsA Neoral, prednisone and MMF. 
Patients started with the conventional 2g1day MMF dose, in two divided 
administrations. Eighteen of them, however, required MMF dose reduction within the 
frrst 2 months post-transplant due to adverse events, i.e. leukopenia, thrombocytopeni, 
diarrhoea and CMV infections. Changes in MMF dosing was performed by the 
physicians on the basis of clinical parameters suggesting drug-induced toxicity and not 
based on MP A pharmacokinetics. Thereafter MMF daily dose remained fixed, ranging 
from 500 mg to 2g1day according to patient needs. At the time of the evaluation all 
patients had stable graft function. 
Study design 
The study was described in detail to all patients before admission and informed consent 
was obtained in each instance. On the morning of the study, blood samples were 
collected for routine haematological analysis, and for determination of trough blood 
level of esA and plasma total MPA and MPAG. Then each patient was given the 
morning dose of CsA and MMF and underwent evaluation of simplified 
pharmacokinetic profiles. Thus for CsA pharmacokinetics blood samples were collected 
in heparinized tubes at 60 and 180 minutes after dosing [61] and stored at -20 O( until 
analysis. For MP A and MP AG pharmacokinetics blood samples in EDT A-tubes were 
drawn at 20, 40, 75 and 120 minutes [37]. Thereafter samples were centrifuged at 3000 
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g, plasma separated, and stored at -20°C until analysis for MPA and MPAG 
concentration. In a subgroup of patients (n=23) the percentage of free ~IPA 
concentration at time 0, in addition to total MP A trough level, was determined. 
MPA, MPAG and CsA measurement 
MP A (total and free) and MP AG plasma concentrations as well as CsA whole blood 
. levels were measured by reverse phase HPLC as described in Chapter 3. 
Pharmacoldnetic parameters 
Trough levels of MPA and MPAG were determined. The MPA AUCo-12 was predicted 
using the equation of Hale et al [37]. AVC from 0 to 2 h (AUCo-2) was calculated using 
the trapezoidal rule. For the 2- to 12 h interval, the concentrations (CJ at 6, 8 and 12 h 
were estimated by the empiric equation: 
Ct = 0.14 + 1.25 x Co 
In which Co is the predose MP A level. Main MP A phannacokinetic parameters were 
adjusted for the daily MMF dose and expressed as per g MMF. Free MPA was 
expressed as percentage rate of unbound / total MP A. 
Trough level of blood CsA was determined and the CsA AVCo-12 was calculated using a 
three-point strategy (sampling at 0, 1 and 3 h post CsA dosing) with the follo\\ing 
equation: 
AUCO-12 = 5.189 x Co + 1.267 X C1 + 4.150 X C) + 135.079 [61] 
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Statistical analysis 
Results are reported as means ±SD. Data were analyzed with paired or unpaired t test 
for normally distributed parameters. For non-normally distributed parameters the 
Wilcoxon test was used. The statistical significance level was defined as P<O.OS. 
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Results 
Variability of MP A pharmacokinetics 
Table 9 summarizes baseline graft function and MP A phannacokinetic parameters. 
Serum creatinine and urea concentrations were widely distributed ranging from normal 
to moderate renal insufficiency values. In each patient, however, these values were 
. comparable to those measured during the previous 3 months, indicating stable graft 
function. 
Plasma MPA trough levels ranged from 0.24 to 7.04 mg/L, and the estimated MPA 
AUCO-12 values were in parallel from 10.1 to 99.8 mg·hIL. Similar wide range values 
were found for average MP AG concentration. 
Since in these patients the MMF daily dose was not uniform, although fixed for a given 
patient we normalized MP A pharmacokinetic parameters for the dose regimen. As 
shown in Figure 8 (panel A), only 37% of patients had similar normalized MPA trough 
level, the remaining being largely distributed in the low or high range of the frequency 
profile for a given plasma MPA value. Similarly, a large interindividual variability in 
MPA AUCO-12h was documented (Figure 8, panel B). 
Association between MP A pharmacokinetics and kidney graft function 
Figure 9 reports the correlation between MP A pharmacokinetics parameters and graft 
function. Plasma MP A trough levels were positively and significantly correlated with 
patients' creatinine clearance values (panel A, r=O.50, p<O.O 1). A significant correlation 
was also found between MPA AUCO-12 and renal function measured as creatinine 
clearance (panel B, r=0.52, p<O.Ol). Both MPA trough levels and MPA AUCO-12, 
however, did not correlate with the given MMF dose (r=O.I). 
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Table 10 shows demographic characteristics and functional and pharmacokinetic 
parameters in two subgroups of transplant patients characterized according to MP A 
AUCO-12 > or <40 mg*hIL. The two groups were comparable for gender, body weight, 
kidney donor age as well as number of rejection episodes. Patients with MP A AUCo-12 
group >40 mg*hIL were slightly but significantly younger than those of group <40 
mg*hIL (p<O.OS). Patients with MP A AUCO-12h >40 mg*hJL had better renal function, 
as documented by a significantly lower serum creatinine concentration (p<O.05), and 
higher creatinine clearance (p<0.01) values, than those with lower MPA AUC. This 
finding was confmned even after normalizing creatinine clearance values for body 
surface area to limit the potential influence of gender and body weight on renal function 
estimation. However, no difference in CsA dose, blood CsA trough level as well as 
CsA-AUC was found between the two groups of patients. Similar fmdings were 
achieved when patients were considered according to plasma MP A trough level > or 
<1.5 mg/L (data not shown). 
We also analyzed values of MP A phannacokinetic parameters in patients arbitrarily 
subdivided according to tertiles of serum creatinine concentration, namely <1.3 mgldL 
(mean 1.1 mg/dL normal graft function), >1.3 to <1.6 mgldL (mean 1.5 mgldL mild 
renal insufficiency) and > 1.6 mg/dL (mean 2.1 mg/dL moderate renal insufficiency). As 
shown in Figure 10, the highest MPA AUCO-12 value was associated with the lowest 
terti Ie of serum creatinine concentration. At variance the lowest mean MP A AUCO-12 
values were found in patients with the highest serum creatinine (moderate renal 
insufficiency). Similar findings were observed for MPA trough level: the highest MPA 
trough level (2.33±1.80 mg/L) was linked to the lowest serum creatinine tertile, whereas 
the lower MPA trough level (1.17±O.71 mg/L) was associated with the highest tertile of 
serum creatinine concentration. The difference between MP A AUC or trough levels and 
serum creatinine tertiles was statistically significant (p<0.05). However, CsA dose (130, 
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152, 134 mg/day), blood CsA trough level (194.9, 182.5, 168.5 ng/mL) and CsA-AUC 
(4981,4825,5045 ng/mL.h) were comparable between the tertile groups. 
Plasma free MPAfraction and blood cell count 
The percentage of free MP A trough concentration in plasma of patients with anaemia 
was higher than that in patients with normal red blood cells (RBC) count (RBC <4.2 
x106/JlL: 2.31±0.71 %; RBC >4.2 x106/JlL: 1.63±0.88 %, P<0.05). Similar findings 
were observed with free MPA trough concentration (RBC <4.2 x106/JlL: 0.064±0.025 
Jlg/mL; RBC >4.2 x106/JlL: 0.030±0.022, P<0.05) By contrast total MPA trough 
concentration was comparable in anaemic and normocytemic patients (RBC <4.2 
x106/JlL: 3.32±2.26 Jlg/mL; RBC >4.2 x106/JlL: 3.53±2.57 mgIL). Moreover, the 
percentage of free MP A and the free MP A concentration but not total MP A trough 
values significantly correlated with RBC count (% free MPA: r=0.51, P<0.05; free 
MPA concentration: r=0.50, P<0.05; total MPA: r=0.13, P=0.54; Figure 11) or 
hematocrit values (% free MPA: r=0.46, P<0.05; free MPA concentration: r=0.54, 
P<0.05; total MPA: r=0.27, P=0.21; Figure 11). 
A significantly negative correlation was also shown between percent free but not free or 
total MPA trough level and leukocyte cell count (% free MPA: r=0.45, P<0.05; free 
MPA concentration: r=0.13 P=0.30; total MPA: r=0.18, P=0.41; Figure 12). 
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DisCUJsion 
The first finding of the present study is that in kidney transplant recipients with stable 
graft function given MMF as a part of their antirejection therapy, both plasma MP A 
trough level and MPA AVCO-12h were highly variable despite patients received a fixed 
daily dose of the prodrug, even after norma1ization of values for the different total MMF 
. dosage used by single patients. Difference in MP A pharmacokinetic values can not be 
attributed to poor reproducibility of the assay, since our coefficient of variation for 
MPA measurement by HPLC was 3.4%. On the other hand, our results confinn 
previous observation that, although the bioavailability of MP A is high and approaches 
94% in healthy subjects and renal transplant patients [60], the 12-h dose interval MPA 
AVC showed a > 1 O-fold range for renal transplant patients on a fixed MMF dose of 2 
g/day [60,63]. Moreover, it has been reported in healthy subjects and kidney transplant 
recipients that the plasma MP A concentration-time profile for a single dose of oral 
MMF, after an overnight fast, rapidly increased and peaked approximately after 1 h, 
followed by an initial rapid decrease, and then a secondary peak at 6-12 h [64]. This 
pattern is probably attributable to an enterohepatic pathway involving MP AG passage 
into the gastrointestinal tract via biliary excretion, conversion to MP A via glucuronidase 
action in gut flora, and reabsorption of the latter into the systemic circulation [56]. Thus, 
the interpatient MP A pharmacokinetic variability as well the documentation of an 
enterohepatic circulation pathway for MP AGIMP A, would suggest that, as currently 
performed with CsA or tacrolimus, dosage adjustment to achieve an appropriate plasma 
MP A trough level or MP A AVC target concentration should be advisable. 
Somewhat earlier in the clinical development of MMF, a retrospective statistical 
evaluation of MP A dose-interval AUe data in relation to the incidence of acute 
rejection was performed in patients enrolled in a MMF Japanese renal transplant clinical 
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study [65] and given fixed doses of 1, 2, 3, or 4 g MMF daily. A 
Pharm.acokinetic/pharmacodynamic correlation between MP A AUCO-12 and the risk for 
acute rejection [60] was observed in that the risk for acute rejection decreased with 
increasing MP A AUC. A more recent prospective concentration-clinical response study 
confirmed a strong significant relationship between rejection risk and MPA AVC but 
not MMF dose [31]. Moreover, similar results were found in heart transplant patients in 
. which the incidence of acute rejection episodes were clearly related to the MMF plasma 
trough level [66,61], in the presence of therapeutic CsA or tacrolimus blood levels. 
These studies strongly support the need of therapeutic drug monitoring to optimize 
MMF dosing and reduce the risk of graft rejection early post-transplant. Here we 
extended these observations and found a significant correlation between MPA AUCO-
12 and graft function (as creatinine clearance) in kidney transplant recipients 6 to 9 
months post-surgery. Moreover patients with renal function in the highest tertile of 
serum creatinine concentration had the lowest MPA AUCO-12 and trough level, despite 
no difference in CsA exposure between the tertiles. Certainly these findings do not 
allow us to conclude for a causal relationship between plasma MP A levels and renal 
function. However, some considerations may indirectly help to confinn the possible 
association between these parameters. It is known that MP A levels and probably 
metabolism are influenced by protein binding, since MP A is avidly and extensively 
bound to human serum albumin [44]. Many reports describe reduced drug binding in 
disease associated with hypoalbuminemia, e.g. liver disease, various types of renal 
dysfunction, burn injuries and malnutrition [68,69]. However, our transplant patients 
were in good health, with normal serum albumin level, and no clinical and laboratory 
evidence of liver disease, which could exclude a reduced binding of MPA. Moreover, 
free MP A concentrations and free fraction of MP A are elevated in many patients with 
severe renal dysfunction (creatinine clearance <20 mUmin) when on chronic MMF 
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therapy [70], due to both the uremic state per se and by competition for albumin binding 
sites with the renally eliminated metabolite MPAG. This was not the case for the 
patients we studied, who had normal renal function or mild to moderate renal 
dysfunction and average plasma MP AG level <100 mgIL. Furthermore, differences in 
graft function in the two groups of patients with MP A AUC > or <40 mg·hJL were not 
due to different immunological response or CsA exposure, since the number of rejection 
. episodes early post-surgery and CsA dose and pharmacokinetic parameters were 
comparable. This would also exclude that difference in plasma MP A levels were due to 
different blood concentrations of CsA, given the fact that CsA has been previously 
shown to influence MPA trough level in kidney transplant recipients [71]. 
On the other hand, attempts to define the pharmacokinetic relationship for MMF-related 
adverse events have not been always successful and experience suggest that drug dose 
(not MPA pharmacokinetics) provide the most predictive information for adverse events 
such as diarrhoea [50,51,72]. Others, however, have documented that increased level of 
MP A were significantly related to the occurrence of overall side-effects, albeit in a 
small group of patients [73]. Moreover, haematological side-effects such as the low 
haemoglobin level but not low leukocyte count were also related to MP A trough 
concentrations [74]. All these MPA pharmacokinetic data related to total plasma MPA 
concentrations, i.e. the sum of both protein bound and free MP A, but it is only the free 
MPA concentration that has pharmacological activity [75]. Thus, post-transplant total 
MP A plasma concentration may not reflect changes in free MP A level and hence the 
occurrence of MMF -related side-effects. Here, we evaluated the percentage of free 
MP A trough concentration as compared to total MP A level in relation to different blood 
cell counts in a subgroup of the same kidney transplant recipients. Actually, the 
percentage of free MP A concentration over total MP A better reflects the actual 
exposure of patients to the drug than the free MPA concentration itself. We found that 
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the percentage of free plasma MP A but not total MP A significantly correlated \\ith the 
risk of anaemia., indicating the importance of measuring unbound MP A fraction at least 
to monitor changes in blood cell count possibly related to MMF administration. 
Although in most of our patients white blood cell count was in the normal range, a 
significant correlation between free MP A plasma fraction and total leukocyte count was 
also observed. 
In summary, we have confirmed that in kidney transplant recipients given MMF at a 
fIXed dose regime~ as a part of a triple immunosuppressive therapy including CsA and 
steroid, MP A pharmacokinetics parameters are highly variable. We also showed 1) an 
association between MPA AUCO-12 or plasma MPA trough level and graft function, 
and 2) that percentage free but not total plasma MP A trough concentration negatively 
correlated with RBC as well as leukocyte count. 
Altogether these findings suggest that a fixed dose regimen of MMF might no longer be 
the best approach for the management of transplant patients. MP A phannacokinetic 
monitoring might contribute to limit the risk of MMF -related toxicity. Whether 
optimizing MP A dose by monitoring levels may help to maintain graft function in the 
long-term is an intriguing possibility raised by the present fmdings. Prospectively 
designed clinical trials are required to definitely address this important issue. 
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Legend to Figures 
Figure 8. Frequency distribution plot of plasma MP A trough levels (panel A) and MP A 
area under the time concentration curve from 0 to 12 h post-MMF dosing (AUCo.ll) 
(panel B) in 46 kidney transplant patients . 
. Figure 9. Relationship between plasma MP A trough levels (panel A) or MP A AUCo-12 
(panel B) and creatinine clearance values in kidney transplant recipients (n=46). 
Figure 10. Relationship between mean MP A AUCO-12 values and tertiles of serum 
creatinine concentration in 46 kidney transplant recipients. Values are mean + SO. 
*p<O.OS versus <1.3 mgldL serum creatinine tertile. 
Figure 11. Correlation between total MP A trough levels (panel A) or percentage of free 
MPA (panel B) and red blood cell count (RBC) in 11 kidney transplant recipients. 
Relationship between total MP A trough levels (panel C) or percentage of free MP A 
(panel D) and hematocrit in the same patients. 
Figure 12. Correlation between total MP A trough levels (panel A) or percentage of free 
MPA (panel B) and leukocyte cell count (WBC) in 11 kidney transplant recipients. 
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Table 8. Patient demographics and donor characteristics 
No. of patients 
Age (yr) 
Weight (kg) 
Time after T x (months) 
Cadaver/living donor 
Donor age (yr) 
M, male; F, female; Tx, transplantation. 
Range 
46 (29 M/17 F) 
19-6-1 
44-97 
6-9 
46/0 
15-58 
Table 9. Baseline graft function and MPA pharmacokinetic parameters 
Mean Range 
S.creatinine(mgjdL) 1.4 0.8-2.5 
Creatinine clearance (mLjmin) 74.2 22.6-117.6 
S. urea (mg/dL) 58 37-115 
C trough MPA (~lg/mL) 1.82 0.24-7.04 
MPA AUCO- 12 h (pg/mL . h) 42.0 10.1-99.8 
MPAG (pg/mL) 35.7 12.3-93.6 
Table 10: demographics, graft function, ~fPA r.d CsA 
pharmacokinetic parameters in kidney transplant recIpIents 
according to MP A A YC > or < 40 mg*hIL 
NPA AUC0-12h p-values 
>40 j.1Q;mL· h < 40 Jl~FnL· h 
Patients (n) 21 25 
Age(yr) 31.9±9.0 39.0 ± 12.4 p<O.a5 
Sex 11 M,,10F 18 M:6 F 
Weight (kg) 61.7 ± 11.3 67.0 ± 12.9 ns 
Rejection 2 3 ns 
episodes 
Donor age {yr} 33.0 ± 15.5 38.0 + 17.0 ns 
C trough MPA 2.82 ± 1.59 0.97 ± 0.46 p<0.01 
~g/mL} 
MPA AU~12h 61.6 ± 18.8 25.6 + 7.4 p<O.01 
(j.tg/mL· h) 
S. creatinine 1.3 ± 0.3 1.5 + 0.4 p<O.05 
(mg/dL) 
Creatinine clear- 85.7 ± 23.2 64.5 + 17.5 p<0.01 
ance (mLJmn) 
GsA dose (mg/d) 141 ± 24 140+34 ns 
C trough ~ 190 ± 51 197 ± 59 ns 
(ng/mL) 
GsA AUCo...12 h 5201 ± 1011 5340:: 1277 ns 
(ng,;mL' h) 
Chapter 7 
GLUCORTICOIDS INTERFERE \VITH :\IYCOPHE~OLA TE 
MOFETIL BIOA V AILABILITY IN KID:\EY TRA:\SPLA:\TA TIO:\ 
Introduction 
Three large double-blind randomized trials [49,50,51] in kidney transplant recipients 
have shown that the addition of the novel antirejection drug MMF to an 
immunosuppressive regimen consisting of CsA and prednisone significantly reduced the 
rate of acute rejection during the first 12 months after transplantation as compared to 
azathioprine- or placebo-treated patients. Since then, MMF has been widely used in a 
flXed daily dose of 2 g, in two divided administrations, as adjunctive therapy in 
combination with a calcineurin inhibitor, CsA or tacrolimus, and steroids. Recent 
evidence, however, suggests that a fixed dose regimen of MMF might no longer be the 
best approach for the management of transplant patients, and drug pharmacokinetic 
monitoring is advised [19,37,60,66]. 
Following oral administration MMF is rapidly absorbed and hydrolyzed to the active 
compound MPA, by non-specific intestinal esterases [56]. MPA is then converted to 
inactive metabolites by glucuronidation mediated by the human uridine diphosphate 
glucuronosyltransferase (UDp-On enzyme family [56]. The main metabolite, 7-
hydroxy-glucuronide (MP AO), is excreted in urine but may contribute to the 
enterohepatic circulation of MP A after excretion into the bile and hydrolysis in the 
gastrointestinal tract [75]. Recent reports also demonstrate that at least two acyl 
glucuronides ofMPA can be detected in the blood and formed in vitro [76]. 
Modulation of MP A metabolism by concomitant administration of drugs other than 
MMF may, therefore, result in the modification of MPA clearance and eventually 
bioavailability. Previous studies in transplant recipients have indeed sho\\n that CsA 
influences MP A phannacokinetics to the extent that a significant difference was found 
in the MP A trough level between CsA versus non-CsA treated patients, despite they 
~ --ted with an identical MMF dose [71]. Changes in ~fPA exposure may be 
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ally and clinically relevant, as indicated by increasing evidence of a causal 
__ ~hip between MPA phannacokinetics and acute rejection [19J7,60,66] or 
incidence of MP A-related side effects [73,77]. 
Glucocorticoids have been reported to induce glucuronosyltransferase expression, 
enhancing the activity of UDP-GT in rat hepatocyte cells in culture and in vivo in 
rodent animal models [78]. Both UDP-GT lA and 2B isoforms are up-regulated by 
dexamethasone in a dose- and time-dependent manner [79]. Moreover, a precocious 
development of UDP-GT activity occurred in fetal rats after glucocorticoid 
administration to the mothers [80]. All together these observations led us to hypothesize 
that glucocorticoids, by modulating UDP-GT activity could interfere with MP A 
metabolism in transplant patients given steroids and MMF as a part of their 
immunosuppressive therapy. The theoretical impact of steroids on MPA 
pharmacokinetics, however, has not been investigated so far. 
In the current study - which is a part of a multicenter clinical trial aimed at investigating 
the steroid-sparing potential of a MMF-based regimen in kidney transplants - we 
sought: 1) to compare the MP A pharmacokinetic profiles in the early post-transplant 
period (within the first month), when patients were given relatively high dose steroids, 
with those in the later phase (6 months post-transplant) under a lower maintenance 
corticosteroid regimen, while receiving a fixed daily dose of MMF; 2) to examine the 
effect of steroid withdrawal on MP A bioavailability in the same kidney transplant 
patients by comparing MPA pharmacokinetics at 6 month post-surgery (while on MMF, 
steroids and CsA), at the end of the steroid tapering phase (9 months post-transplant) 
and of follow-up (21 months post-transplant). 
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Patients 
Twenty-six consecutive adult renal transplant patients (IS males, 11 females) - enrolled 
as a part of a clinical trial aimed at investigating the steroid sparing potential of a MMF-
based immunosuppressive regimen [38] - were included in the present study. All were 
recipients of first kidney transplant from cadaver donors, and aged from 19 to 61 years. 
They were on triple-drug immunosuppressive regimen consisting of CsA Neora1~ 
methylprednisolone (MP) and MMF during the first 6 months. In this period Neoral 
dosing was established on the basis of blood CsA trough levels targeted to 250-440 
ng/mL, 200-300 nglmL and 150-250 ng/mL from day 0 to 7, day 8 to 30, and month 2 
to 6 post-transplant, respectively. After intraoperative infusion of 500 mg 
methylprednisolone (MP), steroid dosing was then progressively tapered to 16 mg/day 
up to day 12 post transplant, with maintenance 8 mg/day dose achieved by 4 months 
post surgery and maintained for 2 months (month 6). MP was then progressively 
tapered over 90 days, and then withdrawn. Patients in the control group were on triple 
immunosuppressive therapy with CsA, MP (8 mg/day) and MMF. All patients started 
with the conventional 2 g/day MMF dose, in two divided administrations. Ten of them, 
however, required MMF dose reduction within the first 6 months post-transplant due to 
adverse events. Changes in MMF dosing were performed by the attending physicians 
based on clinical parameters suggesting drug-induced toxicity, but not on MPA 
pharmacokinetics. Thereafter, MMF daily dose remained fixed, ranging from SOO mg to 
2 g/day according to patient needs. 
At 6 months post-transplant~ patients were allowed to enter the steroid-sparing phase if 
the following inclusion criteria were met: serum creatinine ~ 2.0 mgldL; stable renal 
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function in the last 3 months; proteinuria < 1 glday; no more than 2 acute rejection 
episodes in the fll'St 6 months; no previous steroid-resistant acute rejection episodes. 
The study was described in detail to all patients before admission and informed consent 
obtained in each instance. 
Study design 
In this prospective study we first examined the effect of steroids on MP A 
pharmacokinetic profiles by comparing kinetic parameters early post-transplant (within 
the frrst month), when patients were given relatively high dose of steroids, with those at 
6 months post-surgery under a lower maintenance steroid dosage, but still on triple 
immunosuppressive drug regimen (Figure 13). In the same patients we then assessed the 
impact of steroid withdrawal on MP A bioavailability evaluating MP A pharmacokinetic 
par~eters and MP AG trough concentration at different time points, namely at month 9 
(end of steroid tapering phase) and month 21 (end of follow-up) post-transplant (Figure 
13). As control for this second phase of the study, an additional group of 12 kidney 
transplant recipients were also monitored at month 21 post-transplant, when they were 
still on triple-drug therapy with esA Neoral, steroids, and MMF. 
Moreover, in a subgroup of 12 study patients the percentage of free MPA at time 0, in 
addition to total MP A trough level, was determined within the first month and at 6, 9 
and 21 months post-transplant. 
On the morning of the pharmacokinetic studies blood samples were collected for routine 
biochemical analysis and for determination of trough level of plasma MP A, MP AG and 
blood esA. Each patient was then given the morning dose of MMF and esA and 
underwent evaluation of simplified pharmacokinetic profiles. For MP A 
pharmacokinetics, blood samples in EDT A-tubes were dra\W at 20, 40, 75 and 120 
minutes [37]. Thereafter, samples were centrifuged at 3000 g, plasma separated, and 
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stored at -20°C until analysis by HPLC. For CsA pharmacokinetics, blood samples 
were collected in heparinized tubes at 60 and 180 minutes after dosing [61] and stored 
at -20°C until analysis. 
MP A, MP A G and CsA measurement 
MPA (total and free) and MPAG plasma concentrations as well as CsA whole blood 
levels were measured by reverse phase HPLC as described in Chapter 3. 
Pharmacokinetic parameters 
Trough levels of MPA and MPAG were determined. The MPA AUCO-12 was predicted 
using the equation of Hale et al [37]. AUC from 0 to 2 h (AUCO-2) was calculated using 
the trapezoidal rule. For the 2- to 12 h interval, the concentrations (C t) at 6, 8 and 12 h 
were estimated by the empiric equation: 
Ct = 0.14 + 1.25 x Co 
In which Co is the predose MP A level. Main MP A pharmacokinetic parameters were 
adjusted for the daily MMF dose and expressed as per g MMF. Free MPA was 
expressed as percentage rate of unbound / total MP A. 
Trough level of blood CsA was determined and the CsA AUCO-12 was calculated using a 
three-point strategy (sampling at 0, 1 and 3 h post CsA dosing) with the following 
equation: 
AUCO-12 = 5.189 x Co + l.267 X C1 + 4.150 X C3 + 135.079 [62] 
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Statistical Analysis 
Results are reported as means -+- SD. Data were analyzed with paired and unpaired t test. 
Correlation between CsA AUCO_12 and plasma MPA clearance was perfonned by 
regression analysis. The statistical significance level was defmed as p<O.OS. 
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Results 
MPA and MPAG pharmacokinetics in the early post-transplant period 
Mean MMF dose was numerically but not significantly higher within the fust month 
than at 6 months post-transplant (1846+375 vs. 1596+530 mg/day). Dose-normalized 
MP A trough levels in the fust month post-transplant tended to be lower than 6 month 
post-Tx values, but the difference did not reach statistical significance (1.3 7+0.62 
versus 2.00+1.26 mg/L). Similarly, a significantly lower dose-normalized maximum 
plasma MP A concentration in the fust month as compared to 6 months post-transplant 
was found (7.34+5.47 vs. 17.16+10.01 mg/L; p<0.05). As shown in Figure 14 (panel 
A), dose-normalized MPA AVCO-12 was lower at 1 than 6 months post-surgery, \\ith 
values achieving statistically significant difference (32.94+10.98 versus 50.87+22.37 
mg*hIL/g MMF; p<O.OI). Consistent with the change in AVC, mean apparent plasma 
clearance of MP A was significantly higher in the first month than at 6 months post-
transplant (p<0.01, Figure 14, panel B). When absolute, non-normalized values ofMPA 
trough, maximum plasma concentration and AVC were considered, similar results were 
found. 
By contrast, MPAG trough levels were significantly higher in the first month as 
compared to month 6 post-transplant values (50.72+34.06 versus 33.28+14.22 mg/L; 
p<0.05). 
In the subgroup of patients, in whom the percentage of free MP A was also measured. 
higher values in the first month as compared to 6 months post-surgery were found 
(5.98+l.63 versus 2.23+0.59%, p<O.OI). 
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MPA and MPAG pharmacokinetics after steroid \dthdrawal 
Table II summarizes the variation in MP A pharmacokinetic parameters at the end of 
tapering and after complete steroid discontinuation. 
Dose-normalized MP A trough level progressively increased from month 6 (triple 
therapy) to month 9 (end tapering) and month 21 (dual therapy) post-transplant. The 
latter MP A trough level value was significantly higher (p<0.05) than that measured at 
the same time point post-surgery in control patients who were still on triple therapy \\ith 
CsA, steroids and MMF. Dose-normalized peak MP A concentration also tended to 
increase with time as compared to month 6 values. Therefore, at the end of follow-up 
(month 21), peak MP A levels were significantly higher (p<0.05) than at month 6 and 9 
post-transplant. In patients who discontinued steroids, higher (p<0.05) peak MP A levels 
than in controls on triple drug therapy at month 21 post-surgery were also found. 
Similarly, normalized MPA AUCO_12 progressively increased, reaching statistical 
significance (p<0.05) at month 21 as compared to month 6 post-transplant. The 
difference in MP A AUCO_12 values were even more significant (p<0.0 1) when patients 
who discontinued steroids and controls were compared. Apparent plasma clearance of 
MPA showed progressive and significant decline (p<0.01) up to month 21 post-
transplant in patients with steroid withdrawal (Figure 15). A statistically significant 
difference in plasma MP A clearance between steroid withdrawal and control groups 
was also documented (p<0.01). Consistently, MPAG trough levels progressively 
declined in patients who discontinued steroids reaching statistical significance at month 
21 as compared to month 6 post-transplant (24.30+ 1l.43 versus 33.28+ 14.22 mglL: 
p<0.05; Figure 16). At this time point MP AG trough levels were also significantly 
lower than in control group (36.43=17.65 mg!L: p<O.05). 
Despite changes in these phannacokinetic parameters associated with taperIng and 
discontinuation of steroids. percentage of free ~IP:\ measured in the subgroup of 
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patients was comparable at the three observation time points (month 6: 2.23=0.59~,o: 
month 9: 2.40+0.53; month 21: 2.51 +0.34%). 
Impact of CsA on plasma MP A pharmacokinetics 
Since lowering CsA exposure per se may be a factor that affects ~IP A phannacokinetics 
[39,71], we also measured CsA pharmacokinetic parameters in the same patients 
undergoing steroids tapering and withdrawal, and in controls still on triple-drug regimen 
up to month 21 post-transplant, and related them to changes in plasma MPA clearance. 
As reported in Table 12, there was a numerical reduction in CsA dose in patients who 
discontinued steroids from month 6 to 21 post-surgery. This was paralleled by a 
tendency to decline of CsA trough levels and AUCO_12 values. Changes in CsA 
pharmacokinetic parameters were associated with decrease in plasma MP A clearance 
(Table 12). In control patients at month 21 post-transplant both blood CsA trough and 
CsA AUCO_12 values were even numerically lower than those in patients with steroid 
withdrawal at the same time-points (Table 12). Nevertheless, control patients on triple-
drug therapy had significantly higher plasma MP A clearance than patients on dual-drug 
regimen at month 21 post-transplant (Table 12). By regression analysis, no significant 
correlation was found between AUCO-12 and plasma MPA clearance values when data 
of the two groups of patients were considered (r=0.012, P=0.914, Figure 17). 
Biochemical and haematological parameters 
Table 13 shows renal function. as serum creatinine and serum urea concentration. as 
well as serum albumin level - factors that could potentially affect ~ lPA binding and 
pharmacokinetics [44,69] - in the study patients and controls. Serum conccntrations of 
creatinine and urea did not change to a significant extcnt during the follow-up in 
patients who discontinued steroids, and mean values were comparable to those of 
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controls at month 21 post-transplant. Similarly, serum albumin concentration remains 
stable and comparable in the two groups of patients. 
There was a progressive reduction of red and white blood cell count in parallel \\ith 
tapering and discontinuation of steroids, which was associated with the increased :\IPA 
exposure (Table 13). A significant correlation between MPA AUCO-12 and red blood 
cell count during the study period was also found (r=0.33; p<O.Ol). 
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Discussion 
Potential pharmacokinetic interactions between MP A and other immunosuppressive 
agents may induce significant changes in MP A exposure with relevant clinical 
consequences in term of efficacy and side effects. 
Here we found that in cadaver kidney transplant recipients on immunosuppressive 
. therapy with CsA Neoral, steroids and fixed dose of MMF, plasma clearance of MP A 
was higher early post-surgery than at 6 months when patients were still on triple-drug 
regimen. This translated into a lower MP A daily exposure within the first month post-
transplant. 
The reasons for lower MP A exposure early post-transplant could be multifactorial. Poor 
gastrointestinal absorption of MMF in the peri operative phase may account, at least 
partially, for these MP A pharmacokinetic differences. This possibility is supported by 
the fact that the maximum MP A concentration achieved in the plasma, which reflects 
the degree of drug absorption, was also lower in the first month post-transplant than at 6 
month. 
In addition, a potential effect of CsA on MP AG enterohepatic circulation pathway can 
not be excluded [39,71]. Different MPA levels could also reflect differences in the rate 
of drug metabolism through modulation of the glucuronosyltransferase enzyme in the 
liver. In this respect, in vitro evidence is available that glucocorticoids, which are 
usually given at high daily doses in the early postoperative period as a part of the 
immunosuppressive therapy, enhance the activity of UDP-glucuronosyltransferase in 
adult rat hepatocytes in culture and in human liver specimens [78,79,80]. These fmdings 
raise the possibility that in our patients high dose steroids early post-transplant activate 
pathways of MP A metabolism, eventually leading to lower than expected exposure to 
MPA. Induction of liver UDP-glucuronosyltransferase by glucocorticoids might also 
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enhance the production of the main MP A metabolite, MP AG [75], which in tum 
displaces MP A from the albumin binding sites increasing the free plasma fraction of the 
compound [44]. This was indeed what we have found in the present study in which the 
MP AG concentration and the percentage of free MP A were almost 2 fold higher early 
post-transplant than at 6 months when patients were on low maintenance steroid dose. 
On the other hand, the high percentage of free MP A might compensate the overall lower 
MP A bioavailability early post-transplant, which was expected to translate in less 
MMF-induced immunosuppression. 
While together these results are quite supportive of the involvement of steroids in the 
metabolism ofMPA, at this stage they are still indirect and not conclusive. We therefore 
sough to examine in the same kidney graft recipients the impact of steroid withdrawal 
on MP A pharmacokinetic parameters starting at 6 months post-surgery. Although MMF 
dose was unchanged, the apparent MP A plasma clearance and the MP AG trough levels 
progressively declined during the three month steroid tapering, and further reduced after 
discontinuation of the drug, resulting in higher MP A exposure. By contrast, control 
patients, still on triple-drug therapy including steroids at the end of follow-up, had 
significantly higher MP A plasma clearance and MP AG trough values. All together, 
these findings confirm our initial observation that steroids affect MP A 
pharmacokinetics. 
However, an additional confounding factor in the interpretation of our results derives 
from published observations that also esA may interfere with MPA metabolism [39,71]. 
Lowering esA exposure, as it occurred in patients discontinuing steroids, is indeed a 
factor that could have decreased the MP A plasma clearance and then enhanced MP A 
bioavailability. To explore this possibility we compared esA and MPA bioavailability 
in patients who underwent steroid withdrawal and in controls still on standard 
immunosuppression with esA, steroid and MMF at 21 months post-transplant. 
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Although in patients who discontinued steroids CsA relative bioavailability was higher 
than in the control group, MP A plasma clearance was markedly lower in the fonner 
group. This indicates that the contribution of CsA to the observed MP A 
pharmacokinetics changes in patients discontinuing steroids was marginal, if any. 
Failure of CsA to affect MP A metabolism was also supported by the lack of any 
correlation between patient exposure to CsA and MP A plasma apparent clearance 
values considering the whole patient and control population, although possible 
deficiencies of MP A clearance calculation can not be excluded. These findings are 
seemingly at variance with results of MP A monitoring in kidney transplant recipients 
showing highly significant difference in MP A concentration between patients treated 
with or without a CsA-based regimen [39,71,81]. It should be considered, however, that 
in the latter studies the influence of CsA on MP A pharmacokinetics was documented 
through comparison with a completely CsA-free regimen, whereas our patients were 
still on CsA-treatment. This is in line with evidence by other investigators that in a 
comparative study on the effect of conventional CsA or tacrolimus dose, no impact of 
CsA on MPA trough level was reported [82,83]. Thus we can speculate that CsA may 
interfere with MP A pharmacokinetics only when significant variations in patient's 
exposure to CsA may occur, or when we compare CsA-based with tacrolimus-based 
regimens, under comparable treatment with steroids [84]. 
It is known that MP A concentrations and metabolism are influenced not only by co-
medication but also by protein binding - MP A is avidly bound to human serum albwnin 
[44] - renal dysfunction, and liver disease [69] which could have also contributed to the 
changes in MP A pharmacokinetics we found during follow-up. However, the patients 
were in good health, with normal serum albumin level and no clinical and laboratory 
evidence of renal or liver disease during the entire study period. 
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Changes in MP A exposure may be biologically and clinically relevant. Ind~ed. 
according to previous observation [74], RBC count simificantlv correlated \\ith the 
- ~ 
~PA AUCO-12 as documented by a progressive reduction in RBC values associated 
with increase in MPA exposure. More important, however, is the fact that normal renal 
function and no acute rejection episodes were reported in patients who discontinued 
steroids but without any changes in the remaining immunosuppressive regimen. This 
would imply that the enhanced MP A exposure compensates, at least in part. the 
apparently lower immunosuppressive level achieved with the dual therapy of CsA and 
MMF. 
Our present findings may be of clinical value also in the light of recent data that \ 1\IF 
reduced the risk for development of chronic allograft failure and late renal allograft loss 
independently of acute rejection [85]. 
In conclusion, this is the first demonstration that corticosteroids interfere with \IPA 
bioavailability in solid organ transplant patients. Discontinuation of steroid dosing 
reduces the apparent plasma MP A clearance and thus enhances the total bioavailability 
of the compound. Higher MP A exposure may help to overwhelm the lower overall 
immunosuppression provided by the remaining unchanged dual drug regimen, while 
allowing patients to safely avoid the side effects of long-tenn steroid administration. 
Whether MP A pharmacokinetic changes induced by steroid withdrawal translate into 
lower risk of acute graft rejection than that reported in patients on conventional 
azathioprine-based therapy undergoing per protocol corticosteroid discontinuation to 
avoid the long-tenn sequelae of the treatment [86], is under investigation in a 
prospectively designed multicenter clinical trial. 
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Legend to Figures 
Figure 13. Study design is reported of MP A pharmacokinetic evaluation during the 
early period post-transplant (high dose steroids), at month 6 Qow maintenance steroid 
dosage), at month 9 (end of tapering steroids), and at month 21 post-Tx (1 year after 
steroid withdrawal) in 26 kidney allograft recipients. A control group of 12 kidney 
transplant patients on triple immunosuppressive therapy at month 21 post-Tx was also 
evaluated. 
Figure 14. AVC (panel A) and plasma clearance (panel B) of MP A within the first 
month after transplantation (while patients were on high dose steroids) and at month 6 
post-transplant (under a lower maintenance steroid regimen) in 26 kidney graft 
recipients on triple immunosuppression with MMF, CsA and steroids. *p<O.OI versus 
fust month post-surgery. 
Figure 15. Changes of plasma MPA clearance during tapering and after steroid 
withdrawal starting at 6 month post-transplant. Month 6 post-Tx: patients on triple-drug 
regimen with CsA, steroids, and MMF; month 9 post-Tx: end of steroid tapering; and 
month 21 post-Tx: one year after steroid withdrawal. #Control patients on triple 
immunosuppressive therapy still at month 21 post-surgery were also included. *p<O.O 1 
versus month 6 and controls; °p<O.05 versus month 9. 
Figure 16. Change of plasma MP AG trough level during tapering and after steroid 
withdrawal starting at 6 months post-transplant. #Control patients still on triple 
immunosuppressive therapy at month 21 post-surgery. *p<O.05 versus triple therapy at 
month 6th and versus controls at month 21 st post-transplant. 
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Figure 17. Regression analysis of the relationship between CsA daily exposure (AUCO-
12h) and plasma MPA clearance in study and control kidney transplant patients. 
R=O.012; P=O.914. Closed and open circles indicate patients who discontinued steroids 
and controls, respectively. 
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Table 11: 
Time post-tx 
6'}, month 
I}, 
9 month 
sl 
21 mOllth 
sl 
21 month 
(Colltrols) 
MMF dose and dose-nonnalized MP A phannacokinetic parameters 
MMF dose 
(mg/day) 
1596 +530 
1500 +598 
1500 +559 
1458 +582 
CtMPA 
(rrg/Vg MMF) 
2.00+ 1.26 
2.15 + 1.52 
3.13 ±2.35 # 
1.64+0.77 
Cmax MPA 
(rrg/Vg MMF) 
17.16 +10.91 
16.78 +9.47 
o 
20.49 +8.77 
15.23 +5.06 
AUCo_12 MPA 
(mg*hlVg MMF) 
50.87 +22.37 
54.91 +24.17 
66.66 +30.92 • § 
45.51 + 13J>6 
Values an: meani SD. ·p<O.05 vs month 6; § p<O.O I vs controls; #p<O.05 vs controls; °p<O.05 vs month 6, 9, and controls 
alld controls. 
Table 12: Impact of esA phannacokinetics on plasma MP A clearance at month 6, 
9 and 21 post-transplant 
6 'hmonth 
/11 h 9 mont 
21' month 
\/ 
J 1 month 
(C 'oil/rots) 
CsA dose 
(mg/12h) 
145+26 
142+31 
128+26 
125+18 
CtCsA 
(ng/mL) 
191+52 
197+63 
178+71 
106+35· 
AUC 0-12 CsA 
(ng·hlmL) 
5313+ 1150 
5093+1252 
4202+869· 
• 3536+769 
CLMPA 
(mVmin) 
398.4+205.4 
368.0JJ57.5 
*#§ 298.4+120.9 . 
402.9+ 147.2 
Values arc meall.1 SD. • p ..... O.OI ~'.\" month 6; #p<O.OI vs month 21 (Controls); §p<O.05 V.f month (). 
Table 13: Biochemical and hematological parameters 
Time post-tx S.Creatinine S. Urea S. Albumin RBC WBC 
(mg/dL) (mg/dL) (g/dL) (xl 06/ JLL) (xl0 3/ ILL) 
III 6 month 1.30+0.33 53.5 + 18.9 3.9+0.4 4.7+0.9 9.2+2.5 
III 9 month 1.42 +0.41 56.6+19.1 3.8+0.3 4.5 +0.8 6.8+2.0 
sl 
21 month 1.34+0.16 58.3 + 14.4 4.0+0.3 4.3 +0.8 * 6.9 ±1.1 
sl 
2 J month 1.33 +0.37 65.1 +26.3 3.7+0.6 4.8+0.6 8.0+2.2 
(Colltrols) 
Values an~ mean + SD. ·p<0.05 vs controls 
Chapter 8 
INFLUENCE OF CO-MEDICATION ON MYCOPHENOLIC ACID 
PHARMACOKINETICS IN ORGAN TRANSPLA~T A TIO:\ 
- lie) -
Introduction 
MP A, the active immunosuppressant form of the pro-drugs MMF and the new 
mycophenolate sodiwn, is a widely used component of immunosuppressive regimens in 
organ transplantation [87]. This immunosuppressant is commonly administered in a 
fixed daily dose. Recent evidence, however, suggests that a fixed dose regimen no 
longer might be the best approach for the management of transplant patients, and drug 
pharmacokinetic monitoring is advised [19,37,60,66]. Indeed, a significant predictive 
value for assessment of the risk for acute rejection [19,37,60], renal function [88] and 
drug-related side effects [74,77] has been shown for the 12-h dose interval MPA AUCO-
12 and, although the data are less precise, for the predose trough MP A concentration. 
Following oral administration, MP A is converted to inactive metabolites by 
glucuronidation mediated by the human UDP-GT enzyme family [56,87]. The main 
metabolite, 7 -hydroxy-glucuronide, is excreted in urine but may contribute to the 
enterohepatic circulation of MP A after excretion into the bile and hydrolysis in the 
gastrointestinal tract [75]. Recently, three carboxyl-linked additional glucuronides have 
also been detected in vitro and in vivo [89]. 
Previous studies have shown that concomitant immunosuppressive therapy significantly 
influences MP A bioavailability. In particular we have documented that glucocorticoids, 
by inducing UDP-GT expression, interfere with MMF bioavailability [90]. Other 
investigators reported significantly increased MP A concentrations in patients treated 
with MMF plus tacrolimus [81,83]. These fmdings led to the hypothesis that the major 
cause for increased MP A levels during co-administration of tacrolimus is inhibition of 
the glucuronidation ofMPA by tacrolimus [83,91]. At variance, Others have shown that 
combining MMF with the other calcineurin inhibitor CsA reduced MP A exposure 
[39,71], suggesting that CsA may inhibit the transport of MPA metabolites into bile 
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from hepatocytes and reduce enterohepatic cycling of MPA, ultimately leading to a 
decrease in MPA concentrations in the 4 to 12-h window of the Aue profile [39]. 
SRL is a new immunosuppressant characterized by a unique mechanism of action and a 
potential ability to synergize with other antirejection drugs [35]. In the clinical practice 
SRL is usually given in association with low-dose calcineurin inhibitors and steroids or 
antimetabolites such as MMF and AZA [92]. However, the use of novel induction 
. therapies (Le. with the humanized anti-CD52 monoclonal antibody Campath-I [93]), 
that provide enough immunosuppression, is allowing the development of different 
immunosuppressive-sparing regimens [93,94,95]. SRL can, therefore, may be safely 
used in combination with Campath-I H induction and MMF avoiding the administration 
of calcineurin inhibitors. 
Emerging data suggest that MP A phannacokinetics in patients receiving concomitant 
SRL therapy might be comparable to the situation observed for tacrolimus. Indeed some 
Authors have previously found that MP A trough levels were significantly higher in 
kidney transplant recipients treated with MMF in combination with SRL as compared 
with those given MMF with CsA [96,97]. However, prospective studies, with strict drug 
monitoring and full pharmacokinetic evaluations aimed at formally assess the effects of 
SRL on MP A exposure are still lacking. 
The current study - which is a part of a protocol aimed at investigating the efficacy of 
Campath-lH induction therapy in a steroid-free regimen in kidney transplantation - was 
designed to test the different, if any, effects of SRL- or CsA-coadministration on MPA 
exposure. To address this issue we : I) measured serially MPA trough levels in patients 
treated with low-dose SRL or low-dose CsA both in addition to low-dose MMF over 12 
months post-operatively; and 2) compared 12-b MP A phannacokinetic profiles in both 
groups perfonned at month 6 and 12 after surgery. 
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Methods 
Patients 
Twenty-one patients (13 men; 8 women) with end-stage renal disease who underwent 
primary kidney transplant were enrolled under an Ethics Committee-approved protocol 
at the Ospedali Riuniti Bergamo, Italy, following written informed consent They were 
allocated to one of the following two study groups according to a randomization design: 
Group 1 (n 11) was assigned to Campath-1H, low-dose SRL and low-dose MMF; 
group 2 (n 10) entered a regimen with Campath-lH, low-dose CsA and low-dose 
MMF. 
Campath-l (Alemtuzumab, Schering Plough, Milano, Italy) was given as a single 
intravenous infusion (30 mg, over 2 hours) intraoperatively on the day of transplant 
(day 0). Corticosteroids were administered for the first 2 days after transplantation. 
Thereafter, patients were free of steroids. Patients randomized to SRL received the drug 
(Wyeth, Rome, Italy) at the oral dose of 4 mg/day in a single morning administration 
starting on the day 1 after transplant. SRL dosing was adjusted to maintain whole blood 
levels within the 5-10 ng/mL range. In the CsA-based group, the drug was started just 
after surgery (1-2 mg/kg/day) and CsA doses were adjusted to achieve trough blood 
concentration of 120 to 200 ng/mL in the first month post-surgery, and of 70 to 120 
ng/mL thereafter. Patients of both groups were given MMF at the oral low dose of 250 
to 750 twice a day starting on day 1 postoperatively according to total blood leukocyte 
count. MMF dosing was adjusted according to plasma trough level targeted to MP A 
concentration of 0.5-1.5 mg/L. 
The administration of prokinetic drugs, resins, or any agent known to interfere with 
MP A absorption, distribution, metabolism and/or elimination was not allowed during all 
the study period. 
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Study Design 
This prospective study first examined the effects of SRL and CsA on dose-adjusted 
MP A trough levels measured every 5 days starting from day 5 plst-Tx, when patients 
reached steady-state of drug distributio~ to day 90, and then at month 4,6 and 12 plst-
surgery. 
Moreover, at month 6 and 12 post-transplant, all patients underwent a 12-hour MPA 
pharmacokinetic profile. On the morning of the pharmacokinetic studies blood samples 
were collected for routine biochemical analysis and for the determination of trough 
levels of plasma MP A and blood SRL or CsA. Each patient was then given the morning 
dose of MMF and SRL or CsA. All the drugs were given orally (MMF and CsA b.i.d., 
SRL once a day). The pharmacokinetics of MP A was based on an analysis of EDT A-
tubes collected from the antecubital vein at 20, 40, 75, 120 minutes and 3, 4, 5, 6, 7, 8, 
10 and 12 h after drug administration. Thereafter, samples were centrifuged at 3000 g, 
plasma separated, and stored at -20°C until analysis. For SRL and CsA 
pharmacokinetics, blood samples were collected in heparinized tubes at 0.5, 1,2,3,4,5, 
6, 8, 10 and 12 hours after dosing and stored at -20°C until analysis. All drug 
measurements were performed by high-performance liquid-chromatography (HPLC) as 
previously described in Chapters 3-5. MP A, SRL and CsA concentration-time profile 
was recorded for all patients, together with the time to reach the maximmn 
concentration (Tmax) and the maximum drug concentration (CmaJ. The AVC from time 
equal to 0 to the last sampling point (12 h) was calculated by the trapezoidal rule. 
Experimental studies have shown that CsA, but not tacrolimus, decreased the 
enterohepatic cycling of MP A [17]. To test this hypothesis, we also estimated the MP A 
AUC from 4 h to 12 h after drug administration (AUC4-12), an interval time 
corresponding to the appearance of a secondary MP A peak due to enterohepatic cycle 
with conversion of MP AG to MP A. 
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The AVCo-12 is recognized as the best predictor of drug exposure. This approach is, 
however, time consuming and increases the discomfort of the patient as it requires 
multiple sampling analysis. As an alternative, abbreviated AVC profiles with limited 
sampling protocols have been proposed [98]. Therefore, as additional analysis, we 
tested the feasibility of a previously published equation to predict daily MP A exposure 
using a limited sampling strategy [37]. This approach requires only 5 samples collected 
in the first 2 hour after MMF admjnistration (at 0,20,40, 75 and 120 min). 
As stated above, MMF dose for each patient was modified according to white cell blood 
count. To take into account this confounding factor MP A trough levels measured from 
day 5 to month 6 post-surgery, as well as MPA pharmacokinetic parameters assessed at 
month 6 and 12 post-Tx, were adjusted for the daily MMF dose. 
Statistical analysis 
Results are reported as means + SD. Unpaired t-test was used to compare MPA levels 
(dose-adjusted trough concentrations throughout the study period and MP A 
pharmacokinetic parameters measured at month 6 and 12 post-surgery) between group 1 
(given MMF with SRL) and group 2 (given MMF and CsA). The statistical significance 
was defined as p < 0.05. The ratio between each MPA value measured in the SRL group 
and the corresponding value measured in the CsA group was used to estimate the degree 
of the differences between the two groups as follows: 
MPA Pharmacokinetic parameter (Co, AUC) measured in the SRL group 
ltatio -- -----------------------------------------------------------------------------------------
MP A Phannacokinetic parameter (Co, AUC) measured in the CsA group 
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Linear regression analysis between MP A AUCO-12 predicted with the equation proposed 
by Hale et a1 [37] and measured CsA AUCo.12 was performed. Agreement between the 
predicted and measured MP A AUC was estimated using the Bland and Altman 
approach [99,100], where the percentage difference is plotted against the mean MP A 
AUC between the two series. We considered acceptable values within 1 SO of the 
differences. 
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Results 
Recipients' demographics 
All patients enrolled in the study were Caucasians. Mean age of recipients was 49 years 
with a range of 24 to 71 years. The majority of renal transplants were performed from 
cadaver donors (90%). Patients randomized to SRL- or CsA-based maintenance 
immunosuppression were comparable as for the distribution of baseline demographics, 
including age, sex, and HLA matching among the donors and the recipients (data not 
shown). 
Immunosuppressive drugs monitoring 
Mean immunosuppressive drug dose, whole blood trough SRL and CsA, and plasma 
trough MP A concentrations are shown in Table 14. As anticipated, the mean SRL 
trough levels fell within the planned range of 5 to 10 ng/mL. The mean dose used to 
achieve these levels was between 3.6 and 4.3 mg/day. Similarly, mean CsA trough 
levels were maintained within the expected range low target range during the 12 month 
follow-up (Table 14). 
Mean MP A trough levels during this period were within the chosen range of 0.5-1.5 
mgIL. However, we observed that, despite quite comparable MMF doses during all the 
study period, MP A levels were close to the high threshold for patients belonging to the 
SRL group and to the low threshold for those of CsA group. To better investigate this 
unexpected finding, we adjusted MP A trough levels for the daily drug given to each 
patient and then studied the temporal distribution of MP A concentrations in the two 
groups of patients. As shown in Figure 18, at each time point starting from day 10 post-
surgery, dose-adjusted MPA trough levels were significantly higher in patients given 
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SRL as compared to those treated with CsA The average ratio of dose adjusted MP A 
trough levels between SRL and CsA groups was 4.4. 
Pharmacokinetic studies 
As shown in Table 14, there were no differences in SRI.. or CsA trough levels within all 
the study period. Similarly, SRL AUCo-24 (283 at month 6 vs 334 ng·h/mL at month 12, 
. p=O.40) and CsA AUCO-12 (3246 at month 6 vs 3080 ng·h/mL at month 12, p=O.63) 
were comparable during the two pharmacokinetic evaluations. 
Results of the MPA 12 h pharmacokinetic studies, performed at month 6 and 12 post-
transplant, are given in Tables 15 and 16. To take into account different MMF doses as 
potential confounding factor, we adjusted all pharmacokinetic parameters for the daily 
drug dose administered to each patient. 
At month 6, we found that MP A trough levels were significantly higher in the SRL 
group compared to CsA. The ratio between the two series of MP A trough levels was 
4.5. Although less pronounced, the same trend was confirmed at month 12 (2.3 + 1.3 vs 
0.9 + 0.4 mgIL/g MMF, p=0.0151). Despite the observed significant differences of 
MP A trough levels, looking at the pharmacokinetic profiles (Figures 19-20), we found 
only slight differences for MP A T max and Cmax between the two groups of treatment At 
variance, dose-adjusted MPA AUCO-12 at month 6 was significantly higher in the SRL 
group as compared with patients given CsA. It should be pointed out, however, that the 
ratio between the two series of AUCO-12 was 1.8, thus greatly inferior to that observed 
with dose-adjusted MP A trough levels (4.5). Again, at months 12 post-Tx, the 
differences ofMPA AUCo-12 were less pronounced, with a ratio between the two groups 
of 1.4. 
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Different effects ofSRL and CsA on MP A enterohepatic cycle 
As shown in Figures 19-20, the main differences in the pharmacokinetic profiles 
between SRL and CsA groups were found in the late phase starting 4 hours after MMF 
administration, whereas no significant differences were observed in the first part of the 
kinetic profile. 
It is now well established that metabolites of MP A undergo enterohepatic recirculation 
. (EHC) and, after hydrolysis in the gastrointestinal tract, release a secondary peak of 
MPA, usually 4 to 12 hours after MMF administration [75]. To assess whether SRL and 
CsA might affect the MPA EHC we measured MPA AUC from 4 h to 12 h after drug 
dosing (AUC4-12). Using this approach we found that dose-adjusted MP A AUC4-12 were 
significantly higher in patients given SRL as compared with those treated with CsA 
both at month 6 (19.9 + 9.2 vs 6.5 + 3.3 mg·hIL) and 12 post-surgery (17.2 + 6.5 vs 6.8 
+ 2.5, mg·hIL; Figure 21). Of note, the ratio of AUC4-12 between SRL and CsA groups 
were higher (month 6: ratio=3.1; month 12: ratio=2.5) as compared with that estimated 
for corresponding AUCO-12. The lack of secondary MP A peak in patients treated with 
CsA may therefore explain the significantly low MP A trough levels in these patients. At 
variance, all patients given SRL had a secondary MPA peak 4 to 12 b after MMF 
administration, ultimately leading to higher MP A trough levels than those given CsA. 
MP A A UCO-11 prediction by limited sampling strategy 
The above mentioned data suggested that trough levels are not the best way to monitor 
daily MPA exposure. Therefore, as additional analysis, we also extrapolated AUCo.l1 
using a previously published equation [37] routinely used in our Clinical Centre to 
monitor patient's exposure to MPA [88,90]. Despite a tendency to overestimate MPA 
exposure (Tables 15-16), the correlation between the measured and predicted AUC was 
good (r=O.90). Bland & Altman analysis [99.100] showed that 85% of values were in 
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the accepted range of + 1 SD. Moreover, this approach reliably predicted the effect of 
concomitant immunosuppressive administration on MP A exposure, as confirmed by 
similar ratios of MP A AUCO-12 between the two groups observed with the measured and 
predicted AUCO-12 (month 6, measured AUCO-12: ratio =1.8, predicted AUCo.12: ratio = 
2.1; month 12, measured AUCO-12: ratio =1.4, predicted AUCo.12: ratio = 1.4). Of note, 
there ratios were lower than that observed with the trough levels (month 6, rati0=4.S; 
month 12, ratio=2.6). 
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Discussion 
Potential pharmacokinetic interactions between MP A and other immunosuppressive 
agents may induce significant changes in MP A exposure with relevant clinical 
consequences in terms of efficacy and side effects, especially when a drug is given in a 
fixed dose regimen. 
. In this study we found that in kidney transplant recipients on immunosuppressive 
therapy with MMF, MPA levels were influenced by the concomitant 
immunosuppressive regimen. Indeed, co-administration of SRL and MMF was 
associated with higher dose-adjusted MP A trough levels and AVC than those measured 
under CsA-based regimen. 
So far, only two studies have previously investigated the impact of SRL co 
administration on MP A levels [96,97]. However, both these observations were 
retrospective, considered only MP A trough levels as surrogate marker of daily drug 
exposure, and patients were monitored for a short time after transplantation (3 months). 
As additional weakness, in these studies MP A concentrations were assessed using an 
immunoassay, a method that cross reacts with MP A metabolites, ultimately 
overestimating MPA values [32]. At variance with these studies, we have fonnally 
compared two cohorts of kidney transplant recipients randomized to receive SRL or 
CsA in addition with MMF. Patients were monitored, starting immediately after 
transplantation, over a long follow-up (1 year), using a strict sampling of MPA levels 
measured by HPLC, universally recognized as the gold standard method to assess MPA 
concentrations [63]. With this approach we extended previous finding showing that 
dose-adjusted MPA trough levels were consistently 4- to 5-fold higher in the SRL ann 
than in esA group during all the study period. Of note this difference was present also 
at 1 year post-transplantation. 
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SRL and esA are metabolized by the cytochromes P4S0 3A [3S] with phase I reactions, 
whereas MP A is mainly detoxificated by phase n metabolic reaction, Ytithout 
involvement of the cytochromes P4S0 3A [7S,87]. Indeed, we excluded a potential 
influence of SRL or esA on MP A metabolism. 
As alternative hypothesis, we speculated that SRL and CsA may exert a different action 
on MP A absorption, distribution and/or elimination. Therefore, to better investigate the 
. potential mechanisms involved in this unexpected pharmacokinetic interaction, we 
studied the 12 h MP A kinetic profiles in the two groups of patients, both at month 6 and 
12 after transplantation, when patients were in stable clinical conditions and fixed 
immunosuppressive therapy. Using this approach we confirmed that dose-adjusted 
MPA trough levels were 3-S fold higher in the SRL group. Subsequently, we analyzed 
the daily MP A exposure and found that dose-adjusted MP A AUCo.12 was nearly I.S-2 
fold higher in patients given SRL than those treated with CsA. However, moving from 
time 0 to time 12 h after MMF dosing we observed no significant differences for MP A 
e max and T max between the two groups. This finding led us to conclude that different 
effects of SRL or CsA on MP A absorption, if any, were negligible. 
The plasma concentration-time profile of MP A after oral MMF administration is usually 
characterized by a sharp initial peak around 1 hour and the occurrence of a secondary 
peak usually 6 to 12 hours post dose [7S]. This late peak has been attributed to 
glucuronidated MP A metabolites that undergo enterohepatic recirculation (EHC). EHC 
is the process by which drug, or a drug metabolite, is excreted by the liver into the bile 
and is then reabsorbed back into the portal circulation [60]. In the case of conjugated 
drug metabolites, as MP A metabolites, deconjugation mediated by the colonic bacteria 
in the gut flora precedes the uptake process. After deglucuronidation of the metabolites. 
MP A was reabsorbed in systemic circulation as shown by the appearance of the 
secondary peak [7S]. Any drugs, such as cholestyramine [10 I], able to influence EHC 
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of MP A metabolites may, therefore, affect daily MP A exposure. Indeed, a previous 
study in animals have shown that esA, by inhibiting the transport of MP A metabolites 
into bile from hepatocytes, decreased the enterohepatic cycling of MP A and thereby 
significantly reduced MPA concentrations in the 4- to 12-h window of the AVC profile 
as compared with rats treated with MMF alone or in combination with tacrolimus [39]. 
For the fust time, we have documented a similar trend observed in animals by Van 
. Gelder et al [39] also in humans. Indeed, looking at the pharmacokinetic profile we 
found that, despite no significant differences in MP A AVC in the first few hoW'S after 
MMF administration, patients in the esA group experienced the absence of a second 
MP A peak as documented by significant low MP A AUC4-12 levels compared to patients 
given SRL. According to this analysis of the data, therefore, the post-absorption, post-
distribution phase of the MP A AUe profile during which enterohepatic cycling of MP A 
is most prominent was suppressed in the esA-treated patients. We can therefore 
speculated that interruption of the EHC secondary to inhibition of MP A conjugated 
metabolites' transport across biliary duct epithelium into bile by CsA explained the 
significantly higher values for dose-adjusted MPA eo and AVC in patients receiving 
concomitant SRL and MMF compared to those given CsA and MMF. 
At variance with animal studies [39], we did not measure MPAG levels. We did it in the 
past [88,90]. However, interest in measuring MPAG levels has declined in the last few 
years after the understanding of its pharmacological inactivity and the discovery at least 
other 2-3 acyl glucuronidated MP A metabolites [89]. Although data of MP AG are 
lacking, we are confident that our results may be strong enough to support the 
hypothesis that the observed differences in MP A pharmacokinetic profile in patients 
given SRL or esA are mainly driven by the different effect on MP A enterohepatic 
recirculation. 
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Since EHC usually manifests 6 to 12 hours after MMF dosing, MP A levels 12 h 
(trough) were mainly influenced by the inhibitory action of CsA, with values 3-5 fold 
higher in the SRL group. Given the fact that the secondary MP A peak is usually 50-
70% lower than the Cmax, its contribution to daily MP A exposure is less prominent, as 
documented by only a 1.5-2 fold difference in MP A AUCO-12 between the two groups. 
These findings suggested that trough levels may not be the best way to monitor daily 
MP A exposure, especially when patients are treated with different MMF-based 
therapies. In our routine clinical practice, we estimate MP A AUCO-12 using an equation 
that requires 5 samples collected within the first 2 hours after MMF dosing [37]. In the 
present study we have shown a good correlation between MP A AUCo.12 measured and 
predicted using the equation of Hale et al [37]. Of note, the degree of the 
pharmacokinetic interaction between MP A and SRL or CsA was better predicted with 
the estimated AUC rather then by MP A Co levels. This approach may, therefore, 
represent a useful tool to monitor daily MP A exposure when the full 0-12h 
pharmacokinetic sampling can not be performed, as usually happened in the clinical 
conditions. 
In conclusion, to our knowledge this is the first clinical demonstration that CsA inhibit 
MP A enterohepatic recirculation, ultimately resulting in higher MP A daily exposure as 
compared with other CsA free regimens. As additional finding, the MP A Co-based 
monitoring may overestimate the degree of this pharmacokinetic interaction. These 
results should be carefully taken into account when MMF -based regimen are 
implemented, especially when the drug is administered at a fixed daily dose and patients 
are switched to different poly-pharmacological therapies. 
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Legend to Figures 
Figure 18. Mean dose-adjusted ~ A trough levels from day 5 to year 1 after 
transplantation in kidney transplant recipients treated with SRL or CsA. both in addition 
to MMF. °p<O.Ol vs esA group; *p<O.05 vs esA group. 
Figure 19. Dose-adjusted MP A concentration-time curves from 0 to 12 hours after 
MMF administration in patients at month 6 post-surgery and treated with SRL or Cs.\. 
°p<O.Ol vs esA group; *p<O.05 vs esA group. 
Figure 20. Dose-adjusted MPA concentration-time curves from 0 to 12 hours after 
MMF administration in patients at month 12 post-surgery and treated with SRL or Cs.-\. 
°p<O.OI vs esA group; *p<O.05 vs CsA group. 
Figure 21. Area under the curve from 4h to 12 h (AUC4-12) after ~l\lF administration in 
kidney transplant recipients treated with SRL or CsA. 
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Table 14. lmmWlosuppressive drug dosing and trough levels 
Sirolimus group (n--ll) 
Time Mean SRL Dose Mean SRL trough Mean MMF Dose Mean MPA trough 
Post-Tx (mglday) (nglmL) (mg/day) (",glmL) 
J week 3.6 ± 1.7 4.5 ± 1.9 542 ± 144 0.61 ± 0.56 
1 weeb 4.3 ±0.8 9.1 ±2.2 484 ±63 0.88 ± 0.63· 
J manlll 4.3:t 1.7 9.4 ± 3.2 571 ± 182 1.13 ± 0.94° 
J manilas 4.3 ± 1.8 8.3 ±2.7 621 ± 430 1.54 ± 1.05° 
6 months 4.0 ± 1.5 7.9 ± 2.3 591±202 1.67± 1.12· 
11 mon/hl 4.0 ± 1.0 10.1 ±4.S 1200:t 447 2.7S ± 1.63 0 
Cyclosporine group (n=JO) 
Time Mean CsA Dose Mean CsA trough Mean MMF Dose Mean MPA trough 
Post-Tx (mg/day) (nglmL) (mg/day) (llg/mL) 
I H'ed 343 ± 191 145 ± 110 688 :t 372 0.22 ± 0.14 
1weeu 243± 106 134 ± 59 550 ± 158 0.33 ± 0.32 
I monlh 279 ± 109 133 ± 61 S59 ± 166 0.26 ± 0.14 
J mOIJ/lu 263 ± 74 124 ± 52 608 ±204 0.41 !: 0.34 
6 monllu 269 ± 78 119 ±34 7'0 ± 267 0.49 ± 0.38 
11 months 207 ±'7 101 ± 31 813 !. 2'9 0.66 ± 0.24 
-pcO OS VI CaA poup. umc tiac ~ -p<o 01 VI CaA poup at ... lime poinI 
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Table 15. MP A pharmacokinetic parameters at month 6 post-transplantation in patients 
treated with SRL or CsA both in combination with MMF 
UP A Pharmacokinetic SRLGroup CsA Group P-value 
parameters (n=ll) (n=lOJ 
MMF Dose (mg/day) 591 ±202 750+267 0.1570 
MP A Co (mg/L) 1.67 ± 1.12 0.49 ± 0.38 0.0117 
CJDose (mg/Ug MMF) 2.87 ±2.08 0.63 ± 0.40 0.0082 
Cmu (mg/L) 10.66 ± 9.28 11.74 ± 6.56 0.7829 
C...JDose (mg/Ug MMF) 17.09 ± 8.97 15.28 ± 5.60 0.6221 
Tmu (min) 63 ± 100 46± 19 0.6444 
AUCO-ll (mg·hlL) 24.63 ± 13.88 18.78± 11.47 0.3441 
AUCO-lfDosc (mg·hlUg MMF) 41.52 ± 14.76 23.66 ± 7.77 0.0006 
AUCO-llo (mg·hlL) 32.25 ± 18.41 19.97 ± 11.08 0.1129 
AUCO-l~o (mg·hlUg MMF) 54.59 ± 28.54 25.53 ± 7.10 0.0124 
AUC4_11 (mg·hlL) 11.45 ± 6.14 5.07 ±3.73 0.0186 
AUC4-lfDosc (mg·hlUg MMF) 19.93 ± 9.31 6.46 ± 3.31 0.0012 
• AUC predided ..... die 0Ip .... by fWI c:c .. P7] 
Table 16. MP A pharmacokinetic parameters at month 12 post-transplantation in patients 
treated with SRL or CsA, both in combination with MMF. 
MP A Pharmacokinetic SRLGroup CsA Group P-value 
parameters (n=JJ) (n-JO) 
MMF Dose (mg/day) 813 ±259 1200+447 0.0706 
MPA Co (mg/L) 0.66 ±0.24 2.75 ± 1.63 0.0037 
CJDosc (mg/Ug MMF) 0.89 ±0.44 2.30 ± 1.30 0.0151 
Cmax (mg/L) 12.53 ± 3.91 13.46 ± 6.32 0.7471 
C..IDose (mg/Ug MMF) 15.89 ±4.30 11.11 ± 2.96 0.0528 
T .... (min) 30 ± 11 24±9 0.3193 
AUCO-I2 (mg·hlL) 20.37 ± 6.57 43.92 ± 24.60 0.0236 
AUC0-11J)ose (mg·hlUg MMF) 26.00 ± 8.61 35.45 ± 10.02 0.0914 
AUCO-I2° (mg·hlL) 23.03 ± 6.08 S2.88 ± 26.34 0.0092 
AUC~IIJ)ose° (mg·hlUg MMF) 30.23 ± 10.11 43.89 ± 16.31 0.0936 
AUC .. 12 (",g·WL) 5.14±2.18 21.38 ± 13.04 O.OOSI 
AUC .. 11J)ose (",g·WUg MMF) 6.81 ±2.52 17.18 ± 6.49 0.0016 
Chapter 9 
PHARMACOKINETICS OF THE NEW El\TERIC-COATED 
MYCOPHENOLATE SODIUM AND COMPARISON \VITH THE 
TRADITIONAL MOFETIL FORMULATION 1:\ KID:\EY 
TRANSPLANT RECIPIENTS 
- i·e -
Introduction 
Mycophenolate mofetil (MMF), the ester prodrug of mycophenolic acid (MP A), is a 
potent immunosuppressive agent actually used as a part of standard immunosuppressive 
regimens in combination with a ca1cineurin inhibitor or sirolimus, and steroids [107]. 
MMF is usually administered at a fixed oral dose of 1000 mg twice daily, and 
therapeutic drug monitoring is not routinely performed. Recent evidence, however, 
suggests that a flXed dose regimen of MMF no longer might be the best approach for the 
management of transplant patients, and drug pharmacokinetic monitoring is advisable 
[19,88,90]. 
Despite excellent efficacy, MMF is associated with tolerability problems, particularly 
because of gastrointestinal (01) adverse events such as nausea/vomiting, diarrhoea, 
abdominal pain and gastritis [87,103]. Additionally, also haematological toxicity has 
been reported after MMF use [74]. These adverse events often lead to a reduction in 
drug dose or discontinuation of MMF from the immunosuppressive regimen, leading to 
sub therapeutic dosing and impaired clinical outcomes [104,105]. 
To overcome the problems associated with MMF use, an enteric-coated fonn of 
mycophenolate sodium (EC-MPS, MyforticR) has been recently developed, which, via 
its advanced formulation, has the potential to extend the therapeutic window of MP A 
through enhanced tolerability relative to MPA exposure [87,106]. Unlike MMF, which 
releases MP A in the stomach, EC-MPS releases MP A in the small intestine. 
Previous studies [107,108,109] have shown that 720 mg of EC-MPS and MMF 1000 
mg deliver near, equimolar doses of MP A and provide bioequivalent MP A exposure, 
defined as the AVC. Therefore, it is now generally accepted that these two doses are 
therapeutically equivalent [106,109]. Results of pivotal phase III studies have shown 
that EC-MPS has a comparable efficacy and safety profile to MMF in de novo and 
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maintenance renal transplant patients [109,110]. The incidence of GI adverse events 
was similar for MMF and EC-MPS, though the severity of GI side effects 'With EC-MPS 
tended to be lower in the study of maintenance patients [110]. Furthermore, a non-
significant trend for fewer de novo patients receiving the new formulation requiring 
dose reduction, drug withdrawal, or interruption due to GI adverse events compared to 
the traditional MMF formulations has been observed [109,110]. 
Up to now, only few studies have formally compared the pharmacokinetics of MPA 
released from EC-MPS with that obtained after MMF administration [111,112]. 
Nevertheless, most of these studies were incomplete, with no baseline patient 
demographic or statistical analysis included, and an omission of full kinetic profiles. 
Moreover, they focused on the comparison between the two MP A-releasing 
formulations only after single drug dose administration [111] or providing only 
pharmacokinetic data from the early period after transplantation [112]. Therefore, 
complete data on the pharmacokinetics of MP A after chronic EC-MPS administration in 
stable kidney transplant recipients are still lacking. 
Indeed, the current study was designed to: 1) investigate the full phannacokinetics of 
MP A after EC-MPS administration in stable renal transplant patients at month 6 post-
surgery; 2) to assess the intra- and inter-patient variability of MP A pharmacokinetics 
by comparing values at month 6 with those obtained at month 12 post-surgery; 3) to 
compare the above mentioned pharmacokinetic parameters with those observed in a 
control group of patients, well matched for concomitant immunosuppressive therapy 
and time after transplantation, given MMF instead of EC-MPS; 4) to estimate the 
correlation between each sampling time points and daily MP A AUCo-12 for both 
formulations. 
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Materials and methods 
Study population 
Ten adult renal transplant patients (4 malesl6 females) referred to the Kidney Transplant 
Centre of the Ospedali Riuniti Bergamo, and enrolled in an intensified multi-factorial 
therapy open trial, were included in the present study. They were on triple 
immunosuppressive therapy, including CsA Neoral, corticosteroids and EC-MPS. 
All patients received EC-MPS twice daily, every 12 hours in the morning and in the 
evening, at starting dose of 720 mg (2 enteric coated tablets of 360 mg b.i.d). EC-MPS 
was commenced as soon as possible after transplant at a daily dose of 1440 mg and drug 
dose remained flXed through all the study period. Some of the patients, however, 
required drug dose reduction, due to adverse events. In case of leukopenia (leukocyte 
count <4000/mm3), neutropenia (absolute neutrophil count <1500/mm3), or other 
moderate/severe adverse events, EC-MPS dose was reduced by 50%. In any case, 
changes in EC-MPS dosing were perfonned by the attending physicians based on 
clinical parameters suggesting MP A-induced toxicity, but not according to MP A 
pharmacokinetics. For comparison, ten adult renal transplant recipients (6 males! 4 
females) transplanted in the same period in our Transplant Unit, well matched for time 
post-transplantation and concomitant immunosuppressive therapy, given MMF instead 
of EC-MPS were also included in the pharmacokinetics evaluations. 
Only patients with stable renal function in the previous 4 months (defined by less than 
15% differences in serum creatinine values during monthly evaluations) were included 
in the present pharmacokinetic study. Patients with existence of any surgical or medical 
condition, other than the current transplant, which might significantly alter the 
absorption, distribution, metabolism or excretion of the study medications, and/or 
presence of severe diarrhoea or active peptic ulcer disease, were excluded from the 
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study. The study protocol was described in detail to the patients before admission and 
written informed consent to enter the study was obtained. 
Study design 
This prospective study first evaluated the MP A pharmacokinetic parameters at month 6 
post-surgery in patients given EC-MPS or MMF. The MPA complete 12-hour plasma 
concentration-time profile was recorded for all patients, together with the time (T max> to 
reach the maximum concentration (Cmax) and MP A AUCO-12, calculated with the 
trapezoidal rule. On the morning of the pharmacokinetic studies, blood samples were 
collected for routine haematological analysis and for the determination of trough levels 
of plasma MP A. Then, each patient was given the morning dose of EC-MPS or MMF 
under fasted conditions. Thereafter, no particular restrictions on food intake were 
applied during the day. For MPA pharmacokinetics, blood samples in EDTA-tubes were 
drawn at 20,40, 75, 120 minutes, and 3, 4, 5,6, 8, 10 and 12 hours. Thereafter, samples 
were centrifuged at 3800 x g, plasma separated, and stored at -20°C until analysis by 
HPLC as described in Chapter 3. At month 12 post-transplantation, all patients given 
EC-MPS or MMF underwent a second pharmacokinetic evaluation, together with 
routine haematological analyses. Using this approach, we were able to estimate both 
intra- and interpatient variability from both MP A-releasing formulations. 
As additional analysis, each sampling time was correlated with the daily MP A 
exposure, expressed as MP A AUCQ-12, with the goal to identify time points useful for 
the development of limited sampling strategies aimed at predicting daily MP A exposure 
after EC-MPS administration. 
Patients experiencing drug-related toxicity were allowed to modify the daily EC-MPS 
or MMF dose. To take into account this potential confounding factors. all the MPA 
pharmacokinetic parameters were adjusted for the daily drug dose, and expressed as 
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equivalent of MP~ assuming a 1:1 equivalence between EC-MPS 720 mg and ~lMF 
1000 mg, as previously documented [106-112]. 
Statistical analysis 
Results are reported as means + SD. Differences in MPA pharmacokinetics within and 
between the two MPA-releasing formulations at month 6 and 12 post-surgery were 
. analyzed using the ANOV A test. Within- and between-patient variability of the main 
MP A pharmacokinetic parameters were expressed as CV%. Correlation between plasma 
MPA concentrations ranging from 0 to 12 hour post dosing and MPA AUCO-12 were 
performed by linear regression analysis. The statistical significance level was defined as 
p < 0.05. 
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Results 
Recipients' demographics 
All patients enrolled in the present study were Caucasians, and recipients of first kidney 
transplant from cadaver donors. As shown in Table 17, patients given EC-MPS were 
comparable to those given MMF as for demographics, renal and liver function, as well 
as for haematological profile both at month 6 and 12 post-surgery. 
Pharmacokinetics of the two MP A -releasing formulations 
The mean MP A pharmacokinetic parameters for the EC-MPS and MMF groups are 
shown in Table 18. Absorption was slower for EC-MPS than for MMF, consistent with 
a functional enteric coating for EC-MPS. Indeed, at month 6 post-surgery, mean Tmax 
was 130 min for EC-MPS and 46 min for MMF (p<0.01). Mean MPA exposure, defined 
either by dose-adjusted AUCO-12 and MP A Cmax, were not different between the two 
groups. The same findings were confirmed also at month 12 post surgery (Table 18). 
However, at variance with previous observations, we found that dose-adjusted MP A 
trough levels were 4.7-fold higher in patients given EC-MPS than those given MMF 
(Table 18, Figure 22). To better investigate potential differences in the MP A 
pharmacokinetic profiles between the two formulations, we looked at the single kinetic 
curves for each patient. As shown in Figures 23 and 24, unexpected, atypical kinetic 
profiles ofMPA in patients given EC-MPS were observed both at month 6 and 12 post-
transplantation. Of note, all patients given EC-MPS presented multiple peaks of MPA 
(on an average of 3 peaks per patient). Interestingly, some patients had MPA emu at 
480 minutes after drug dosing (Figure 22), whereas others had MP A Cmax peaking at 
time 0 (basal). Conversely, the control group of patients treated with MMF presented 
regular MP A pharmacokinetic profiles, consistent with previous observations [75]. with 
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maximum peak of MP A always within 2 hours (Figw-e 22), and the presence of a 
second, flat peak at 6-12 hours post MMF dosing, corresponding to the well-known 
enterohepatic recirculation ofMPA metabolites [75]. 
Variability of MP A pharmacokinetics parameters 
All patients underwent pharmacokinetic evaluations both at month 6 and 12 after 
. transplantation. As a measure of the intra-patient variability of plasma MP A levels, the 
CV% was calculated for main pharmacokinetic parameters between the two study visits 
in patients given EC-MPS and, for comparison, in those given MMF. We found a higher 
variability of MP A pharmacokinetics in patients given the new enteric coated 
formulation than those treated with the traditional MMF formulations (Table 19). 
Despite the low number of patients (n 10 for each group), these differences reached 
statistical significance (Cmax: CV: 45.7% vs 15.1%, p<0.05). 
As additional analysis, we also evaluated the inter-patient variability of MP A 
pharmacokinetics in the formulations both at month 6 and 12 post-surgery. As 
documented in Table 19, we confirmed that the use of the new EC-MPS formulation 
was associated with significant variability in MP A pharmacokinetics as compared with 
MMF. 
Correlation between MP A A UCO-12 and single sampling points 
As demonstrated in Table 20, the regression analysis between individual plasma MP A 
concentrations and MP A AUCO-12 documented an overall better correlation with the 
MMF formulation. Of note, this findings applied for all single time points (with the only 
exception of the sampling at 20 minutes), with differences in the correlation coefficient 
(r) that, in some cases, were more than double (at 20, 75, 120, 240, and 600 minutes 
post drug administration) between the two MP A-releasing fonnulations. 
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Given the observed low correlation between single MP A sampling points and daily 
MP A exposure, we were not able to develop feasible limited sampling strategies useful 
to predict MPA AUCO-12 in patients given EC-MPS (data not shown). 
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Discussion 
The main finding of the present study was that the pharmacokinetics of MP A released 
from the new enteric-coated formulation of mycophenolate sodium is extremely 
variable and irregular as compared with that found in stable kidney transplant recipients 
given MMF. Despite no apparent differences in mean MP A exposure expressed as MP A 
AUCO-12, we observed aberrant kinetic curves in single patients, with an extremely high 
variability both in the T max and MP A Co. Additionally, patients given EC-MPS 
presented multiple peaks of MP A, an effect never observed after MMF administration. 
These fmdings were at variance with those recently published by Arns et al [111], 
. 
showing that, after single EC-MPS or MMF administration, the pharmacokinetic curves 
for all treatments were similar. It should be pointed out, however, that in that study only 
mean pharmacokinetic profiles were presented, with no data showing the variability 
associated with single MP A sampling points. Moreover, as stated above, only single 
drug administration were considered. Therefore, these results can not be applied to 
patients, as ours, chronically exposed to EC-MPS. 
Only a very few studies have compared the pharmacokinetics of MP A released from 
EC-MPS with that from MMF in patients chronically treated with these drugs 
[111,112]. As a result of differences in the molecular weight, EC-MPS 720 mg contains 
a near equimolar quantity of MP A as MMF 1000 mg. Pharmacokinetic analysis have 
shown that the administration of EC-MPS at 720 mg and MMF 1000 mg resulted in 
similar MP A Cmax and AUC, documenting bioequivalence between the two 
formulations. Actually, the bioequivalence guidelines for approval of generic 
formulations require a similar average bioavailability compared with the reference 
formulation, with the 90% confidence interval of the relative mean AUe and Cmax of the 
test to reference formulation within 0.8 to 1.25 [113] . However, this approach presents 
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some important limitations, one of the most important being the assumption to consider 
average bioavailability instead of single evaluations. This concept was underlined and 
emphasized by our findings. Indeed, looking at mean MP A Cmax and AUCG-11, we found 
no differences between EC-MPS and MMF, confirming bioequivalence between the 
two formulations. However, looking at the single MP A pharmacokinetic profiles, we 
documented enormous differences between the two formulations. In particular, patients 
given EC-MPS presented MP A trough levels 4- to 5-fold higher that those found in 
patients given MMF, despite no differences in the MPA AUCG-12. It can be reasonably 
speculated that our results may have important clinical consequences when Co-based 
monitoring is used as a guide to optimize MP A therapy, as recently suggested by 
international consensus conferences [114]. 
Enteric-coating was designed to improve the OI adverse event profile of MMF releasing 
MPA in the small intestine, an effect evidenced by a delay in the MPA Cmax [87,106]. 
Overall, this trend was confmned also by our data, showing that mean MP A T max was 
longer in patients given EC-MPS than those given MMF. However, when we looked at 
the single data, we observed a very huge distribution in the Tow" covering a period from 
o to 480 min after EC-MPS administration. These unexpected findings allow us to 
speculate that some patients, actually via unknown mechanisms, may experience some 
problems in the absorption of EC-MPS, a pattern also confirmed by the presence of 
multiple MP A peaks. This trend resembles early observations after cimetidine 
administration [115], suggesting a potential influence of food intake in the absorption of 
EC-MPS but not MMF. Since all patients from both groups received the morning dose 
of the study medication under fast conditions, but had no particularly restriction to food 
thereafter, we were not able to draw definite conclusion on this issue. 
It is now generally accepted that the measurement of MP A AU412 is the most reliably 
tool for the assessment of daily MPA exposure [114]. However, this approach is seldom 
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feasible in the routine clinical practice an~ therefore, limited sampling strategies for the 
prediction of AUC have been early advocated for MMF [37,75,114], but are still 
lacking for EC-MPS. To pursue this goal we have tried to identify a few, near-the-~ 
sampling points useful to predict MPA AUCO-12 in patients given EC-MPS. However, 
we found a very high variability, both intra- and inter-patient, among all the 
pharmacokinetic parameters of MP A obtained from patients treated with mycophenolate 
. sodium. This was also documented by poor correlations between single sampling points 
and MP A AUC 0-12 after EC-MPS, but not MMF, administration. For all these results, 
we were not able to provide an equation useful to reliably predict MP A daily exposure 
in patients given the new enteric-coated formulation ofMP A. 
In conclusion, we have shown that, despite average bioequivalence, the 
pharmacokinetic of MP A released from EC-MPS is extremely variable and irregular as 
compared with that observed after MMF administration in stable kidney transplant 
recipients chronically exposed to these two formulations. Given the emerging strong 
support for the clinical outcome benefit of MP A monitoring in transplant setting, further 
studies are warranted to better investigate the mechanisms underlying differences in the 
absorption processes between EC-MPS and MMF. 
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Legend to Figures 
Figure 22. Distribution ofMPA Tmax and dose-adjusted Co in patients treated with EC-
MPS or MMF. Data are depicted as mean, minimum and maximum values for each 
phannacokinetic parameter. *p<0.0 1 vs Tmax and CO in the MMF group. 
Figure 23. Temporal distribution (from time 0 to time 720 minutes after drug 
administration) of single daily MP A concentrations in kidney transplant recipients at 
month 6 after surgery given EC-MPS or MMF. 
Figure 24. Temporal distribution of single daily MP A concentrations in kidney 
transplant recipients at month 12 after surgery given EC-MPS or MMF. 
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Table 17. Demographic and hematological data of kidney transplant recipients given 
mycophenolate sodium (EC-MPS, n 10) or mycophenolate mofetil (MMF, n=10). 
EC-MPS MMF 
Monlh6 Month 12 Monlh6 Month 12 
Age (yr) 41 ± 12 39± 13 44± 12 44± 12 
Body Weight (leg) 72.1 ± IB.5 70.1 ± 16.9 75.3 ± 17.3 77.7 ± 17.3 
S.Creatinine (mg/dL) 1.54 ±0.42 1.51 ± 0.56 1.66 ± 0.36 1.56 ± 0.27 
Creatinine cl. (mUm In) 64.3 ± 17.4 67.0 ± 17.B 55.4 ± IB.9 65.4 ± 17.B 
S.Urea (mg/dL) 64± 13 59± 17 66±2B 63±20 
AST(lUIL) 17±4 17 ±5 20± 10 19 ±4 
ALT (lUlL) IB±5 15±4 27±26 IB ± 10 
GGT(IUIL) IB± 10 20± IB 35±43 36±33 
RBC (I (Jd/jdJ 4.28 ±0.71 4.37 ± 0.45 4.10 ± 0.31 4.37 ± 0.52 
WBC (I (Jd/jdJ 7.70 ± 3.51 7.69 ± 2.81 5.39 ± 2.18 5.90 ± 1.61 
Table 18. Pharmacokinetic parameters of kidney transplant recipients given EC-MPS (n=10) or 
MMF(o 10). 
Pbannacokinetic EC-MPS MMF 
parameters 
Month 6 Month 12 Month 6 Month 12 
Dose (MPA eqlday) 1040 ±379 997 ±365 750 ±267 850±242 
Co (mglL) 4.07 ±4.07- 6.50 ± 6.56- 0.49 ±0.38 0.72 ± 0.26 
CofDose (mglL IMPA eq) 5.93 ± 5.01- 7.98 ± 7.01° 1.26 ± 0.80 1.64 ± 0.62 
C_ (",glL) 18.11 ± 10.20 15.95 ± 7.03 11.74 ± 6.56 12.23 ± 3.54 
C../Dose (",glL IMPA eq) 25.51 ± 11.30 25.57 ± 14.78 30.56 ± 11.21 29.84 ±8.67 
T_(",In) 130 ± 107- 118 ± 129- 46± 19 30 ± II 
AUCo.12 (IItg·1rIL) 36.65 ± 11.7r. 41.04 ± 19.53° 18.94 ± 11.62 21.14 ± 6.01 
AUCe.111Dole (IItg-WLlMP A eq) 53.11 ± 12.72 51.16 ± 11.29 47.64 ± 15.77 SI.2I ± IS.37 
-,.co.OS ft""'. -p<G.OI ft"'" 
Table 19: Intra- and inter-patient variability of main MP A phannacokinetic parameters in kidney 
transplant recipients given EC-MPS or MMF at month 6 and 12 post-surgery. 
Pharmacokinctic 
parameters 
CjDosc (mKIL IMPA ell) 
CmajDose (mglL IMPA eq) 
T IOU (mill) 
AlJCO.1 2 /Dosc (mg·h/UMI'A eq) 
.p' 0 OS V5 MMF; °p<O.OI vs MMF 
Intrapatient variability 
(CV % month 6 vs J 2) 
EC-MPS MMF 
32.8 38.7 
45.7· 15.1 
66.7 32.5 
24.9 12.4 
Interpatient variability 
(CV% at month 6) 
EC-MPS MA4F 
84.4· 63.9 
44.3 36.7 
82.4· 41.2 
23.9 33.1 
Interpatient variability 
(CV % at month J 2) 
EC-MPS MMF 
87.8° 37.8 
57.8 29.1 
109.4· 35.1 
31.1 29.') 
Table 20: Correlation between single MP A sampling points and MP A AUC 0-12 in patients given 
EC-MPS orMMF. 
Time-point of EC-MPS MMF 
sampling (min) r Regression equation r Regression equation 
Co 0.76 AUC = 2.21 Co + 27.08 0.87 AUC -18.60 Co + 8.87 
<;0 0.69 AUC=3.41 <;0+25.75 0.16 AUC = 0.58 <;0 + 22.47 
C40 0.14 AUC = 0.57 C40 + 36.92 0.75 AUC = 1.93 C40 + 0.52 
C;, 0.18 AUC - -0.58 C;, + 42.8 0.89 AUC = 2.29 C;, + 9.6 
CllO 0.28 AUC = 0.53 CllO + 35.05 0.91 AUC:II 5.16 CI20 + 7.65 
ClIO 053 AUC = 2.41 ClIO + 29.73 0.75 AUC = 7.82 ClIO + 11.27 
<;40 0.35 AUC - 2.36 ~40 + 33.96 0.80 AUC = 11.52 Cm + 9.18 
0.42 AUC = 1.33 C. + 33.27 0.59 AUC:oo 8.82 ClOO + 13.87 CJOO 
0.58 AUC =: 4.29 ~ + 29.75 0.82 AUC- 19.19 ~ +4.31 ~ 
C. 0.59 AUC - 3.82 C410 + 30.94 
0.93 AUC == 23.88 C410 + 5.58 
C600 0.47 AUC .. 6.05 C600 + 27.62 
0.91 AUC" 13.04 C600 + 13.61 
Cno 0.68 AUC" 11.05 Cno + 21.76 0.88 AUC CII 15.65 Cno + 12.3 
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Chapter 10 
THERAPEUTIC DRUG MONITORING OF SIROLIMUS: EFFECT 
OF CONCOMITANT IMMUNOSUPPRESSIVE THERAPY AND 
OPTIMIZATION OF DRUG DOSING 
- 103 -
Introduction 
SRL is a macrocyclic lactone isolated from Streptomyces hygroscopicus characterized 
by a potent immunosuppressive activity [116]. Interest in the use of sirolimus in organ 
transplantation derives from its unique mechanism of action, its low side-effect profile, 
and its ability to synergize with other immunosuppressive agents [117]. SRL has no 
effect on calcineurin enzyme, but it reduces T -lymphocyte activation at a later stage in 
the cell cycle, by inhibiting the post interleukin-2 receptor mTOR signal transduction 
pathway [118]. 
The drug is metabolized by the cytochrome P4S0-3A4 isoenzyme (CYP3A4), a family 
of enzymes involved in the metabolism of several immunosuppressive agents currently 
used in combination as antirejection treatments in organ transplantation [24]. This may 
lead to potential pharmacokinetic interactions that eventually affect SRL blood 
concentrations and ultimately may result in over- or under-immunosuppression or 
toxicity [119,120]. So far, this issue remains ill defmed. Monitoring blood sirolimus 
levels is mandatory to optimize the drug dosing regimen, since the dose is itself a poor 
predictor of drug exposure [121]. At variance, SRL trough levels (CO> show good 
correlation with the daily drug exposure, defined as the area under the time-
concentration curve (AUC0-2J, and with clinical outcomes, both as rejection episodes 
and drug-related toxicity [40]. HPLC, with either UV or MS detection, is now the only 
available technique for the assessment of SRL whole blood levels [35,122]. 
In the past two years our laboratory served as a centralized institution in Italy to 
measure SRL concentrations in blood samples of kidney transplant recipients on 
different SRL-based immunosuppressive regimens. These samples referred only to SRL 
trough levels, and no complete phannacokinetic profiles were perfonned to study 
additional phannacokinetic parameters. Although the AUe is an accurate index of 
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patient exposure to the drug, this measurement is quite expensi\"e. time-consuming. and 
increases the discomfort for the patients, making it seldom feasible in routine clinical 
monitoring. Therefore, the Co-based SRL monitoring is commonly used as a surrogate 
marker of daily drug exposure in the routine clinical practice. Thus, given the large 
number of SRL measurements available in our laboratory referring to different time 
samplings post transplant and to different settings of drug combination, we sough to 
investigate the possible effect of concomitant immunosuppressive agents on SRL trough 
levels (Co) as an index of patient exposure to the drug. In particular, we examined: 1) 
the potential influence of CsA, tacrolimus (TRL), M~IF and steroids on dose-
normalized SRL trough concentration; and 2) the variability of SRL trough levels 
according to different time points post surgery. In addition, we tested an algorithm 
based on measured SRL trough levels useful to guide changes of SRL dosing. 
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Materials and Methods 
Patients and blood sampling 
Four hundred ninety-five transplant recipients of cadaver kidneys from 40 Italian 
Transplant Centres were included in the present study. Patients were at a median of 258 
days post-surgery (from day 0 to 14 years), and treated with different 
immunosuppressive regimens that include CsA, TRL, MMF, and steroids. In most 
patients, SRL was given in association with a ca1cineurin-inhibitor (CsA 58%; TRL 
19%) in dual (28%) or triple therapy with steroids (46% ). Alternatively, patients were 
treated with SRL in combination with MMF (7%), or steroids (9%) alone, or in triple 
combination (8%). For a detailed description of the different immunosuppressive 
regimens see Table 22. The patients received SRL 4 hours after the morning CsA dose, 
as suggested by the drug manufacturer. 
Study design 
Serial SRL blood levels centrally assayed in our Laboratory between June 2001 and 
October 2003 were considered (n 2,658). Samples were collected in EDT A-containing 
tube and sent (frozen at -20°C) to the central Laboratory. At the same time the Centres 
were asked to provide information on: day of transplant, actual SRL daily dose, 
concomitant immunosuppressive regimen and graft function as serum creatinine. 
Complete required data were available for 689 SRL trough levels, which belong to 189 
patients. Measured SRL concentrations were initially divided in three groups according 
to immunosuppressive regimen: 1) SRL, CsA with or without steroids; 2) SRL, TRL 
with or without steroids; 3) SRL, MMF with or without steroids. The impact of CsA, 
TRL, MMF, or steroids on SRL trough levels was first examined. We also assessed the 
consistency of SRL trough levels measured at different time points post transplant \\ith 
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the recently proposed guidelines of target SRL blood concentrations, according to the 
adopted immunosuppression regimen [123]. Moreover, similarly to what has been 
recently proposed for CsA Neoral dose adjustment [124], we also evaluated the 
feasibility of adjusting SRL dose to a given blood trough target using the following 
equation: 
NewSRLdose 
Predicted SRL Cone. = Old SRL Cone. X ---------------
Old SRLdose 
SRL concentration measurement 
Whole blood sirolimus concentrations were measured using a validated HPLC method, 
already described in Chapter 4 [122]. 
Statistical analyses 
Dose-normalized SRL trough values were compared between different groups 
according to different immunosuppressive regimens by ANOV A. Bonferroni t-tests of 
difference between means were performed when ANOV A showed a significant 
difference (p<O.05). 
Agreement between blood SRL concentrations measured and predicted with the above 
mentioned equation was assessed using a linear regression analysis. In addition, the 
Bland and Altman approach [99], where the percentage difference [100] is plotted 
against the mean SRL value, was used. We considered acceptable values within 1 
standard deviation (SO) of the difference. 
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Results 
Concomitant immunosuppressive therapy and SRI levels 
In patients given CsA or TRL as a part of their immunosuppressive therapy. mean SRL 
dose as well as trough levels were lower than in those recei\ing ~1~IF but not 
calcineurin inhibitors (Table 21). Normalization of SRL trough level to dru~ dose, 
however, resulted in a significantly higher trough values in patients on Cs.-\, than in 
those treated with TRL (p<O.05) or MMF (p<O.O 1). 
Since some patients were also given steroids, we further characterize the potential 
additional effects of corticosteroids on SRL trough levels by comparing dual or triple 
immunosuppressive regimens with or \\ithout steroids. As sho~ in Table 22, the 
addition of steroids to CsA- but not to TRL-based immunosuppressive regimen 
significantly lowered the dose-normalized SRL trough levels as compared to the dual 
regimen without steroids (p<O.OI). A similar trend was found for ~t\tF-based 
immunosuppression, in which steroids resulted in numerically lower normalized SRL 
trough levels than steroid-free patients. 
Considering the impact of MMF on SRL blood concentration, normalized SRL trough 
levels were lower with (2.91+1.52 ng/mL/mg SRL; p<O.05) than without \t\tF 
(4.15+2.23 ng/mL/mg SRL) added to a dual regimen of SRUCsA. ~Ioreover. 
combining MMF with SRL resulted in a significant reduction in dose-normalized SRL 
trough levels (3.26+ 1.86 ng/mL/mg SRL) compared with the dual Cs.\-SRL regimen 
(p<O.05). When dual SRL-based regimens were compared, dose-nonnJlized SRI. 
trough levels were significantly higher with CsA (p<O.05) than TRL and \ t\ 1F but not 
steroids. 
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Distribution of SRL trough levels with- or without CsA 
Blood SRL trough concentrations measured by HPLC ranged from 1.0 to 46.4 nglmL. 
To evaluate the agreement of SRL trough levels with current regulatory guideline 
ranges - according to whether patients were given or not CsA - SRL concentrations 
were divided based on samples from patients with or without CsA as a part of their 
immunosuppressive regimen. As shown in Figure 25, 71.2% of SRL trough levels from 
. patients receiving the drug in combination with CsA fell in the proposed therapeutic 
range of 5-15 nglmL. Among these samples,. 72% were between 5-10 nglmL. 
Conversely, only 36.7% patients without CsA fell in the proposed SRL trough range 
(10-20 nglmL), while the majority of samples (75.0%) were in the range of5-15 nglmL. 
Modelling SRL dose according to drug levels 
In 166 patients who did not change SRL dose and concomitant immunosuppressive 
therapy during consecutive visits (503 determinations), the intrapatient and interpatient 
variability of SRL trough levels, defined by the mean coefficient of variation, were 19% 
and 47%, respectively (Table 23). These parameters were significantly affected by the 
time post-surgery, with the first week after transplantation associated with the greatest 
intra- and interpatient variability (Table 23). 
To provide an algorithm that would help in choosing the appropriate SRL dose and 
ultimately limiting the drug trough level variability, a simple dose-adjustment fonnula 
recently proposed for CsA monitoring [124] was tested. To this purpose we used data 
from 82 patients who underwent 186 modifications of SRL dose, and correlated the 
measured and predicted SRL trough levels. As shown in Figure 26, a significant 
correlation was found between SRL concentrations measured after drug dose change 
and those predicted with the proposed fonnula. The mean percentage error of prediction 
was 4.1 + 34%, with 71 % of estimations within the threshold acceptable error of ~ 300/0. 
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This arbitrary value results from the sum of the mean intrapatient variability found in 
patients who did not undergo to SRL dose change (20%), and the performance of the 
method used to assess SRL levels (an imprecision and accuracy of nearly 10%). To 
overcome the limitation of the arbitrary estimate of this threshold in error, a more 
conservative approach [99], that defines as acceptable 1 SD of the mean in the 
percentage difference of SRL values [100], was considered. As shown in Figure 27, 
73% of predicted SRL values fell in the proposed range. 
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Discussion 
In this study we found that in kidney transplantation the degree of patient exposure to 
SRL is not only influenced by drug dosing, but also by the concomitant 
immunosuppressive regimen. Concomitant administration of SRL and CsA was 
associated with higher dose-normalized SRL blood trough levels than those measured 
under TRL- or MMF -based regimens. These findings indicate potential 
phannacokinetic interaction between different immunosuppressants. They confirmed 
drug interactions previously reported in animal models [125-127], and in humans [128], 
in which CsA was found to significantly increase SRL blood levels. 
Different mechanisms may underlay this drug interaction. CsA and SRL share common 
transport and metabolic pathways, thus, both drugs may compete for the binding to P 
glycoprotein and for the metabolism by intestinal and hepatic CYP3A4 enzyme [129]. 
Because the molar quantity of CsA in a typical daily dose far exceeds that of SRL (> 1 0 
times), it might be expected that CsA preferentially interacts with CYP3A4 and thus 
inhibits SRL metabolism [35]. In addition, CsA acts not only as substrate but also as 
inhibitor of CYP3A4 [130]. Both these mechanisms explain the high normalized SRL 
trough levels we found when the drug was given as part of a CsA based 
immunosuppressive regimen. Conversely, TRL is only a substrate but not an inhibitor 
ofCYP3A4 [130]. Moreover, therapeutic blood concentrations ofTRL are in the molar 
quantity close to those of SRL. This implies that one molecule of TRL may compete 
with one molecule of SRL for CYP3A4. Thus, the likelihood of TRL to interact with 
this enzyme is similar to that of SRL, but far lower than that of esA. This ultimately 
may explain why the influence of TRL on SRL metabolism, if any, is less evident This 
is further supported by studies in liver and kidney-pancreas transplant recipients 
showing that neither pharmacokinetic profiles of SRL nor those of TRL were altered by 
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simultaneous administration of the two drugs [131]. Similarly, Ciancio et al have 
recently shown that dose-nonna1i:red SRL trough levels, expressed as bioavailability 
index, were significantly higher in patients receiving CsA, than in those given TRL 
[128]. 
Intestinal CYP3A4-mediated drug metabolism, P-gp expression, and cell membrane 
permeability are factors that most likely affect the bioavailability of SRL, CsA and 
. TRL. It is therefore possible that the drugs interact not only at hepatic level but also at 
the small intestinal level where drug absorption occurs. Experimental studies in rats 
have indeed shown marked pharmacokinetic interactions when SRL and CsA were 
administered simultaneously by gavage but not via continuous intravenous infusion, 
suggesting that the gastrointestinal surface may be an important site of drug interaction 
[127]. Moreover, in healthy volunteers given a single oral dose of SRL the rate and 
extent of SRL absorption and exposure were significantly affected not only after 
simultaneous but also after staggered drug administration with Neoral [132]. This was 
also true in kidney transplant recipients [133]. The finding that in our patients - who 
were given SRL dose 4 hours after CsA morning dose - SRL trough levels were still 
affected by CsA administration, confirm previous observations and implies that the 
interaction between the two drugs occurs not only in the liver but, at least in part, at the 
gastrointestina1level. 
At variance with CsA, co-administration of MMF resulted in a significant reduction of 
dose-normalized SRL trough levels. Indirect evidence of mutual pharmacokioetic 
interaction between MMF and SRL is available in transplant patients. A multicenter 
clinical trial [96] has shown that, despite low MMF dose employ~ patients treated 
with MMF and SRL have MP A (the active compound of the prodrug MMF) trough 
levels significantly higher than in patients treated with a ca1cineurin-inhibitor and 
nonnal MMF dose. Similarly, others have found in renal transplant recipients that MMF 
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may be given at lower dose than conventional when used in association with SRL in 
renal transplant recipients [134]. Both these studies provide clear evidence that SRL 
significantly affect MP A pharmacokinetics. Conversely, we found that c0-
administration of MMF and SRL resulted in a significant reduction of dose-normalized 
SRL trough levels. The mechanisms of MMF-SRL interaction, however, remain ill 
defined. The possibility exists that MP A, by affecting cytokine production [135], may 
. induce the expression of P glycoprotein and/or CYP3A4, resulting in a significant 
reduction in dose-normalized SRL trough levels. Alternatively, but not mutually 
exclusive, MP A and SRL may interact at metabolic level. This is supported by the fact 
that a phase I metabolite of MP A produced by CYP3A4/S (the same enzyme involved 
in SRL metabolism) has been recently identified [136], although in the past MPA was 
thought to be metabolized exclusively by phase II reactions. 
Here we also documented that even steroids influence SRL trough concentration. So far, 
available data on the effects of steroids on SRL patient exposure are conflicting, with 
some studies [137] but not others [138] showing pharmacokinetic interactions between 
SRL and prednisolone. In vitro and in vivo evidence show that glucocorticoids increase 
the expression and activity of CYP3A4 [139,140]. These findings raise the possibility 
that steroids activate pathways of SRL metabolism, eventually leading to a lower 
exposure than expected to SRL. This was indeed what we found in the present study. 
The addition of steroids to a dual therapy regimen of CsA and SRL resulted in a 
significant reduction in dose-normalized SRL trough levels; the same trend was 
observed when this class of drugs was associated with MMF and SRL. Conversely, the 
combination of steroids with TRL and SRL, did not result in a significant reduction in 
dose-normalized SRL concentrations. Several confounding factors may have, however, 
influenced the latter observation. Indeed, it has been recently shown that steroids 
influence TRL pharmacokinetics [141], suggesting a complex scenario of interactions 
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between TRL, steroids and possibly SRL. Moreover, our patients on triple therapy with 
steroids, TRL and SRL had higher degree of renal dysfunction (measured as serum 
creatinine levels) than those given only TRL and SRL, which could have resulted in 
SRL accumulation and higher than expected SRL blood levels. The accumulation of 
SRL due to renal dysfunction may have ultimately masked the possible trend to lower 
SRL levels secondary to TRLISRL pharmacokinetic interaction. 
. We then investigated whether the distribution of SRL trough levels in patients given the 
drug with or without CsA, meets the registration guidelines for SRL target blood ranges 
[35,40,123,142]. This was feasible since our samples did belong from different 
Transplant Centres, each with a given drug combination and SRL blood target protocol 
for routine drug monitoring. The recommended therapeutic window for SRL trough 
levels, when the drug is given concomitantly with a calcineurin inhibitor, is 5-15 ng/mL 
[35,40]. More than 70% of the samples assayed in our study fell within this range, 
although most of them were in the lower 5 to 10 ng/ml window. Two double blind 
randomized clinical trials [123,142] have recently shown that CsA can be safely 
discontinued three months after kidney transplantation, provided that SRL dose is 
increased to target blood trough levels of 20 to 30 ng/mL (if measured by 
immunoassay) [123] or of 10 to 20 nglmL (if assayed by HPLC) [142]. Such difference 
in the target range relates to the fact that the immunoassay gives cross-reaction with 
SRL metabolites resulting in a significant overestimation [143]. Here we showed by 
HPLC that most of patients who 'per protocol' discontinued esA had SRL trough levels 
lower than the recommend blood window of 10 to 20 ng/mL or more close to the 
expected 5 to 15 ng/mL range for triple therapy including esA. These findings 
underline the tendency of most transplant physicians to underdosing SRL in the dual 
immunosuppressive regimen of SRL and steroid, when esA has been withdrawn from 
the initial triple therapy. While this strategy may still be safe in respect to the risk of 
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acute rejection and/or on long-term graft outcome, formal data derived from ad hoc 
designed study are not yet available. Therefore, they should go forward warily in 
adopting this SRL regimen without a clear rationale. 
As previously reported [144], SRL levels exhibited a great intra-patient variation that 
further supports the need of therapeutic drug monitoring for this novel 
immunosuppressant. A correct drug monitoring approach should rely on reliable 
methods to assess drug level and on adequate tools to calculate the drug dose required to 
obtain a given drug level. Here we described and provided evidence of reliability of a 
prediction equation to calculate the new SRL dose required to target a given therapeutic 
range, when adjustment of SRL dosing is needed to meet clinical requirements. To our 
knowledge, this is the first attempt to provide such a tool for the improvement of SRL 
monitoring in transplant patients. 
The present study has certainly some shortcomings. This is a retrospective analysis of 
the available data of SRL trough levels provided by different transplant Units. They, 
however, did not include doses and levels of the other immunosuppressive agents co-
administered with SRL. With this limitation, it should be pointed out that so far data on 
the effects of currently used immunosuppressive agents on SRL trough levels are 
scanty. This is the first demonstration that not only esA and TRL, but also MMF and 
steroids may affect SRL blood levels in kidney transplant patients. 
An additional shortcoming is that the apparent concentration of the drug measured in 
the blood, as in our study, may not accurately reflect the drug level in the lymphoid 
organs and in the graft. Alternative approaches have been recently proposed to tailor the 
best immunosuppressive regimen. For instance, pharmacodynamic monitoring involves 
measurement of the biological effect of the drug at its target site [15], and 
phannacogenomics, a genome-wide approach aimed at identifying the nenvork of genes 
that govern an individual's response to drug therapy [41]. These novel strategies hold 
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many promises for the future. However, they will never replace traditional therapeutic 
drug monitoring completely but, rather, act as complementary fields resulting in a better 
patient management. 
Prospectively designed multicenter clinical trials are now needed to assess whether SRL 
pharmacokinetic changes related to drug-drug interaction would translate to a different 
risk of rejection or graft outcome. 
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Legend to Figures 
Figure 25. Frequency distribution of the dose-nonnalized SRL trough le"els in patients 
treated with SRL and with- (panel A), or without esA (panel B). Shaded areJS represent 
SRL therapeutic windows, according to the immunosuppressive therapy (panel A: 5-15 
ng/mL; panel B: 10-20 ng/mL). 
Figure 26. Linear regression plot between SRL levels measured with a HPLC method 
and predicted with a proposed fonnula in 82 patients who underwent 186 modifications 
ofSRL dose. 
Figure 27. Bland and Altman plot for measured and predicted SRL concentrations. The 
percentage difference from the measured SRL concentration is plotted against the mean 
SRL value. The mean percent difference is displayed by a bold solid line. Dotted lines 
represent + 1 SO of difference. 
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Table 21. SRL blood trough levels according to the immunosuppressive regimens 
Therapy 
SRL + CsA (n=400) 
SRL + TRL (n= 128) 
SRI. + MMF (n=J02) 
• p<-O.O 1 vs SRLt MMF 
o p<O.05 vs SRL + TRL 
SRL Dose 
(mglday) 
2.7 + 1.4 
3.1+1.5 
4.3 + 1.6 
SRLCt 
(nglmL) 
8.58 + 4.38 
8.09 + 4.44 
10.57 + 4.93 
C t / Dose 
(nglmUmg SRL) 
3.77 + 2.35 • 0 
3.24 -+- 2.16 
2.84..t 1.81 
Table 22. SRL blood trough levels according to different immunosuppressive regimens 
Therapy SRLDose SRLCt Ctl Dose S. Creal 
(mg/day) (ng/mL) (ng/mUmg SRL) (mg/dL) 
SRL + CsA + Ster (n=221) 2.7 + 1.7 7.92 + 4.07 3.53 + 2.45 2.21 + 1.59 
SRL + CsA (n= 165) 2.6 + 1.0 9.58 + 4.66 4.15 + 2.23 a,b 2.03 + 1.55 
SRL + CsA+ MMF (n=14) 2.8 + 1.3 7.21 + 3.48 2.91 + 1.52 2.16 + 0.80 
SRL + TRL + Ster (n=98) 3.1+1.4 8.15 + 4.34 3.26 + 2.22 2.64 + 1.08 0 
SRL + TRL (n=30) 3.1+1.8 7.89 + 4.84 3.18 + 1.97 2.00 + 0.69 
SRL + MMF + Stcr (n=57) 4.5+1.1 10.54 + 5.38 2.52 + 1.73 c,d 2.32 + 1.09 
SRL t tv1MF (n-45) 3.9 +2.0 10.60 + 4.35 3.26 + 1.86 2.16 + 1.20 
SI{L + Stcr (nc-:5Y) 3.1 + 2.0 8.46 + 3.77 3.85 + 2.91 2.77+1.19· 
• p' () 01 vs SRLtCsAtStcr. SR1.tTRLtSICl ~ p<005 vs SRUTRL. SRUMMF, and SRUCsAtMMF • p<O.OI V5 SRUCsA 
• p' 001 vs SRLt C!;A t Stcr. SRLtCsA. and SRLtStcr 4 p<O.05 vs SRL-tTRL+Stcr 0 p<005 V5 SRLtCsA 
Table 23. Iotra- and ioterpatieot variability of SRL blood trough levels according to time post-surgery 
Time post-surgery 
1 week (0-19) 
1 month (0=27) 
3 moots (n=21) 
6 months (0=29) 
> (, months (n=70) 
Ovt:rall (n~166) 
SRLDose 
(mglday) 
2.6 + 1.0 
2.9 ± 1.2 
2.9 + l.2 
2.6 + l.6 
2.9 + 1.6 
2.9 + 1.4 
SRLC1 (nglmL) 
7.2+4.5 
7.5 +3.9 
8.2 + 3.9 
7.9+3.9 
8.2 + 3.7 
8.0 + 3.8 
Intrapatient 
CVO/o 
27%* 
160/0 
15% 
17% 
18% 
19% 
• p < 0.01 vs month 3; p < 0.05 vs months 1,6 and> 6 0 p<O.05 vs other groups 
Interpatient 
CVO/o 
63%0 
52% 
48% 
49% 
45% 
47% 
Part IV 
PHARMACOGENETIC-BASED THERAPEUTIC 
DRUG MONITORING: PRELIMINARY 
EXPERIENCE WITH CYCLOSPORINE 
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Immunosuppressive drugs are often associated with high risk of serious adverse events. 
including infections and cancer [145]. The narrow therapeutic index unique to each 
patient, as well as variable absorption, distribution and elimination properties give 
reason for individual response and risk of side effects related to the treatment with 
immunosuppressants. Therefore, periodic monitoring of plasmalblood concentrations of 
drugs is required. The goal is to maintain levels of immunosuppressive drugs within 
. their therapeutic ranges, as variations outside these limits are often associated with 
adverse clinical outcomes or under treatment [64]. Moreover, as emphasized in the 
previous chapters, pharmacokinetic-based therapeutic drug monitoring may be helpful 
also to study and eventually predict potential drug-to-drug interactions. It should be 
pointed out, however that, although the extensive literature on immunosuppressive drug 
monitoring to guide therapy [17,64], there is still controversy amongst the effective 
impact of a concentration-controlled based immunosuppressive regimen [14], since in a 
significant proportion of patients acute rejection or drug-related toxicity occur despite 
drug levels fell within the therapeutic range [146]. Therefore, we are in need of novel 
strategies for a better management of transplant recipients, which could support the 
conventional TDM. 
By examining the genetic factors that contribute to variability in drug response in 
individual patients, pharmacogenetics could provide a promising and complementary 
tool in this field. The field of pharmacogenetics could not have evolved without the 
development of new technological resources that allow scientists to access and process 
the enormous amount of information embedded in the human genome. Actually, the 
most diffuse technological advances are focused on single-nucleotide polymorphisms 
(SNPs), which form the backbone of molecular genetics technology. SNPs are common 
variations in the structure of a gene and consist of one-nucleotide alteration in the 
sequence of a gene [147]. It has been estimated that there are 30 millions of SNPs in the 
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human genome, accounting for 90% of all inter-individual variations. These genetic 
variations can result in altered catalytic activity of enzymes, with gain or loss of 
function by gene replication, gene deletion or gene miss-splicing. Certain SNP's will 
also exert a more indirect influence by altering genes or promoter regions that determine 
transcription and translation of the gene of interest. Thus, SNPs offer a potentially 
useful tool for pharm.acogenomics to identify genetic markers that might be predictive 
. of toxicity, side effects or lack of response to a drug. However, it should be pointed out 
that this approach is expected to be clinically relevant for those SNP's that are strongly 
linked to a corresponding phenotype [148], whereas those characterized by a bell-
shaped distribution [149] and less evident phenotypes might have a limited clinical 
impact. These promising technologies could be useful tools to address the main 
challenge of pharmacogenetics: to predict which individual will benefit most from 
which drug. This task applies for all drugs but is of particular importance for those 
characterized by a NTI, such as the immunosuppressive agents that represent the ideal 
candidates for phannacogenomic approaches. 
Today, the key-point is to understand whether clinical pharmacogenetics is already 
applicable today to organ transplantation. Early observations focused simply on drug 
metabolism [150,151]. However, there is also great interest in the full spectrum of drug 
disposition, including absorption, distribution and pharmacological targets. One of the 
potential advantages of this type of approach lies on the common metabolic pathways 
for several immunosuppressive agents. CsA, TRL, SRL and the novel rapamycin-
analogue everolimus are all mainly transported and metabolized by the cytochrome 3A-
P-glycoprotein system [24]. Thus, the study of patient's genotype can provide predictive 
value for multiple drug therapy as in transplant patients. In particular, P-glycoprotein, a 
member of the A TP-binding cassette family encoded by the multidrug resistant gene 
(MDR 1) regulates the cellular efflux of several substrates, including the 
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immunosuppressive drugs [152]. Several SNP have been identitied for ~1DRI gene. all 
potentially important in predicting the efficacy and/or toxicity of these drugs. The 
presence of variants in genes encoding for drug targets or other genetic polymorphisrns 
with indirect effects on drug response are less known. Thus, they represent an exciting 
challenge for the future. 
Following there are preliminary results of a study aimed at inyestigating whether the 
identification of SNPs in the MDRI gene could be used as useful tool to predict drug 
exposure in organ transplant recipients. Chapter 11 focused on CsA. However. it can be 
reasonably speculated that the same approach could be applied in the near future also 
for other immunosuppressants [41]. 
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Chapter 11 
MDRI POL YMORPHISMS IN EXON 26, BUT NOT 12, 
INFLUENCES INDIVIDUAL CYCLOSPORINE LEVELS IN 
KIDNEY TRANSPLANT RECIPIENTS 
- 188 -
Introduction 
CsA is one of the main immunosuppressant currently used to prevent graft rejectio~ 
which has significantly contributed to improve allograft and patient survival [153]. This 
drug is, however, characterized by a narrow therapeutic index, an unpredictable 
absorption profile, and important side effects [11,154]. Given the appreciable inter-
individual variation in blood CsA concentration despite the same drug dosage, major 
efforts have been devoted in the past to individualize CsA dose to maximize the efficacy 
and minimize toxicity of the treatment. To this purpose, several approaches have been 
proposed to monitor daily CsA exposure as useful tools to tailor drug dosage for each 
patient [20]. In particular, two blood sampling points, at time zero (CO) or at 2 hours 
after CsA dosing (C2) are currently used in the clinical practice [25]. However, this 
pharmacokinetic-based therapeutic drug monitoring is not without pitfalls. Indeed, some 
Authors failed to document a significant association between CsA pharmacokinetic 
parameters and patient's clinical outcome [14]. Therefore, complementary strategies 
have been advocated. 
The advent of the genomic era has provided new insights into the molecular basis of 
human genetic disorders, and pharmacogenetics - a science that studies how the 
genome may affect the full spectrum of drug disposition - is undoubtedly a potential 
source of additional information, as complementary field to the traditional 
pharmacokinetics. In the past few years, large number of studies has shown that genetic 
polymorphisms in drug-metabolizing enzymes and transporters may predict drug 
efficacy as well as drug toxicity [23,41]. 
CsA disposition is mainly influenced by the P-glycoprotein (p-gp), the product of the 
MDRI gene [155]. This protein is an effiux pump, which removes lipophilic drugs, like 
CsA, from the intracellular space. P-gp is mainly found in the hepatocytes, kidney 
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proximal tubular cells, and the brush border surface of enterOC)1eS [155]. The function 
and the anatomic localization of P-gp suggest that this transporter acts as a protective 
barrier to keep toxins (drugs or xenobiotics) out of the body by excreting thes~ 
compounds into bile, urine, and the intestinal lumen. To date. about 30 S~Ps hav~ been 
reported for the MDRI gene [155]. However, only SNPs in exons 12.21 and 26 were 
associated with lower P-gp expression/activity. SNP in exon 12 is silent. whereas S:\Ps 
at exon 21 result in two distinct amino acid changes, namely, Ala863Ser (G2677T) and 
Ala893Thr (G2677 A). The silent SNP in exon 26 (C3435T) was the first variant to be 
associated with altered protein expression [156]. More recently, also SNPs in exons 12 
and 21 were found to be associated with altered drug disposition [157,158]. 
Genetic polymorphisms of MDRI gene in transplant recipients may therefore result in 
significant reduction in P-gp expression, eventually increasing the exposure of patients 
to immunosuppressants, such as CsA, with potential clinical consequences in terms of 
efficacy and adverse effects. So far, only few studies have investigated the impact of 
MDRI SNPs on the bioavailability of immunosuppressive agents. Whereas studies 
focusing on TRL have consistently shown that genetic polymorphisms of the MDRI 
gene in exons 12,21 and 26 can predict drug bioavailability and toxicity [159]. those 
dealing with CsA led to contradictory results [41,159], possibly due to the limited 
number of patients studied or inadequate pharmacokinetic monitoring. 
Therefore, the present study was designed to assess whether single nucleotide 
polymorphisms in MDRI gene (exon 12 CI236T and exon 26 (3435T), alone or in 
combination (as haplotypes and genotypes). were associated with variable Cs.\ levels 
(at week 1 and at month 1, 3 and 6 after transplantation) in a large cohort of 120 kidney 
transplant recipients enrolled in the \IYcophenolate Steroid-Sparing (\1Y.S.S.) Tri~u 
[38]. 
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Material and ~Iethods 
Patients 
120 Caucasian patients ~17 years old), enrolled in the MY.S.S. Trial - a prospective, 
randomized, multicenter, European study of first cadaver renal transplant recipients 
randomly allocated to receive azathioprine or mycophenolate mofetil in addition to the 
Neoral microemulsion fonnulation of CsA and steroids for the flIst six months post-
surgery (for a detailed description of the study see reference [38]) - entered this 
phannacogenetic study. 
CsA was initially infused intravenously (on average 4 mglkg daily) from the day of 
surgery (day 0) to day 3 and then, given orally twice a day (Neoral ~ovartis, Basel. 
CH). CsA dose was adjusted to maintain blood drug trough levels within 250-440 
ng/mL from day 0 to 7, and within 200-300 ng/mL from day 8 to the end of the first 
month. Thereafter, CsA trough concentrations were targeted to 150-250 ng/mL up to 6 
months postoperatively. Patients were randomly assigned to receive treatment with 
mycophenolate mofetil (l g twice a day), or azathioprine (100 or 150 mg/day according 
to body weight < or > of 75 Kg). Corticosteroid dosing early post-transplant was 
dictated by the participating centre's practice, whereas all patients received 16 mg/day 
of methylprednisolone from day 12 to 60 post-transplant tapered to 8 mg/day ther~after. 
None of the patients was given medications known to interfere with P-gp function 
(inducers or inhibitors). A control group of 100 healthy volunteers was also considered 
to assess the frequency distribution of ~IDRI S~Ps (ex on 12 and 26), All study 
participants (kidney transplant recipients and controls) provided \\Titten informed 
consent for genetic testing. 
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CsA pharmacolcinetic parameters 
Whole blood samples were collected immediately before (CO) and at 2 hours after CsA 
administration (C2) daily within the first week after surgery, and every two weeks until 
the end of month 6 post-transplant. To limit intra-individual variability of CsA values, 
blood drug concentration was calculated as the mean of three replicate measurements by 
HPLC, using a validated method described in Chapter 5. Each CsA concentration was 
. adjusted for the corresponding 12-h drug dose, expressed as mg/kg body weight CsA 
exposure, defined by the area under the time-concentration curve (AVCO-12), was 
estimated using the two-point equation proposed by Keown et a1 [160], as follows: 
AVC = 12.34 x (CO) + 2.48 x (C2) + 441.42. The apparent clearance of CsA was 
calculated as the ratio between CsA dose and CsA AVC. 
DNA collection and isolation 
Blood from kidney transplant recipients and healthy volunteers was drawn from an 
anticubital vein into vacutainer containing K3EDTA. One vacutainer was collected for 
each patient (4 mL of whole blood), and the samples were placed at -20°C. For 
genotype determination, genomic DNA was isolated from EDTA-anticoagulated whole 
blood using the Nucleon BACC2 kit (Amersham, Biosciences, Buckinghamshire, UK). 
According to the Manufacturer instruction, in order to minimise damage to DNA in 
collected blood samples, blood should be extracted within 8-12 months of collection. 
All the samples used for the present study were processed within one month of 
collection. V sing as aseptic procedure we added 4 times the volume of reagent A to the 
blood sample, then we rotary mixed 4 minutes at room temperature and centrifuged at 
3000 RPM for 8 min. The supernatant was discarded and to the pellet we added 2 mL of 
reagent B. We vortexed briefly to resuspend the pellet and transferred the suspension to 
a 15 mL screw capped propropylene centrifuge tube. Following resuspension and 
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transfer to a clean tube we added 3 J.1L of a to J.1g1mL RNase solution and incubated the 
tube in a water bath at 37°C for 30 minutes. Subsequently we added 500 J.1L of sodium 
perchlorate solution (for the deproteinisation), mixed by hand, inverting the capped tube 
at least 7 times. For DNA extraction 2 mL of chloroform was added and each sample 
was mixed by hand, inverting the capped tube at least 7 times. Without remixing the 
phases we added 300 J.1L of Nucleon resin and centrifuged at 2800 RPM for 5 min. For 
DNA precipitation, we transferred the upper phase (holding the tube vertically, without 
disturbing the brown Nucleon resin layer) to a clean tube of minimum volume 7.5 mL 
and added 2 volumes of cold absolute ethanol. The tube was mixed by inversion until 
the DNA precipitate appeared. For DNA washing, we centrifuged at top speed for 5 min 
to pellet the DNA and discarded the supernatant. We added 2 mL cold 70% (v/v) 
ethanol, mixed several time by inversion, re-centrifuged and discarded again the 
supernatant (this step can be repeated if necessary). Finally, we aired dry the pellet for 
10 min (ensuring that all the ethanol has been removed), re-dissolved DNA in an 
appropriate volume of water or TE buffer (TRISIHCI and EDT A). The DNA should re-
dissolve within 2 h when using a rotary mixer. 
Genotyping 
MORt exon 12 (C1236n and exon 26 (C3435n SNPs were considered in the present 
study. The genotypes ofMORl were identified by a Polymerase Chain Reaction-Single 
Stranded Conformational Polymorphism analysis (PCR-SSCP). This analysis is based 
on two steps. First the DNA sequence of interest is PCR-amplified, and second, the 
amplified DNA is heat-denaturated and size-fractionated by native polyacrylamide gel 
electrophoresis (native PAGE). After heat denaturation the mobility of single-stranded 
DNA fragments is size-and sequence-dependent with single-stranded DNA molecules 
adopting secondary structure conformations by intramolecular base pairing. For a given 
- 193 -
double-stranded fragment there will be two bands identified following SCCP, one 
corresponding to each of the two original DNA strands. If the two fragments differ by 
as little as single base pair the denaturated strands are likely to adopt different 
conformations and therefore to be distinguishable following native PAGE. The 
difference is identified by a shift in mobility of one or both of the mutant bands relative 
to the wild-type control strands. The migration of single-stranded DNA and the 
conformational changes are influenced by the percentage of acrylamide, the 
electrophoresis temperature and the ionic strength of the electrophoresis buffer. 
Therefore, before to analyse our samples, I worked to identify the appropriate and 
reproducible conditions for each of the given fragments from exon 12 and 26. 
peR-seep 
PCR is a process that can amplify minute amounts of nucleic acid, thus generating 
ample material for further analysis. Subsequently PCR products are analyzed by gel 
electrophoresis for size separation. Scan for sequence alterations were perfonned using 
SCCP and confirmed by direct sequencing. Conventional PCR thennocycling is based 
on three steps: denaturation (separation of the complementary strands), annealing (the 
oligonucleotide primers hybridize to the template) and extension (polymerization of the 
fragment of interest), as three separate reactions that occur after reaching equilibrium at 
defined temperatures. 
For the PCR we need two oligonucleotide primers for each of the exons, which act as 
sites for initiation of the replication, and the DNA polymerase enzyme, for the 
amplification of the region of the template DNA that will be copied. 
The sense primer: 5' -AGTCAGTICCTATATCCTGTGTCTGTGA-3' and antisense: 
5'-GCAGTCACATIGCACATCTTICT-3' for exon 12 as well as sense primer: 5'-
GACTGCAGCA TIGCTGAGAACA-3' and antisense: 5' -
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. AATITCTCITCACITCTGGGAGACC-3' for exon 26 (Sigma-Aldrich, UK) were 
designed using the Gene-Jockey Software. For DNA polymerization we used AmpliTaq 
Gold (PE Applied Biosystems, Foster City, CA, USA), which is a thermostable D~A 
polymerase. Upon receipt, the AmpliTaq Gold and reagents (GeneAmp PCR Buffer and 
MgCh solutions) were stored at -20°C. 
PCR reaction was performed in a 20 J.1L volume, containing 100 ng DNA, 15 pmol of 
. each primer, 16 nmol deoxynucleoside triphosphates (dNTP), 2.25 mmollL magnesium 
chloride, 1 U AmpliTaq Gold polymerase. The PCR thermal cycling conditions for 
exon 12 and 26 consisted of a 10 min denaturation at 94°C, then 35 PCR cycles of 94°C 
for 45 s, 55°C for 30 s, and 72°C for 45 s, followed by a 10 min extension at 72°C. 
Reaction products were mixed with 20 J.1L of loading buffer, denatured at 65°C for 10 
min and electrophoresed onto non-denaturing 6% (62/1 acryllbis) acrylamide gel in 
TAE buffer (PH 6.8) at 35 Watt for 3-5 h at 4°C. SCCP bands were visualized on the 
gels by silver staining. 
Direct sequencing (ABI 377 sequencer, 8000CEQ Beckman Coulter, Fullerton, USA) 
was used to confirm the results in three individuals (one homozygous, one 
heterozygous, and one homozygous mutated on SCCP) for each of the two exons, used 
as controls for genotyping. The different genotypes for C1236T and C3435T SNPs were 
classified as follows: wild type (C/C), heterozygous (Cff) and homozygous for the 
allelic variant (T ff). 
Haplotype and combined genotype analysis 
Haplotype and combined genotype analysis included the SNPs 1236C>T and 3435C>T. 
The term haplotype was originally referred to indicate set of genes that are closely 
linked, however, it has been also recently used to consider different S~Ps allocated in 
the same gene [161]. Here, haplotype analysis included the S~Ps C1236T and C3435T. 
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Each genotype was assigned a haplotype pair. With the assumption th..lt each haplotype 
is predominantly inherited, comparisons were perfonned between carriers and 
noncarriers of a given haplotype. For haplotype coding "1" is referred as "identical to 
the reference sequence (1236C and 3435C) and "2~' as "different from the reference 
sequence". The frrst digit refers to position 1236, the second digit refers to position 
3435. For genotype coding "0" refers as "homozygous identical to the refer~nce 
sequence (1236C, 3535C), "1" as "heterozygous" and "2" as "homozygous different 
from the reference sequence". Different allelic combinations of both variants of S~Ps 
1236 and 3435 can result in four possible haplotypes and nine possible g~notypes. as 
shown in Table 24. 
Statistical Analysis 
For analysis of continuous pharmacologic variables, patient genotypes were used as 
categorical independent variables. The values of CsA pharmacokinetic parameters are 
expressed as the mean ± standard deviation (SD). Between-group comparisons for 
MDRI SNPs and genotypes were perfonned by one-way ANOVA using, as the 
multiple comparisons post-test, the Bonferroni test. P value less than 0.05 wa;; 
considered statistically significant. 
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Results 
Frequency of MDRI variants in renal transplant patients 
The genotype and allelic frequencies for ex on 12 and 26 are shown in Table 25. Of the 
120 kidney transplant recipients, 35% had the MDRI wild type genotype in exon 12 
(C/C), whereas 42% were heterozygous (Crn and 23% were homozygous for the 
polymorphic variant (Tff). The frequency of MDRI SNP in exon 26 (C3435T) was 
39.0% (C/C), 42% (Crn, and 19% (T/T). These frequencies were in agreement with 
those observed in a control population of healthy subjects (Table 25) and in the 
available literature [156,158,162]. 
Effect of MDRI SNPs on CsA pharmaco/dnetics 
We first examined the potential relationship between each MDRI SNP and CsA 
pharmacokinetic parameters. As shown in Table 26, there was no significant difference 
in dose-adjusted CsA levels among the different exon 12 genotypes (C1236T) both in 
the early phase (week 1) and in the stable phase (first month) post transplantation. 
Similarly, no difference was found at the end of month 3 and 6 post surgery. These 
results were confirmed also when patients carrying the wild-type exon 12 genotypes 
were compared with those bearing at least one mutant allele (C/C vs crr + Trr, data not 
shown). 
At variance, mean CsA Co and C2 concentration/dose ratio correlated with exon 26 
C3435T SNP (Table 27). Indeed, dose-adjusted CsA levels were significantly lower in 
patients with the wild-type genotype than in those carrying one or two mutants alleles at 
1, 3, and 6 months post transplantation (Table 27). This pattern was confinned also 
considering the AUCO-12 as surrogate marker of daily CsA exposure. 
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Since it has been previously shown that the T allele was associated with reduced P_gp 
activity [156], we also compared CsA pharmacokinetic parameters between wild-type 
subjects (C/C) and those with at least one mutant allele for exon 26 (Cff + TfI). At 
month 1 post surgery, dose-adjusted CsA Co and C2 levels were significantly lower in 
wild-type patients than in those carrying the mutant allele (CsA CO: 35 + 14 
ng/mL/mg/kg vs 46 + 15 nglmUmg/kg, p<O.OOI; CsA C2: 191 + 80 nglmUmglkg vs 
238 + 89 nglmL/mg/kg, p<0.001, Figure 28). The influence of exon 26 C3435T SNP 
was confrrmed also when CsA AUC and oral clearance (CL) were considered (CsA 
AUCO-12: 6193 + 1470 ng*hlmL vs 6874 + 1294 ng*hlmL, p=O.0121; CsA CL: 9.1 + 
5.3 mL/minlkg vs 7.6 + 4.7 mUminlkg, p=O.0125, Figure 29). 
Haplotype analysis 
We then examined by haplotype analysis whether the combined SNPs in exon 12 and 
26 were predictive of CsA exposure. Different allelic combinations of both variants of 
SNPs 1326 (exon 12) and 3435 (exon 26) resulted in nine possible genotypes and 4 
haplotypes (Table 24). All possible genotypes and haplotypes were detected in the study 
population. CsA pharmacokinetic parameters were compared between carriers of 
different SNP variants and different genotypes derived from haplotype pairs, as well as 
between carriers and noncarriers of each haplotype. As shown in Table 28, at week 1 
and month 1 post-transplant patients homozygous wild-types for both SNPs carrying the 
genotype 22 (171236, 173435) had comparable CsA levels to those with the genotype 
00 (CCI236, CC3435), homozygous for the variants in exons 12 and 26. Similarly, no 
significant differences were observed between genotype 01 (CCI236, CT3435) and 
genotype 21 (TI1236, CT3435), and between other genotypes. Only a patient carrying 
the 02 genotype (CCI236fIT3435) showed dose-adjusted CsA trough blood levels 2 to 
3-fold higher than with aU other genotypes, both at week 1 and at month I post-
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transplant Together these findings confirmed that SNPs in exon 12 were not predictive 
of CsA concentrations even when considered together with SNP in exon 26. No 
significant difference was observed between different haplotype carriers, suggesting that 
this analysis may be of poor clinical relevance for the prediction of CsA levels, at least 
when exons 12 and 26 are considered. 
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Discussion 
The present study shows that in 120 kidney transplant recipients CsA pharmacokinetic 
parameters significantly correlated with exon 26 (C3445n, but not with exon 12 
(CI236T) SNP of the MDRI gene. Patients carrying at least one variant allele of this 
gene had higher dose-adjusted CsA CO, C2 and AUC levels than wild-type subjects . 
. This effect was marginal in the first week post-transplant, but became highly significant 
in the more stable phase postoperatively, namely at months 1,3 and 6. 
P-glycoprotein (P-gp), the product of the MDRI gene, is an efflux transporter highly 
expressed in the enterocyte, and, to a lesser extent, in the liver, kidneys, brain, testis, 
muscle and adrenals [155]. Its absence or altered expression results in higher than 
normal absorption of a given drug from the intestine and its accumulation in different 
tissues, an effect of great relevance for narrow therapeutic index agents, such as CsA 
[41]. It has been previously shown that some SNPs in the MDRI gene affect P-gp 
expression/activity [156]. In particular, patients carrying at least one variant allele in 
exon 26 of the MDRI gene (C3435n had marked reduction in P-gp expression [156). 
Since this glycoprotein offers resistance to drug crossing from the enterocyte to the 
bloodstream, patients with impaired P-gp expression are at risk of being exposed to 
drug levels higher than expected for a given drug dose, as early documented for digoxin 
[156]. 
This could have been occurred in our patients who were given CsA as part of their 
immunosuppressive therapy initially as i. v. infusion and then orally from day 4 post-
surgery. This possibility is supported by the finding that MDRI SNP in exon 26 was 
significantly related to CsA levels only later on in a more stable phase, but not in the 
early post-transplant period. Early postoperatively, when the patients were receiving 
CsA intravenously, the contribution of MDRt to CsA exposure by the modulation of 
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intestinal drug absorption would be negligible. Moreover during the first few days of 
oral CsA administration, CsA concentrations might be influenced by environmental 
non-genetic factors, more than MDRI gene polymorpbisms, such as the normaJi71ltion 
of gastrointestinal motility, the level of graft function, and the pharmacokinetic 
interactions with co-administered drugs [17]. Only later, when gastrointestinal function 
normalizes, graft function stabilizes, and concomitant therapy is fixed, the variants in 
. MDRI gene become relevant in regulating patients' exposure to CsA by affecting P_gp 
expression/activity and eventually drug absorption. 
So far, only few studies have investigated the impact of MDRI SNPs on the 
bioavailability of CsA, and most of them with contradictory results. Early 
pharmacogenetic studies failed to document an association between MDRI ex on 26 
SNP and CsA phannacokinetic parameters in healthy volunteers [163], as well as in 
stable renal and heart transplant recipients [164-166]. However, in some of these studies 
a trend, although not significant, of higher CsA values in subjects carrying crr and Trr 
in exon 26 as compared with the ctC group was reported. Therefore, it can not be 
excluded that the low number of patients considered, weakness in study design and in 
pharmacokinetic parameters considered, may have biased the results. At variance with 
these studies, we have prospectively followed a large cohort of kidney transplant 
recipients, monitored immediately after surgery and in a more stable phase, considering 
both the traditional Co-based sampling time and the recently proposed C2-based 
monitoring, together with a predicted AUC, as surrogate marker of daily CsA exposure. 
Of note, to reduce intrapatient variability, CsA levels were calculated as the mean of 
three consecutive measurements and adjusted to the daily CsA dose. These approaches 
led us to limit the influence of potential confounding factors, and underline the role of 
MDRt exon 26 C3435T polymorphism as a major determinant of CsA concentrations. 
Our findings are in agreement with those recently observed in a small cohort of liver 
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transplant recipients given CsA as a part of the immunosuppressive regimen [167]. As 
further support to our results, different studies have documented a significant influence 
ofpolymorphisms of the MDRI gene on tacrolimus bioavailability [159]. Ind~ it has 
been found that SNPs in exon 21, and 26 were positive predictors of tacrolimus 
exposure and drug toxicity in liver [168], heart [169] and kidney [158] transplant 
recipients. As far as exon 26, these studies confirmed that patients carrying at least one 
T allele had dose-adjusted tacrolimus levels significantly higher than wild-types. 
In the past few years, it has been hypothesised that haplotypes, by considering more 
SNPs together, may provide more information than individual SNPs do. Studies in heart 
[27] and kidney [28] transplant recipients have shown that esA levels significantly 
correlated with the MDRI haplotype, suggesting that haplotypes, in addition to single 
SNP genotypes, could influence CsA disposition. Others [170,171], however, argued 
against this conclusion, showing that MDRI haplotypes did not affect esA 
phannacokinetics. In our study population four different haplotypes and nine different 
genotypes were found. Analysis that consider together SNPs from exon 12 and 26, 
found no statistical differences between carriers of different MDRI haplotypes as far as 
pharmacokinetic parameters. Nevertheless, among the 120 studied patients, one was 
homozygous CC for exon 12 and IT for ex on 26 (genotype 02). This patient had the 
highest mean dose-adjusted Co values at the end of first week and first month post-
surgery compared to other genotypes. Although we can not exclude that this observation 
could be biased by several confounding factors (i.e. gastrointestinal disorders, altered 
CsA metabolism, etc), this atypical pattern merits further investigations, as it might 
potentially affect CsA pharmacokinetics and ultimately clinical outcome. 
In conclusion, the present study has shown that patients carrying mutant alleles for ex on 
26, but not exon 12 ofMDRl gene, are exposed to higher esA levels compared to wild-
type subjects, with potential increased risk to experience drug-related toxicity. The 
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identification of variant MDRI alleles performed before transplantatio~ while patients 
are in the waiting list, could provide useful information to tailor esA dose as early as 
possible after transplantation, with the ultimate goal to improve efficacy, decrease 
toxicity and increase long term graft survival. 
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Legend to Figures 
Figure 28. Correlation between exon 26 SNP (C3435T) and dose-adjusted CsA levds 
(Co and C2) recorded in 120 kidney transplant recipients 1 month after surgery. The box 
plot showed CsA concentrations, clustered according to the allelic variation in ~vfDRl 
ex on 26 (pure wild-type versus patients with at least one mutant allele). 
Figure 29. Correlation between exon 26 SNP (C3435T), CsA AUCO-12 and CsA oral 
clearance recorded in 120 kidney transplant recipients 1 month after surgery. The box 
plot showed CsA phannacokinetic parameters. clustered according to the allelic 
variation in MDRI exon 26 (pure wild-type versus patients with at least one mutant 
allele). 
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Table 24 :Nine genotypes and four haplotypes ofMDRI derived from SNP C1236T (exon 12) and SNP C3435T 
(exon 26) 
Genotype 00 Genotype 01 Genotype 02 Genotype 10 Genotype 11 Genotype 12 Genotype 20 Genotype 21 Genotype 22 
Pos 1236 C C C C c C C T C T C T T T T T T T 
Pos 3435 C C C T T T C C C T T T C C C T T T 
Haplotype 1 1 1 1 11 12 12 12 11 21 11 22 12 22 21 21 21 22 22 22 
Ocnocypc codin&: 0, bomoz)'IOIII idcnlk:ll to the refcrcncc lCquaIQC (l236C, 343SC); I, bctcrozyaous; 2. homozygous different from"fcrcnce aequcooe. The first disit 
rdcn to poIilioa 1236,abc second digit to poIition 3435. HIpIotypc codina: I, idcatical to abc rcf.eraM:c JCqUCIICC (l236C, 343SC); 2, difrcrent &om "fi:RnCC 1Cquc:ncc. 
Tbc finI diJit rem 10 position 1236, the ICCODd disit to positioa 3435. for FKJlYpO 11 a second hlplotype pair (12121) is pouiblc, but hlplotypc pair 11122 II much 
more likely baed 011 prcyiouI bIpIoIypo frcqucncics. 
Table 25: Frequencies of the two SNPs on MDRt gene evaluated in renal transplant recipients and 
in healthy controls 
Exon 12 (C1236T) Exon 26 (C343ST) 
C/c CIT Tff C/c en Tff 
Patient genotype (0=120) 42 (35.0%) SO (41.7%) 28 (23.3%) 42 (3S'()OIo) 49 (40.8%) 29 (24.2%) 
Control genotype (n=I00) 30 (30.0-10) 44 (44.0-10) 26 (26.0-10) 31 (31.0-10) 51 (51.0010) 18 (18.0010) 
Table 26 :distribution of CsA phannacokinetic parameters in 120 kindey transplant recipients 
according to MDRI exon 12 genotype (CI236T) 
CsA pharmacoldnetic parameters MDRJ exon J 2 genotype 
JVeek 1 post-TX C/C crr rrr 
Mean Co (ng/mL) 252 + 87 253 + 75 265 + 114 
Mean C2 (ng/mL) 1139 + 352* 1404 + 455 1402 + 482 
Mean dose (mg/day) 511 + 130 486+110 501 + 150 
Mean Coldoselbw (nglmL/mglkg) 32 + 13 35 + 13 36 + 14 
Mean Cidoselbw (nglmUmglkg) 189 + 70 196 + 70 186 + 80 
Mean AUC (ng*hlm/,) 6901 + 1423 6956 + 1711 7212 + 2284 
IUon!" J po.\'I-1~\ CIC CIT TIT 
tv1e.m Co (nglmL) 234 + 62 249 + 67 245 + 63 
r--..kan ('2 (nglm/,) 1293 + 357 1289 + 344 1262. 47<) 
Mean Jose (mglday) 395 + 98 406 + 133 382 -t 132 
tv1ean C\/Josc/bw (nglmIJmglkg) 39 + 13 42 + 17 46 + 13 
\ kan C.JJosc/bw (ng/mIJmglkg) 217 + 73 216 i. 87 238. 12] 
Mean AlJe' (ng*hml.) 6541 + 1304 6711+1371 65()() i. 1<)15 
·A..,,( )I 'A 1'l'.\/. P () ()·r 
Table 27: distribution of CsA pharmacokinetic parameters in 120 kindey transplant 
recipients according to MDRI exon 26 genotype (C343 51) 
CsA pharmacokinetic parameters MDRl exon 26 genotype 
CIC crr DT 
Week 1 post-TX 
Mean Co (nglmL) 253 ± 971\ 250 ± 69 296 ± 128 
Mean C;z (nglmL) 1345 ± 365 1434 ± 537 1380 ± 509 
Mean CrJdose/bw (nglmUmglkg) 34 ± 14 36 ± 15 41 ± 18 
Mean C;zfdose/bw (nglmUmglkg) 186 + 80 202 ± 73 189 ± 70 
Month 1 post-TX 
Mean Co (nglmL) 222 + 70· 258 ± 53 251 ± 70 
Mean dose (mglday) 412 ± 118 403 ± 127 376 ± 103 
Mean CrJdose/bw (nglmUmglkg) 35 ± 11· 44 ± 15 44± 14 
Mean C;zfdose/bw (nglmUmglkg) 199 + 80 0 234 ± 80 231 ± 109 
Month 3 post-TX 
Mean Co (nglmL) 200 + 61 217 ± 64 197 ± 46 
Mean C;z (nglmL) 1135 + 315 1106 ± 281 1215 ± 377 
Mean CrJdose/bw (nglmUmglkg) 40 + 11· 51 ± 19 51 ± 18 
Mean C;zIdose/bw (nglmUmg/kg) 231 ± 67 0 261 ± 99 285 ± 94 
Month 6 post-TX 
Mean Co (nglmL) 169 + 50 185 ± 61 169 ± 37 
Mean C;z (nglmL) 907 ± 291 920 -+- 261 902:: 189 
Mean CrJdose/bw (nglmUmg/kg) 36 ± 21· 46:= 17 47:= 1~ 
Mean C;zIdose/bw (nglmUmg/kg) 193 ± 95 0 225 ± 77 2~9 = 77 
,»<0.05 vs IT; .p<0.05 vs CT and IT;"p<O.Ol vs CT and IT; 'p<O.OS \'5 CT; 5p<O.C5 \'5 CT, p<O.Ol \$ IT 
Table 28 :CsA Pharmacokinetic parameters in 120 kidney transplant recipients with different MDRt genotypes and 
haplotypes 
Week I Month I 
n CofD/l1W CfDIBW AUC CoIDlBW C/DIBW AUC 
(nwmllmglKg) (nWmLlmgIKg) (ng·h/mL) (ntYmUmwKg) (IIg1ml1mglKg) (1I8·lt/n.L) 
Gmotype 
00 32 34 ± 13 188 ± 82 6958 ± 1435 37 ± 13 201 ±75 6303 ± 1446 
01 14 44±24 189 ± 21 6084 ±2911 44 ± 13 278±4 6887 ± 917 
02 I 97±S· 144 ± 16 9977 ±212 71 ± 80A 178 ± 11 7398 ± 58 
10 6 22±4 144 ±20 5817 ± 834 2S± 13 164 ±59 6091 ± 2376 
I I 33 3S ± 13 200.±. 71 6741 + 1589 46 + 17 225 ± 91 6981 + 1129 
12 12 41 ± 14 208 ± 77 7838 ± 1741 36± 14 221 ... 85 6160 ± 1007 
20 4 39 ± 16 224 ± 78 764S ± 1451 45 ± 16 241 ± 133 5558 ± 817 
21 2 33 ± 15 196 ± 40 7313 ± 622 46± 15 216±31 6566 ± 214 
22 16 36 ± 14 179 ± 66 7002 ± 2615 46.± 14 239 ± 125 6893 ± 2190 
IIllplotyp~ 
Carrier II 85 35:t 14 194 ±76 6857 ± 1613 40 ± IS 216 ± 80 6660 ~t 1363 
Noncarrier II 3S 40 ± 18 195 ± 89 7556 ± 2162 44 ± 14 231 ± 14 6517 ± 1695 
Camer 12 27 43 ±20 204 ± 79 7664 ± 2029 41 ± 14 241 ± 68 6741 ± 924 
Noncnrricr 12 93 34 ± 13 191 ± 72 6873 ± 1702 42 ± 15 216 ± 92 6591 ± 1559 
Carrier 21 12 30 + 13 185 + 64 6872 ± 1437 36 ± 16 199 + 88 6003 ± 1697 
Noncarrier 21 108 37 ± IS 195±75 7078 ± 1845 42 ± 15 223 ± 88 6702 ± 1409 
Carrier 22 63 36 ± 13 196 ± 69 7032 ± 1852 44 ± 15 228 ± 97 6827.:!: 1527 
Noncarrier 22 57 36 ± 17 191 ± 78 7087 ± 1707 38 ± 14 213 ± 78 6413:t 1430 
• AHOV A ICII p<O 00 I: IkMIfcmJni .... p<o.GOl n ... GIber poI)pCIlI ~ I 
-ANOVA Iat- 0.00": nonf""",, lAC p<O.OOI n FftOCYpO 10", "p<O.~ VI pnoI)1JC 00 .. month 1 
Chapter 12 
CONCLUSION AND FUTURE PERSPECTIVES 
During the past decade, as increasing number of more powerful immunosuppressive 
agents became available, the short-term rate of organ survival significantly improved, 
yet the long-term results did not Although graft survival rate at 1 year post-surgery is 
now exceeding 90%, after a decade it drops to nearly 40% [172]. The initial excitement 
that followed a report that long-term survival of renal allografts may be improving, 
especially in recipients who had never had an episode of acute rejection [173], has faded 
as newer data [174] showed that the long-term risk of graft loss has not improved. The 
reasons for chronic allograft dysfunction involve many factors that concerned variable 
tissue injury at the time of transplantation or during subsequent episode of rejection. 
However, even in the case of grafts with good function in the early years after 
transplantation, progressive tissue damage and slow decrements in function may 
develop, most often with considerable vasculopathy. Chronic allograft dysfunction 
affects all transplanted organs and is the most common cause of graft loss in the long-
term. 
Both immunologic and non-immunologic factors play a key role in promoting poor 
long-term graft survival. Among these, long-term use of immunosuppressive agents 
does contribute to chronic graft injury [175]. Paradoxically, a transplanted organ 
initially protected from the immunological injury by immunosuppressive drugs may be 
subsequently damaged and lost to chronic toxicity caused by these same agents. As a 
matter of fact, all anti-rejection drugs have specific side effects and additively 
contribute to an overall state of immunosuppression, which leads to an increased risk of 
various malignant conditions [176], most commonly lymphoproliferative disorders or 
squamous cell carcinoma of the skin. Such drugs contribute also to the increased risk of 
cardiovascular disease, which is the most common cause of premature death in 
transplant recipients [177]. Moreover. excessive total immunosuppression causes a 
susceptibility to infectious disease [178], such as cytomegalovirus, Epstein-Barr virus, 
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and the more recently recognized polyomavirus, which causes nephropathy and renal 
allograft loss [179]. Indeed, over the past decades major efforts have been done to 
optimize the use of immunosuppressive agents reducing side effects yet maintaining 
graft survival. Nevertheless, this individualization depends on the judgement of the 
physicians, as robust treatment guidelines have not yet been established. 
Major finding of the present research project 
Pharmacokinetic studies in humans often involve analysis of large number of samples 
and therefore require simple, rapid and reliable analytical methods. Furthermore, daily 
analysis of an increasing number of drugs as part of the routine drug monitoring 
activity, urges the need for HPLC methods that can be easily run and rapidly set up. 
Therefore, the fust part of my research activity was devoted to the development and 
validation of analytical methods which could be used to measure plasma levels of MP A 
as well as blood levels of SRL and CsA. 
To date several HPLC methods have been described for determination of total MPA. As 
potential advantages, the method described in Chapter 3 utilizes a simple extraction 
procedures using solid phase extraction (SPE) columns and does not involve any 
centrifugation, use of vacuum or drying of residues following extraction. Additionally, 
the use of PTA as IS, which is the first analytical peak eluted, allow us to stop the 
chromatographic run immediately after the elution of MPA (at 8 min), and to proceed 
fast with a new injection. Moreover, the robustness of the method makes it easy to 
generate reproducible results. More difficult is the assessment of free MP A, since we 
have to manage a signal which is less than 5% of that observed with total MP A. To 
overcome this problem, we have moved from a wavelength of 254 run to 215 nm~ 
doubled the injection volume and used a gradient, with a great improvement in the 
signal. As additional shortcoming, the ultrafiltration procedure is extremely variable. 
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Indeed, we have observed that small variation in the temperature (Le., 1°C) and/or in the 
time of the centrifugation, were associated with great difference in the volume of the 
ultraftltrate obtained. To measure unbound MP A it is, therefore, mandatory to strictly 
monitor the operational conditions. It should be pointed, however, that, despite a greater 
variability in inaccuracy and imprecision than that observed for total MP A, the 
performance of the described method for the assessment of free MP A was still in 
agreement with the FDA Guidelines [36]. 
Quantification of SRL in biological matrices is not easy, given the very low dose of the 
drug routinely employed that reflects its high potency. Moreover, the assay may be 
affected by several variables including the recovery of the analyte during sample 
processing and potential interfering peaks in the chromatograms. Here, we developed a 
new method for SRL determination in whole blood specimens, which is robust enough 
to be run on standard HPLC equipment, using only basic analytical reagents [122]. As 
shown in Chapter 4, the assay has adequate sensitivity, precision and accuracy for 
therapeutic monitoring of the drug in transplant patients. Taking into account the sample 
preparation step and the chromatographic time, at least 60 samples per day can be 
extracted and analyzed by a single technician, using two Vac Elut Manifold chambers. 
This method overcomes the analytical difficulties and the long time required for sample 
preparation described in the previously published procedures together with the need of 
using special (light protected) or treated (silanized) glassware [35]. As previously 
documented for total MP A assessment, the Bond-Elut cartridges with 200 mg of sorbent 
applied also for the detennination of SRL allowed the use of very small volumes for 
either cleaning-up and elution steps, thus speeding up the solidlliquid extraction step 
and further reducing the time of drug measurement. 
Although the present research has mainly focused on TOM of MP A and SRL, some 
additional aims required the assessment of CsA concentrations (see Chaplers 6-11). 
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Thus, as described in Chapter 5, I have also described and validated a HPLC method 
with UV detection for the measurement of CsA in whole blood. It must be pointed ou~ 
however, that the liquid-liquid extraction procedure, used in this meth~ presents some 
problems, mainly related to the use of glass tubes and toxic solvents, as well as a very 
long time for sample processing. Moreover, this method is associated with a poor 
recovery. Therefore, we have very recently planned to develop a HPLC method with 
. SPE extraction also for the assessment of CsA concentrations in whole bl~ given 
alone or in combination with everolimus, a new immunosuppressive agent with a 
structural formula close to that ofSRL [180]. 
The performance of the methods presented in Chapters 3, 4, and 5 was in agreement 
with the FDA Guidelines [36]. Thus, they were applied for TOM of novel 
immunosuppressants (namely MPA and SRL), as described in the second and third parts 
of the thesis (Chapters 6-10). 
Although there is little controversy amongst clinicians prescribing CsA that measuring 
this drug in blood is a useful adjunct to its optimal administration, the same concept 
does not apply to MMF, a new immunosuppressant characterized by a narrow 
therapeutic index. Actually, this drug is widely used in a fixed daily dose, despite 
growing evidence showing that this regimen no longer might be the best approach for 
the management of transplant patients [181,192]. Indeed, we have explored the 
possibility to optimize MMF dosing by MP A pharmacokinetic monitoring by studying 
46 stable adult kidney transplant patients receiving CsA, steroids and MMF at a flXed 
daily dose, guided by haematological parameters [88]. As first finding, we observed an 
over 10-fold variability of MP A dose-adjusted phannacokinetic parameters, allowing us 
to speculate that the knowledge of the daily MMF dose was no guide to drug exposure. 
Moreover, we also found a significant correlation between MPA AUC and graft 
function. Indeed, patients exposed to higher concentrations of MP A presented lower 
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serum creatinine values and higher creatinine clearance than those with lower MP A 
exposure, providing a strong rationale for measuring MP A levels to guide MMF dosing 
(Chapter 6). 
Pharmacokinetic-based monitoring may be useful not only to tailor dosage but also to 
unmask potential drug-drug interactions. This concept applies generally to all NT! drugs 
but is of particular relevance in the transplant setting, where patients are chronically 
treated with several combinations of drugs. For instance, modulation of MPA 
absorption, distribution, metabolism and/or excretion by concomitant administration of 
drugs J3lher than MMF might affect MP A bioavailability and eventually clinical 
'= outcome [39,71,81]. Indeed, as a part of a steroid-sparing clinical trial, we have found 
that glucocorticoids, by inducing enzymes involved in MP A metabolism, interfere with 
drug bioavailability [90]. In particular, steroid reduction and discontinuation paralleled 
with a progressive increase of MP A exposure (Chapter 7). These results are of 
particular relevance for those centres that are adopting steroid-sparing regimens with the 
goal to limit drug-related chronic adverse events. If these approaches are pursued using 
MMF at fixed daily dose, progressive steroid reduction may, therefore, results in 
excessive MPA exposure with increased MMF-related toxicity. 
Beside steroids, MMF is usually given in combination with CsA or TRL. However, the 
introduction in the clinical practice of a new class of immunosuppressive agents, 
namely rapamycins (SRL and everolimus), is allowing the development of calcineurin 
inhibitor-free regimens that combine MMF with sirolimus. As a part of a protocol 
aimed at investigating the efficacy of induction therapy with a new monoclonal 
antibody, Campath-1H, we have found that SRL and CsA exert different effects on 
MP A exposure. Co-administration of SRL and MMF was associated with higher dose-
adjusted MPA levels and AUC than those measured under CsA-based regimens 
(Chapter 8). As working hypothesis, we suggest that CsA reduces the enterohepatic 
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recirculation of MP A from MP AG, its glucuronidated metabolite, whereas SRL did not. 
This was confirmed by the lack of a secondary peak of MP A in almost all patients 
treated with CsA and MMF [182]. Again, these results should be carefully taken into 
account when MMF is given at fixed doses and patients are switched to different poly-
pharmacological therapies. 
As additional confounding factor, a new formulation of MP A, the enteric coated sodium 
salt (EC-MPS), is now in development. A formal comparison of the pharmacokinetic 
profiles of these two formulations, as we did (Chapter 9) has evidenced dramatic 
differ~nces, especially in the absorption process [183]. In particular, patients given EC-
MPS had MPA trough levels 4-fold higher than those found in patients given MMF. 
Our results may have important clinical consequences when Co-based MP A monitoring 
is used to optimize MPA therapy, as recently suggested by International Consensus 
Conferences [114]. The great variability ofMPA Co levels after EC-MPS administration 
does not allow the implementation of trough-based TOM in patients chronically treated 
with the novel MP A-releasing formulation, an event that might potentially translate in a 
sub-optimal clinical outcome. Similarly, the very high variability, both intra- and inter-
patient, among all MP A pharmacokinetic parameters from patients treated with EC-
MPS and the poor correlations between single sampling points and MPA AUCO- l2 after 
the administration of the enteric-coating fonnulation did not allowed the development 
of a suitable equation to reliably predict MP A daily exposure in these patients. 
Therefore, at variance with MMF [37,114], these results argue against the possibility to 
implement a limited sampling strategy-based therapeutic drug monitoring of MP A in 
patients given EC-MPS, with potential detrimental effects for the patient and for the 
graft in the long tenn. 
As mentioned above, a new class of immunosuppressive agents is now available on the 
market, referred as "rapamycins" (namely SRL and everolimus). For SRL. measurement 
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of the drug levels is actually a license requirement in Europe and is recommended in 
specific clinical settings in the USA [184]. In the past 3 years our laboratory served as a 
centralized institution in Italy to measure SRL trough samples from more than 40 Italian 
Transplant Units. These samples corresponded to nearly 500 kidney transplant 
recipients treated with different SRL-based immunosuppressive regimens. A 
retrospective analysis of all the data evidenced some important pharmacokinetic 
interaction that involved SRL. In particular, we found that dose-adjusted SRL trough 
levels were significantly higher in patients given CsA than in those given tacrolimus 
[185]. Moreover, we observed that MMF and/or steroids reduced SRL bioavailability. 
As additional analysis, we proposed a dose-adjustment fonnula which can be used to 
guide SRL dose changes, with the goal to reduce variability in SRL exposure, a 
condition known to affect clinical outcome (Chapter 10). 
Everolimus is a macrolide bearing a 2-hydroxyethyl chain substitution at position 40 on 
the SRL structure, rationally developed to improve the phannacokinetic characteristics 
of the innovator compound. We have recently developed and validated an HPLC-UV 
method for determining everolimus concentrations in human whole blood [186]. 
Unfortunately, this novel immunosuppressant is not yet available on the Italian market. 
We have, therefore no data on TOM studies focusing on everolimus. As future research, 
we will apply our recently developed method to measure daily fluctuations of 
everolimus concentrations, with the goal to assess whether the introduction of the 
chemical modification in position 40, may effectively translate in a better 
pharmacokinetic profile of everolimus as compared with SRL. 
All together, these results pointed phannacokinetics as the most useful approach to 
monitor and optimize drug dosing not only for traditional immunosuppressants (such as 
CsA and TRL), but also for novel anti-rejection agents, namely MP A and SRL. 
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It should be pointed, however, that drug concentration measurements are only a part of 
the decision tree for dose adjustment. They must be viewed in the context of other 
complementary fields that include biochemical and clinical analysis, as well as novel 
therapeutic monitoring approaches. As an example of this concept, we have conducted a 
randomized trial aimed at investigating whether per-protocol biopsies, in combination 
with routine pharmacokinetic studies, could be useful tools to implement steroid or CsA 
. sparing regimens in kidney transplant recipients [187]. As main result, we have found 
that per-protocol biopsy more than one year after transplantation is a safe procedure to 
guide change of immunosuppressive regimen and to lower the risk of major drug-
related side effects. 
Alternative approaches, beside pharmacokinetics, have been recently proposed to tailor 
the best immunosuppressive regimen for each patient. For instance, pharmacodynamic 
monitoring involves measurement of the biological effect of the drug at its target site 
[21]. Indeed, I have also involved in the development of a method for the assessment of 
calcineurin, the pharmacological target of CsA, in whole blood. When we applied this 
assay to monitor kidney transplant recipients we found that CsA levels did not predict 
daily calcineurin (CN) activity, whereas a single determination of CN at baseline was a 
useful surrogate for the daily inhibition of the enzyme by CsA [188]. It should be 
pointed out, however, that pharmacodynamic tests are actually too complex for clinical 
use and often require radioactive materials. As additional drawbacks, studies aimed at 
investigating the potential predictivity of pharmacodynamic approaches in tenns of 
rejection and/or drug toxicity are still lacking. Therefore, alternative roads, beside 
pharmacodynamics, should be travelled. 
Those involved in TOM are now realizing that individual patient's exposure to 
immunosuppressive agents can be influenced by the genetic background. Indeed, it has 
been proposed that interinvidual differences in drug response may be due. at least in 
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part, to sequence variants in genes encoding drug-metabolizing enz:mes. drug 
transporters, or drug targets [41,159]. Accordingly, the identification of an indiyidual's 
genetic make-up may be useful to choose the best treatment for each patient. As 
compared to pharmacokinetic studies, pharmacogenetic studies can be conducted eyen 
before the beginning of treatment, they do not require the assumption of steady-state 
conditions, are constant for an individual's lifetime and can provide predictive yalue for 
multiple drugs. Hence, as last part of my research activity, I have attempted to assess the 
role of pharmacogenetics in the field of organ transplantation. To perform this study we 
.-
took advantage from the large amount of pharmacokinetic data from patients enrolled in 
the MY.S.S. trial [28,38]. Over 2,000 CsA trough and C2 measurements, collected 
during the first 6 months post-surgery, were available. As preliminary analysis we 
studied the potential association between CsA pharmacokinetics parameters and genetic 
variants in the MDRl, the gene encoding for the P-gp (Chapter 11). This protein works 
as an efflux: pump, which removes lipophilic drugs, like CsA, from the intracellular 
space. As working hypothesis we speculated that genetic polymorphisms of the MDRI 
gene could result in significant reduction in P-gp expression, eyentually increasing the 
exposure of these patients to CsA. Indeed, preliminary results, performed in 120 out of 
the 350 patients enrolled in the MY.S.S. trial, documented that a polymorphism in the 
exon 26 of the MDRI (C3435T) was associated with higher CsA levels than wild types. 
suggesting that also genetic assessments can be considered useful tools to guide drug 
dosing [189]. Assuming that P-gp exerts its activity on many lipophilic substrates. it can 
be reasonably speculated that these findings could applied also to other 
immunosuppressive agents. such as tacrolimus. SRL and eyerolimus. 
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Future directions 
Transplantation has transformed the treatment of patients with organ failure in a number 
of clinical settings, and immunosuppressive drug therapy is fundamental to its success. 
During the past decade several new potent anti-rejection molecules with different modes 
of action and different side-effect profiles have become available, and some will be 
available in the near future [190,191]. They include agents that deplete T cell (anti CD3, 
CD52-specific monoclonal antibodies) or B cell (CD20-specific monoclonal antibodies) 
signal transduction pathways, blockers of co stimulatory pathways (CD40-specific 
antibodies, CTLA4Ig, LEA29y), agents that interfere with lymphocyte trafficking 
(LF A-I-specific antibodies, FTY720) and small-molecules drugs (SRL, everolimus, 
MP A-releasing formulations, mizoribine, leflunomide, FK778, JAK3 inhibitors and the 
new CsA analogue ISA247). Nowadays immunosuppression after renal transplantation 
is no longer one single regimen applicable to all patients. In the selection of the optimal 
immunosuppressive protocol, individual drug-related toxicity, recipient-donor related 
risk factors as well as all the available information have to be taken into account. It can 
be reasonably speculated that interest in the measurement of immunosuppressive drugs 
as a guide to therapy will show no signs of waning. As the number of 
immunosuppressive drug combinations increases, so does the complexity of 
interpretating the concentration data. Indeed, also for some of the new 
immunosuppressive agents mentioned above (such as FK778, mizoribine and ISA247) 
will benefit from pharmacokinetic-based TOM as a guide to tailor the best dosage for 
each patient. Periodical evaluations of drug exposure can be able to detect external 
influences (i.e. drug-drug interactions, hormonal levels, kidney and/or liver dysfunctio~ 
etc) that can vary over time. From this point of view, traditional phannacokinetic-based 
TOM will undoubtedly play a key role to optimal drug prescription also for the next 
years. 
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However, it is expected that, in the future, in addition to targeting a patient's drug 
concentrations within a therapeutic range as in traditional TDM, physicians are more 
than likely to be making dosage recommendations for individual drugs based also on a 
large amount of additional information, such as pharmacodynamic profiles, as well as 
according to individual patient's genotype. On pure mechanistic grounds, measurement 
of pharmacodynamic parameters (for example, the biological activity of a drug) may 
more closely correlate with clinical outcomes than pharmacokinetic parameters. This 
approach has shown great analytical limitations when applied to assess calcineurin 
activity after CsA or tacrolimus administration or in the attempts to measure P70S6 
kinase in patients chronically given SRL or everolimus. At variance, still promising is 
the assessment ofIMPDH activity in peripheral blood mononuclear cells [192). Indeed, 
preliminary studies have reported significant associations between IMPDH activity and 
risk of acute rejection as well as MMF-related toxicity. More data are now needed to 
fully establish the prognostic value of IMPDH activity, and longitudinal studies are 
eagerly awaited. 
As exemplified in Chapter 11, pharmacogenetics is another promising science which 
could provide important infonnation for the individualization of the immunosuppressive 
regimen. Almost all the available literature in this field focuses on AZA, CsA and TRL 
[41,159), whereas data on novel immunosuppressive agents are scanty. To date, there 
are only two studies which have investigated the role of SNPs in the MDRI and CYP3A 
genes on SRL exposure [193,194]. Results from these observations, derived using SRL 
trough levels as surrogate markers of daily drug exposure, were controversial. Indeed, 
both these studies have shown that, unlike TRL, SRL trough concentrations and dose 
requirements were not affected by MDRI polymorphisms, whereas the predicting value 
of CVP3As genotyping was documented by Anglicheau et al [193], but not by Mourad 
[194]. These fmdings were not conclusive and provide a rationale for future 
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investigations focusing on genetic determinants of SRL and everolimus exposure. On 
the same line, pharmacogenetic studies on MP A are largely inadequate. It is well know 
that MPA is extensively glucuronidated by several UDP-GTs, a family of enzymes 
characterized by several genetic polymorpbisms [195,196]. In the only article available, 
it has been shown that the T-275A and C-2152T SNPs of the UGTIA9 gene promoter 
are associated with significantly lower MP A exposure in renal transplant recipients 
. treated with the fixed 2 g MMF daily dose and part of this effect was caused by 
interruption in the EHC of MPA [197]. These observations demonstrated for the first 
time that, in vivo, interindividual variability in the pharmacokinetics of MP A can be 
partially explained by genetic variation. Given the high allelic frequency of the 
UGTIA9 SNPs (approximately 15% in white subjects), as well as the 2-fold reduction 
in MP A exposure in comparison with noncamers, these fmdings are also likely to be 
clinically relevant and offer both a rationale and a means for a personalization of MMF 
treatment. As additional confounding factor, it has been recently reported that MP A 
exposure is influenced by the activity of the multidrug resistance-associated protein 2 
(MRP2), a protein expressed at the apical surface of hepatocytes, where it functions to 
excrete conjugation products (such as MPA glucuronidated metabolites) into bile [198]. 
Similarly to what has been reported for MDR1, also SNPs in the MRP2 gene have been 
reported [199]. Therefore, it can be reasonably expected that future pharmacogenetic 
studies will focused also on the potential association between MRP2 allelic variants and 
MPA exposure. 
To strengthen the role of pharmacogenetics in the field of organ transplantation it is 
important that genetic studies will not include only information on inheritance variants 
in gene encoding for enzymes involved in drug disposition but, even more importantly, 
also in genes involved in the pharmacological response. To date, no publications were 
available on SNPs in the pharmacogical targets of immunosuppressive agents 
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(calcineurin, IMPDH, P70S6 kinase, etc). However, it has been recently demonstrated 
that SNPs in the gene encoding for cytokines actively involved in the moJub:ion of the 
immune system influence the outcome of kidney transplantation [200]. These results 
provide indirect evidence that, beside genes encoding for metabolizing eI1Z)mes, also 
allelic variants in the pharmacological target might affect drug response, ultimately 
affecting the outcome of the graft and patient survival. 
It is expected that the availability of complete information on patient's status 
(pharmacokinetics, dynamics, genomics, and clinical data) will allow us move from a 
diagnosis-directed approach to one that is prevention-directed and patient-tailored. 
However, to pursue this ambitious project, we urge need the development of algorithms 
working within neural networks able to incorporate the large amount of data from 
kinetic, clinical, dynamic and genetic testing and providing predictive dosag~ 
algorithms useful for personalised therapies. If we succeed, we will be able to identify 
not only the best drug to be administered to a particular patient, but also the most 
effective and safest dosage from the outset of therapy, already befor~ transplant surgery. 
Nevertheless, it should be reminded that, regardless of whether we are referring to 
traditional TDM or that of the future, we need to ensure that we are providing ideal 
immunosuppression for our patients and are helping to improve the quality of health 
care. Indeed, the ultimate goal of personalized therapy is the improvement of long tl!rrn 
organ survival, eventually leading to indefinite tolerance of the graft. 
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high performance liquid chromatography 
Inosine monophosphate dehydrogenase 
Internal quality controls 
International proficiency testing scheme 
Internal standard 
Kaposi's sarcoma 
Liquid chromatography-mass spectrometry 
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LLOD: 
LLOQ: 
LSS: 
MDRl: 
MMF: 
MP: 
MPA: 
MPAG: 
MS: 
mTOR: 
MY.S.S.: 
NTI: 
PAGE: 
PCR: 
P-gp: 
QC: 
R: 
R2: 
RBC: 
SD: 
SE: 
S~P: 
SPE: 
SSCP: 
SRL: 
TD~t: 
Lower limit of detection 
Lower limit of quantification 
Limited sampling strategy 
Multidrug resistant 1 gene 
Mycophenolate mofetil 
Methylprednisolone 
Mycophenolic acid 
Mycophenolic acid glucuronide 
Mass spectrometry 
Mammalian target of rapamycins 
Mycophenolate steroid sparing study 
Narrow therapeutic index 
Polyacrylamide gel electrophoresis 
Polymerase chain reaction 
P glycoprotein 
Quality control samples 
Coefficient of correlation 
Coefficient of regression 
Red blood cell 
Standard deviation 
Standard error 
Single nucleotide polymorphism 
solid-phase extraction 
Single strand confonnational polymorphism 
Sirolimus 
Therapeutic drug monitoring 
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TRL: 
UDP-GT: 
UV: 
Time corresponding to the maximum drug concentration 
Tacrolimus 
uridine diphosphate glucuronosyltransferase 
Ultraviolet 
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